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Abstract 
 
The aspartic protease BACE1 (β-amyloid precursor protein cleaving enzyme, β-secretase) is 
recognized as one of the most promising targets in the treatment of Alzheimer’s disease (AD). The 
accumulation of β-amyloid peptide (Aβ) in the brain is a major factor in the pathogenesis of AD. Aβ is 
formed by initial cleavage of β-amyloid precursor protein (APP) by β-secretase, therefore BACE1 
inhibition represents one of the therapeutic approaches to control progression of AD, by preventing the 
abnormal generation of Aβ. For this reason, in the last decade, many research efforts have focused at the 
identification of new BACE1 inhibitors as drug candidates. Generally, BACE1 inhibitors are grouped into 
two families: substrate-based inhibitors, designed as peptidomimetic inhibitors, and non-peptidomimetic 
ones. The research on non-peptidomimetic small molecules BACE1 inhibitors remains the most 
interesting approach, since these compounds hold an improved bioavailability after systemic 
administration, due to a good blood-brain barrier permeability in comparison to peptidomimetic 
inhibitors.  
 
Very recently, our research group discovered a new promising lead compound for the treatment of AD, 
named lipocrine, a hybrid derivative between lipoic acid and the AChE inhibitor (AChEI) tacrine, 
characterized by a tetrahydroacridinic moiety. Lipocrine is one of the first compounds able to inhibit the 
catalytic activity of AChE and AChE-induced amyloid-β aggregation and to protect against reactive 
oxygen species. Due to this interesting profile, lipocrine was also evaluated for BACE1 inhibitory 
activity, resulting in a potent lead compound for BACE1 inhibition. Starting from this interesting profile, 
a series of tetrahydroacridine analogues were synthesised varying the chain length between the two 
fragments. Moreover, following the approach of combining in a single molecule two different 
pharmacophores, we designed and synthesised different compounds bearing the moieties of known 
AChEIs (rivastigmine and caproctamine) coupled with lipoic acid, since it was shown that dithiolane 
group is an important structural feature of lipocrine for the optimal inhibition of BACE1. All the 
tetrahydroacridines, rivastigmine and caproctamine-based compounds, were evaluated for BACE1 
inhibitory activity in a FRET (fluorescence resonance energy transfer) enzymatic assay (test A). With the 
aim to enhancing the biological activity of the lead compound, we applied the molecular simplification 
approach to design and synthesize novel heterocyclic compounds related to lipocrine, in which the 
tetrahydroacridine moiety was replaced by 4-amino-quinoline or 4-amino-quinazoline rings. All the 
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synthesized compounds were also evaluated in a modified FRET enzymatic assay (test B), changing the 
fluorescent substrate for enzymatic BACE1 cleavage. This test method guided deep structure-activity 
relationships for BACE1 inhibition on the most promising quinazoline-based derivatives. By varying the 
substituent on the 2-position of the quinazoline ring and by replacing the lipoic acid residue in lateral 
chain with different moieties (i.e. trans-ferulic acid, a known antioxidant molecule), a series of 
quinazoline derivatives were obtained. In order to confirm inhibitory activity of the most active 
compounds, they were evaluated with a third FRET assay (test C) which, surprisingly, did not confirm the 
previous good activity profiles. An evaluation study of kinetic parameters of the three assays revealed that 
method C is endowed with the best specificity and enzymatic efficiency. Biological evaluation of the 
modified 2,4-diamino-quinazoline derivatives measured through the method C, allow to obtain a new lead 
compound bearing the trans-ferulic acid residue coupled to 2,4-diamino-quinazoline core endowed with a 
good BACE1 inhibitory activity (IC50 = 0.8 µM). We reported on the variability of the results in the three 
different FRET assays that are known to have some disadvantages in term of interference rates that are 
strongly dependent on compound properties. The observed results variability could be also ascribed to 
different enzyme origin, varied substrate and different fluorescent groups. The inhibitors should be tested 
on a parallel screening in order to have a more reliable data prior to be tested into cellular assay. With this 
aim, preliminary cellular BACE1 inhibition assay carried out on lipocrine confirmed a good cellular 
activity profile (EC50 = 3.7 µM) strengthening the idea to find a small molecule non-peptidomimetic 
compound as BACE1 inhibitor. In conclusion, the present study allowed to identify a new lead compound 
endowed with BACE1 inhibitory activity in submicromolar range. Further lead optimization to the 
obtained derivative is needed in order to obtain a more potent and a selective BACE1 inhibitor based on 
2,4-diamino-quinazoline scaffold.  
 
A side project related to the synthesis of novel enzymatic inhibitors of BACE1 in order to explore the 
pseudopeptidic transition-state isosteres chemistry was carried out during research stage at Université de 
Montréal (Canada) in Hanessian's group. The aim of this work has been the synthesis of the δ-
aminocyclohexane carboxylic acid motif with stereochemically defined substitution to incorporating such 
a constrained core in potential BACE1 inhibitors. This fragment, endowed with reduced peptidic 
character, is not known in the context of peptidomimetic design. In particular, we envisioned an 
alternative route based on an organocatalytic asymmetric conjugate addition of nitroalkanes to 
cyclohexenone in presence of D-proline and trans-2,5-dimethylpiperazine. The enantioenriched obtained 
3-(α-nitroalkyl)-cyclohexanones were further functionalized to give the corresponding δ-nitroalkyl 
cyclohexane carboxylic acids. These intermediates were elaborated to the target structures 3-(α-
aminoalkyl)-1-cyclohexane carboxylic acids in a new readily accessible way. 
 
Introduction 
 3
 
Chapter 1 
 
Introduction 
 
A case report presented by Alois Alzheimer on November 19071 in a neurology conference 
showed the clinical observation of a 51-years old woman affected by a new disorder, later named 
as Alzheimer’s disease (AD). The patient showed progressive cognition and memory 
impairment, reduced comprehension, aphasia, unpredictable behaviour and disorientation 
associated with evident histopathological findings such as miliary foci, several fibrils and typical 
plaques. Even though these clinical observations still remain nowadays the major characteristics 
of the disease, scientific community had to wait nearly 60 years to formulate a first hypothesis on 
the aetiology of the disorder. Indeed, in the late 70s it was shown that cholinergic neurons and 
synapses of the basal forebrain are selectively lost in AD patients’ brain, accounting for the 
development of cognitive impairments. These findings constituted the premises for the so-called 
“cholinergic hypothesis” of AD, which proposed cholinergic enhancement as an approach for 
improving cognitive function in AD.2 This paradigm has so far produced the majority of 
therapeutic agents (cholinesterase inhibitors) acting as cognition enhancers but representing only 
palliative remedies.3 Among cholinesterase inhibitors, donepezil, galantamine and rivastigmine 
became the standard for the disease, whereas memantine, a non competitive NMDA antagonist, 
reached the market in 2007. 
Nowadays, is fully recognized that β-amyloid (Aβ) deposits in senile plaques represent the 
triggering event in the pathogenesis of AD whereas neurofibrillary tangles (NFT), consisting 
mainly of paired helical filaments of abnormally phosphorylated τ protein may be an important 
secondary event linked to neurodegeneration4 (Figure 1). These two pathological hallmarks 
strengthen the well-known “amyloid cascade hypothesis”. The seminal discovery that Aβ is a 
principal component of neuritic plaque has spurred intense search to investigate the molecular 
mechanism involved in Aβ secretion and neurotoxicity. Certainly, reducing the production of Aβ 
or increasing its clearance are attractive strategies for the treatment of AD. 5 In addition, several 
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lines of evidence support a concomitant role of oxidative stress, metal ion dishomeostasy and 
inflammation6 in AD. Consequently it is not trivial to state that these hypotheses are not 
mutually exclusive, rather, they complement each other, intersecting at a high level of 
complexity. 
 
 
Figure 1. Possible molecular causes of neuronal death and protective mechanisms in AD. The central event in 
AD pathogenesis is an imbalance between Aβ production and clearance.7 
 
According to amyloid cascade hypothesis, the main research involves decreasing Aβ 
production with β-secretase and γ-secretase inhibitors and α-secretase activators, preventing and 
reversing Aβ aggregation using metal ion modulators and antifibrillating agents, or promoting 
Aβ clearance and degradation through immunization. Among these therapeutic strategies, β-
secretase (beta-site amyloid precursor protein cleaving enzyme or BACE1) is recognized as one 
of the most promising targets for a disease-modifying treatment of AD controlling the onset and 
progression of AD. Thus, BACE1 inhibitors might reduce β-amyloid by treating the aetiology of 
pathology and not just the symptoms of the disorder.  
In view of the complexity of AD and the involvement of multiple and interconnected 
pathological pathways, a combination of therapeutic agents may result in a more effective 
strategy of treatment than monotheraphy. Besides the combination of known drugs, acting on 
Introduction 
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diverse imbalanced mechanisms, new therapeutic approaches are based on the development of 
multifunctional molecule able to inhibit BACE1 and interfere with other pathological event, in 
order to address this unmet medical need and to slow or perhaps even halt the course of the 
disease. 
 
1.1. Alzheimer’s disease (AD) 
 
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder clinically 
characterized by a global decline of cognitive function accompanied by behavioural impairment 
and decreasing ability to perform basic daily activities. The cognitive symptoms caused by 
gradual damage memory and inability to learn include memory loss, disorientation, incapacity to 
make judgments, reasoning and communicate with the social environment. Initially, short-term 
memory is affected, due to neuronal dysfunction and degeneration in the hippocampus and 
amygdala. As the disease progresses, neurons degenerate and die in other cortical regions of the 
brain leading to dramatic changes in personality and behaviour, such as anxiety, suspiciousness, 
depression or agitation, as well as delusions or hallucinations.8 Despite accurate 
neurophysiological tests, useful diagnostic tools for an early diagnosis of AD are still not 
available; however verbal memory, executive control, and associated learning are recognized as 
the first impaired functions in AD patients. Moreover, a decrease in attentional ability could 
appear in the early stages of the disease. Diagnosis of AD requires post-mortem examination of 
the brain, which must contain sufficient numbers of “plaques” and “tangles” to qualify as 
affected by AD.9 Indeed, the two major neuropathological hallmarks of AD are: (a) the 
deposition of extracellular neuritic Aβ plaques that reside in hippocampal and cerebral cortical 
regions, and (b) the intracellular NFT that occupy much of the cytoplasm of pyramidal 
neurons.10,11 These two proteins seem to be at the root of the pathogenesis of the disease.12 
Nevertheless, the neuronal death is the trigger event that accounts for the development of 
cognitive impairments. In particular, cholinergic neurons and synapses in the nucleus basalis, 
hippocampus and entorhinal cortex are lost and their projection to the cerebral cortex are marked 
with decreased level of acetylcholine (ACh) and its biosynthetic key enzyme, choline 
acetyltransferase (ChAT).13 The disease spreads from specific limbic regions to the 
hippocampus, neocortex (regions that are associated with higher mental function) and several 
ACh, serotonin (5-HT) and noradrenaline (NA) subcortical nuclei.14,15 Although loss of ACh-
Chapter 1 
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releasing neurones has been associated with diminished cognitive function, recent evidence 
indicates that neuronal loss is also linked to non-cognitive changes in behaviour.16 Other 
neurotransmitters systems such as dopamine (DA), histamine and neuropeptides are 
compromised in AD and undergo severe atrophy throughout the course of disease.17 
Glutamate excitotoxicity is also hypothesised to play a role in AD. Glutamate is the primary 
excitatory neurotransmitter in the brain and overstimulation of glutamate receptors can cause 
seizures and neurodegeneration. In particular, blocking the voltage dependent NMDA glutamate 
receptor allow blocking excessive stimulation at NMDA receptors. Based on these finding, a non 
competitive low-affinity NMDA receptor antagonist, memantine, is now available for the 
treatment of moderate to severe AD and is effective in patients with concomitant cholinesterase 
inhibitor use.18 
Inflammation, evidenced by the activation of microglia and astroglia, is another hallmark of 
AD and is an important source of oxidative stress in AD patients; particularly the induction of 
superoxide production (“oxidative burst”). The inflammatory process occurs mainly around the 
amyloid plaques and is characterized by pro-inflammatory substances released from activated 
microglia.19 Reactive oxygen species (ROS) are the most prominent molecules in the 
inflammatory process, along with prostaglandins, interleukin 1β (IL-1β), interleukin 6 (IL-6), 
macrophage-colony stimulating factor (M-CSF) and tumour necrosis factor (TNF)-α.20,21,22 In 
addition to morphological alterations, AD is associated also with a markedly impaired cerebral 
glucose metabolism.23 
 
1.1.1. The cholinergic deficit in AD 
 
In the 70s and 80s, it was discovered that ACh synthesis, ACh levels, and cholinergic 
receptors were greatly reduced in AD brain.24 Furthermore, the progressive neuronal cell loss in 
AD is associated with region-specific brain atrophy involving ACh system. These findings, 
combined with the known role of ACh in memory and attentional processing,25 led to the so-
called “cholinergic hypothesis”.26  
The origin of the cholinergic theory derives mainly from the effect produced by natural 
anticholinergic agents, such as atropine and scopolamine. Low doses of scopolamine could 
produce a pattern of cognitive disorders that generally paralleled those seen in elderly volunteers. 
A series of publications using non human primates strengthen the observation that the 
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scopolamine induced memory loss closely matched the consistent deficit that naturally occurs in 
aged monkeys.27,28 These findings led to the first demonstration that age related memory loss in 
aged monkeys could be pharmacologically reduced using the acetylcholinesterase enzyme 
(AChE) inhibitor, physostigmine.29 A large number of pharmacological studies have shown30 
that ACh receptor antagonists such as scopolamine reduce performance of animals in learning 
and memory tasks; these deficits can be reversed by AChE-inhibitors (AChEIs). The role of 
cholinergic neurons in the processes subserving learning and memory has been further validated 
by the post mortem neurochemical findings associated with AD pathology.17 
Loss of basal forebrain cholinergic neurons is demonstrated by the reduction in number of 
cholinergic markers, such as ChAT, AChE, and presynaptic M2 muscarinic and nicotinic 
receptors. These findings were almost simultaneously reported by three different 
laboratories31,32,33 and these cholinergic markers changes are highly correlated with the clinical 
degree of dementia observed in AD.34 Nowadays, there are supporting evidences showing that 
the cholinergic projection from the nucleus basalis of Meynert to areas of the cerebral cortex is 
affected early, and most severely, in brains from Alzheimer patients.35 Learning and memory 
deficits observed in patients with AD are, at least partially, caused by the dysfunction of basal 
forebrain cholinergic neurons in early stages of AD.  
Another metabolic step associated with cholinergic transmission is the robustly deficient 
activity in AD brain, namely that catalyzed by pyruvate dehydrogenase complex.36,37 This 
enzyme provides the acetyl coenzyme A, the final product of the glycolytic pathway, required 
for the synthesis of acetylcholine. Pyruvate derived from glycolytic metabolism serves as an 
important energy source in neurons.38 Therefore, the inhibition of pyruvate production, for 
example, by glucose depletion, is considered a crucial factor leading to acetyl-CoA deficits in 
AD brains.  
Based on the findings that (a) AD patients have reduced levels of the enzyme choline 
acetyltransferase and of the neurotransmitter ACh, compared to healthy elderly people and (b) 
ACh is hydrolyzed by AChE, AChEIs were the first drug class successfully introduced for the 
treatment of AD (Fig. 2). 
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Figure 2. Mechanism of action of ACh at a cholinergic synapse. ACh is released in the synaptic cleft where it 
activates both postsynaptic and presynaptic cholinergic receptors [nicotinic (N) and muscarinic (M)] leading to an 
increase of cholinergic transmission, which results in cognition improvement. ACh is removed from the synapse by 
the action of the enzyme AChE, which is the target of the available AChEIs for AD treatment.7 
 
Cognition Enhancer therapeutics 
The cholinergic hypothesis has provided the first rational framework for treatment strategies 
of cognitive dysfunction in AD, so it has led to the development of new medicines and numerous 
ACh-mimetics are under clinical development.26,39,40 Inhibiting AChE, is the most common 
approach. AChEIs were the first drug class successfully introduced for the treatment of 
Alzheimer's patients. In fact, in 1993, the AChEI tacrine, was the first drug to be approved for 
the treatment of AD, now rarely used because of its hepatotoxicity. Later, three other AChEIs, 
donepezil, rivastigmine, and galantamine reached the market, becoming the standard for AD 
therapy for their better profiles. To these AChEIs, recently, memantine, a non-competitive 
NMDA antagonist, was added for AD treatment (Fig. 3). 
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Figure 3. Chemical structures of the five drugs available for AD treatment (mechanism of action indicated in 
parentheses). 
 
In addition to AChE inhibition, rivastigmine inhibits butyrylcholinesterase (BChE), and 
galantamine allosterically modulates nicotinic receptors, although the importance of these 
additional activities is unknown.41 Although AChEIs are widely used, only 25-50% of patient 
respond to the therapy.42 Current work in the field is directed at identifying therapeutics that 
combine AChE inhibition with other mechanism.43 One example is phenserine, an AChEI that 
reduces Aβ in preclinical models.44 Huperzine A, derived from a Chinese herb, has 
neuroprotective activity in addition to AChE inhibition.45 Dimebon has several known activities 
in addition to AChE inhibition: histamine and NMDA antagonism and inhibition of 
mitochondrial permeability transition pores.46 
In addition to AChEIs, efforts to increase cholinergic neurotransmission using M1 agonists, M2 
antagonists, and nicotinic agonists have been investigated. Postsynaptic M1 receptors are spared 
in AD brain,24 while most M2 receptors are presynaptic autoreceptors that inhibit ACh release.47 
For these reasons M1 agonist and M2 antagonist are sought for AD. Although M1 agonist 
development began at the same time as AChEIs, no M1 agonists are approved for AD. The 
reason for the absence of successful M1 agonists for AD may be related to the lack of M1 
selectivity and resultant intolerable effects. Some M1 agonists such as NGX-267, P-58 and 
sabcomeline are under clinical trials. Among the second generation selective M1 agonists that 
have been recently developed, AF267B effectively reduced the two major hallmark 
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neuropathological lesions and rescued the cognitive deficits in a novel triple transgenic model of 
AD.48 On the other hand, M2 antagonist are currently under development.49 
Nicotinic agonists are also being developed as cognition enhancer based on the cholinergic 
hypothesis and epidemiologic data showing a reduced incidence of AD in smokers.50 Unlike M1 
receptors, both α4β7 and α7 nicotinic receptor subtypes, implicated in learning and memory 
processes, are decreased in AD.51 Nicotinic agonist and partial agonist acting at both nicotinic 
receptor subtypes improve performance in attention and working memory tasks.52 
Indirect means to enhance cholinergic and other neurotransmission are also being investigated 
for AD. Serotonin-6 (5-HT6) receptor antagonists enhance signalling of ACh, glutamate, 
aspartate, dopamine and GABA, probably via their effects on interneurons.53 
Definitely, according to the cholinergic hypothesis of AD, the use of cholinomimetic agents, 
able to compensate for ACh deficit should allow alleviation of the symptoms of the disease. 
Indeed, with the sole exception of memantine, the other four commercialized anti-Alzheimer 
drugs (tacrine, donepezil, rivastigmine, and galantamine) are AChEIs. One of the most 
commonly voiced objection against cholinergic hypothesis is the palliative nature of AChEIs 
based strategy. Despite reduction in ACh pathways has been shown in biopsies from patients 
within a year of onset of symptoms,54 it is not completely clear if the cholinergic deficit occurs 
early in the course of the disease or it is a consequence of other pathological events. It seems 
clear that the AChEIs capability to relieve symptoms of AD may depend on the integrity of the 
neuronal cholinergic system and, in severe cases, there may be an insufficient ACh release to 
allow AChEIs to be effective.  
Moreover, significant variability existed in the response to the AChEIs treatment, with some 
subjects apparently unresponsive at any dose tested. While the ultimate goal for AD treatment 
would obviously involve the pathogenesis and aetiology of the disease, clinical use of AChEIs 
have shown a temporary stabilization of cognitive impairment and delaying in the need for 
patients’ placement in nursing homes by several months. Despite the controversial debate upon 
the cholinergic hypothesis and the development of several new approaches to the treatment of 
AD not related to the modulation of cholinergic activity, this theory is far from being considerate 
merely an historical approach. Some investigators have recently reported an apparent retardation 
of the progression of the neurodegeneration process in patients treated with AChEIs. 
Furthermore, the finding that non classical modulation of AChE activity can interfere with the 
accumulation and precipitation of Aβ, hence, downstream, with the deposition of senile plaques, 
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could afford a rational link between the two more important strategies of AD cure.55 Preclinical 
studies identified unexpected mechanisms of action of the anticholinesterasic drugs, underlying 
that they may tackle alterations in Aβ precursor protein (APP) processing in in vitro and ex vivo 
systems. Specifically, convincing results substantiate a consistent relationship between 
cholinergic activation and changes in APP metabolism (see following section 1.1.2). In parallel, 
the recent discovery of the so-called “non-classical function”56 of AChE has renewed interest in 
the search for novel AChEIs, expanding their potential as real disease-modifying agents.57,58,59 In 
particular, it has been reported that AChE might act as a “pathological chaperone” in inducing 
Aβ aggregation through the direct interaction of its peripheral anionic site (PAS) with fibrils of 
the peptide.60 This has led scientists to reconsider this enzyme as a target that mediates two 
important effects in the neurotoxic cascade, that is, Aβ fibrils formation and ACh breakdown. 
The neuroprotective effects exhibited by some currently commercialized AChEIs not only due 
to the mere cholinomimetic mechanisms confirm that cholinergic hypothesis could still represent 
a rationale for promising disease-modifying anti-Alzheimer drug candidates and not only for 
palliative treatment of AD. 
 
1.1.2. The “amyloid cascade hypothesis” 
 
The amyloid cascade hypothesis, proposed more than 25 years ago,61,62 postulates that the 
initiating molecule in AD is Aβ, ultimately leading to neuronal degeneration and dementia. The 
hypothesis, strengthened by pathological evidences, claims that amyloid-β42 (Aβ42) plays an 
early and crucial role in all cases of AD. Aβ42 forms aggregates that are thought to initiate a 
pathogenic cascade.5 In fact, the overproduction of Aβ peptide, or failure to clear this peptide, 
leads to AD primarily through Aβ deposition, which is presumed to be involved in 
neurofibrillary tangle formation, therefore tau aggregation may be an important secondary event 
related to neurodegeneration.  
Extracellular amyloid plaques, consisting predominantly of Aβ42, and intraneuronal 
neurofibrillary tangles, consisting of an aggregated form of the neuronal protein tau, are the two 
pathological hallmarks of AD. These resulting lesions are then associated with cell death, which 
is reflected in memory impairment and, at the end, to dementia, as shown in figure 4. 
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Figure 4. The sequence of pathogenic events that are thought to lead to AD.63 
 
Genetic analysis of the rare familial autosomal dominant AD with early onset has led to the 
identification of three genes (i.e. those encoding APP, presenilin1 and presenilin2) that, when 
mutated, lead to the development of AD.64 The great majority of these mutations increases Aβ42 
production, which is therefore assumed to play a causal role in disease pathogenesis.65,66 By 
contrast, the cause of sporadic late-onset AD remains unknown. Based on the similarities in the 
pathology and clinical presentation of familial early and sporadic late-onset AD, it is widely 
accepted that Aβ42 also plays a crucial role in sporadic AD. Although Aβ42 overproduction 
does not appear to be the primary event in disease pathogenesis, accumulation of Aβ42 in the 
central nervous system (CNS) can be attributed to enhanced aggregation of Aβ42, decreased 
clearance of Aβ42 or other factors. 
Aβ is generated proteolytically from a large transmembrane protein amyloid precursor protein 
(APP) by sequential action of two proteases, β-secretase and γ-secretase (Fig. 5).  
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Figure 5. Schematic representation of APP and its metabolites, relevant to AD.67 
 
The first cleavage of APP is carried out by β-secretase (also called β-site APP cleaving 
enzyme or BACE)68,69 releasing a large soluble fragment (β-sAPP). The carboxyterminal 
fragment C99 peptide is then cleaved by γ-secretase complex at several positions, leading to the 
formation of Aβ40 and the pathogenic Aβ42. Alternatively, cleavage of the protein by α-
secretase allows for the release of a large fragment, α-APPs, which is not amyloidogenic. The C-
terminal C83 peptide is metabolized to p3 by γ-secretase. After Aβ formation from APP 
cleavage, the monomers deposit and aggregate (or aggregate and deposit) in extracellular 
insoluble plaques, whereas soluble Aβ is thought to undergo a conformational change to high β-
sheet content, which renders it prone to aggregate into soluble oligomers and larger insoluble 
fibrils in plaques. In this process, the fibrillogenic Aβ42 isoform triggers the misfolding of other 
Aβ species. Currently, the nature of the neurotoxic Aβ species is very difficult to define because 
monomers, soluble oligomers, insoluble oligomers, and insoluble amyloid fibrils are expected to 
accumulate and exist in dynamic equilibrium in the brain. Initially, only Aβ deposited in plaques 
was assumed to be neurotoxic, but more recent findings suggest that soluble oligomers might be 
the central players. Afterward, Aβ may exert its neurotoxic effects in a variety of ways, including 
disruption of mitochondrial function via binding of the Aβ-binding alcohol dehydrogenase 
protein,70 induction of apoptotic genes through inhibition of Wnt44 and insulin signalling,71 
formation of ion channels,72 stimulation of the stress-activated protein kinases (SAPK) 
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pathway73 or activation of microglia cells leading to the expression of pro-inflammatory genes, 
an increase in reactive oxygen species (ROS), and eventual neuronal toxicity and death.74 
Recently, it has become clear that, in addition to forming extracellular aggregates, Aβ (or its 
precursor APP) has complicated intracellular effects involving a variety of subcellular 
organelles, including mitochondria. Soluble Aβ localizes to mitochondria and interferes with 
their normal functioning, causing overproduction of ROS, inhibiting respiration and ATP 
production and damaging the structure of mitochondria.75 These data offer a potential 
explanation for the well-established observation that mitochondrial function and energy 
metabolism are perturbed early in AD.76 
 
1.1.2.1. β-Amyloid-based therapeutics 
The amyloid cascade hypothesis spurred an intense search to address the overwhelming issue 
of the overproduction and aggregation of neurotoxic form of Aβ. The attention of research 
community was focussed on the enzymes responsible for liberating the Aβ42 residue segment of 
APP and on the physical and immunological mechanisms that inhibit aggregation. As a matter of 
fact, amyloid-based therapeutics include α-secretase stimulators, BACE1 inhibitors, γ-secretase 
inhibitors and modulators, aggregation blockers, catabolism inducers and anti-Aβ biologics (Fig. 
6).  
 
 
Figure 6. The formation of Aβ by cleavage of APP and its conversion to Aβ oligomers and amyloid plaques is 
shown. Potential therapeutic approaches to decrease Aβ toxicity are indicated in the shaded boxes.77 
 
Firstly, the APP processing pathway outlines immediately three putative strategies to reduce 
Aβ generation, actively pursued for more than a decade: inhibition of β and γ-secretase and 
stimulation of α-secretase. In order to synthesize selective and potent modulators of these 
proteases, research has focused its attention on the structural and functional features of these 
enzymes.  
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α-Secretase stimulation 
α-Secretase pathway stimulation might lead to a reduction of the APP substrates available for 
Aβ formation, activating non-amyloidogenic sAPPα. Moreover, α-secretase is stimulated also 
by AChEIs via selective muscarinic activation inducing the translation of APP mRNA with the 
final goal of restricting amyloid fibre assembly. Three members of the ADAM family (“a 
disintegrin and metalloproteinase”) ADAM-10, ADAM-17 and ADAM-9 have been proposed as 
α-secretases. To date, it is accepted that each of these enzymes acts as a physiologically relevant 
α-secretase. Genetic studies revealed that ADAM-10 is a key protein involved in neurogenesis 
and axonal extension.78,79 This underlines the positive, neuroprotective role of ADAM-10 and 
thus of α-secretase like cleavage activity in the metabolic processing of APP.  
In addition to ADAMs, perhaps other membrane-associated metalloproteinases contribute to 
the shedding of APP. Stimulation of α-secretase activities can be achieved via several signalling 
cascades including phospholipase C, phosphatidylinositol 3-kinase and serine/threonine-specific 
kinases such as protein kinases C, and mitogen activated protein kinases. Direct activation of 
protein kinase C and stimulation of distinct G protein-coupled receptors are known to increase α-
secretase processing of APP. Agonists for M1 muscarinic receptors and serotonin 5-HT4 
receptors are currently in clinical trials to test their efficiency in the treatment of AD.80,81 
 
β-Secretase inhibition 
β-Secretase, also called BACE1 is a membrane bound aspartic protease specifically abundant 
in brain, which forms, together with its homologue BACE2, a new branch of the pepsin family68 
(for details, see following section 1.2). The enzyme catalyzes the cleavage of APP to produce N-
terminus of Aβ peptides. The data suggesting BACE1 is the enzyme relevant to AD-related APP 
processing are strong, and have recently been reviewed along with other aspect of BACE 
biology.82 Inhibition of BACE holds promise for the production of safe anti-amyloid therapy, as 
transgenic mice lacking the BACE gene produce little or no Aβ, and do not display any robust 
negative phenotype.67,83 
For these reasons β-secretase appears to be an excellent drug target, even if the absence of 
toxicity in mice does not prove absence of human toxicity. Although the biology of BACE1 
inhibition seems to be a promising line in inquiry, inhibitors development is proving to be 
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challenging.84 Research regarding BACE1 inhibitors has been strengthened by the large amount 
of information available on other aspartic protease, in particular on the highly investigated HIV-
1 protease. Furthermore, the crystal structure of BACE1 active domain bound to a 
peptidomimetic inhibitor has been reported, opening new possibility of rational drug design85 
(for details, see following section 1.3). 
 
γ-Secretase inhibition and modulation 
γ-Secretase is responsible for the final cut of the APP to produce the Aβ peptide implicated in 
the pathogenesis of AD. Thus, this protease is a top target for the development of AD 
therapeutics. γ-Secretase is a complex of four different integral membrane proteins, with the 
multi-pass presenilin being the catalytic component of a novel intramembrane-cleaving aspartyl 
protease. A number of inhibitors of the γ-secretase complex have been identified, including 
peptidomimetics that block the active site, helical peptides that interact with the initial substrate 
docking site, and other, less peptidomimetic, more drug-like compounds. To date, one 
peptidomimetic γ-secretase inhibitor (DAPT) has advanced into late-phase clinical trials for the 
treatment of AD, but serious concerns remain. γ-Secretase cleaves other substrates besides APP, 
the most notorious being the Notch receptor that is required for many cell differentiation 
events.86 Because proteolysis of Notch by γ-secretase is essential for Notch signalling, 
interference with this process by γ-secretase inhibitors can cause severe toxicities. γ-Secretase 
inhibitors may cause abnormalities in the gastrointestinal tract, thymus and spleen in rodents.87 
Thus, the potential of γ-secretase as therapeutic target likely depends on the ability to selectively 
inhibit Aβ production without hindering Notch proteolysis. The discovery of compounds capable 
of such allosteric modulation of the protease activity has revived γ-secretase as an attractive 
target. Structural modification of these γ-secretase modulators has allowed to discover and 
advance one compound in late-phase clinical trials, renewing interest in γ-secretase as a 
therapeutic target.88,89 Small molecules that shift Aβ42 to shorter Aβ species, were discovered 
while investigating the mechanism for the reduced prevalence of AD among users of non-
steroidal anti-inflammatory drugs (NSAIDs).90 Subsequent studies have shown that certain 
NSAIDs modulate Aβ synthesis due to binding to γ-secretase.91 Despite this mechanism, Aβ do 
not cause Notch toxicities.92 The most advanced γ-secretase modulator, R-flurbiprofen, is in 
phase III clinical trials.93 Unlike S-flurbiprofen, R-flurbiprofen does not inhibit cyclooxigenase 
and, consequently, does not cause the gastrointestinal side effects due to cyclooxigenase 
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inhibition. 
 
Aβ-aggregation inhibitors and Aβ-degradation stimulators 
The biosynthesis of Aβ and secretases activity are modulated by several other factors, which 
could be considered as potential target candidates in AD treatment. Several Aβ aggregation 
inhibitors have been discovered. The compound 3-amino-1-propanesulfonic acid (3APS) was 
identified based on the observation that glycosaminoglycans stimulate Aβ aggregation. 3APS 
binds monomeric Aβ, decreases Aβ deposition in transgenic mice,94 and reduces cerebrospinal 
fluid Aβ in human.95 
An essential role for metals in Aβ aggregation96 led to the discovery of small molecule 
chelator that perturbs Aβ-metal binding. The antibiotic clioquinol partially dissolves plaques in 
vitro and prevented plaque deposition in transgenic mice, whereas a second generation chelating 
agent (PBT2) is in phase II.97 Scyllo-inositol binds an Aβ oligomer to inhibit further aggregation 
and toxicity,98 and reduces plaque deposition and cognitive deficits in transgenic mouse model.99 
One potential issue for aggregation inhibitors is a shift in the equilibrium between less toxic 
aggregated forms to more toxic soluble intermediates, such as protofibrils.100 
Method to stimulate Aβ degradation are an additional approach to decrease Aβ 
oligomers.101,102 For example somatostatin103 and plasminogen activator inhibitor-1 (PAI-1) can 
indirectly increase neprilysin and plasmin activity, respectively, which leads to increased 
degradation of Aβ. 
 
Anti-amyloid immunotherapy 
Anti-amyloid immunotherapy for AD has received considerable attention after Elan 
Corporation’s publication,104 which reported that amyloid pathology was reduced in APP 
transgenic mouse model after vaccination with aggregated Aβ42. First described in 1999, 
immunotherapy uses anti-Aβ antibodies to lower brain amyloid levels. Active immunization, in 
which Aβ is combined with an adjuvant to stimulate an immune response producing antibodies 
and passive immunization, in which antibodies are directly injected, were shown to lower brain 
amyloid levels and improve cognition in multiple transgenic mouse models. Mechanisms of 
action were studied in these mice and revealed a complex set of mechanisms that depended on 
the type of antibody used. When active immunization advanced to clinical trials a subset of 
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patients developed meningoencephalitis; an event not predicted in mouse studies. However, it 
was suspected that a T-cell response due to the type of adjuvant used was the cause of the 
meningoencephalitis and studies in mice indicated alternative methods of vaccination. Passive 
immunization has also advanced to phase III clinical trials on the basis of successful transgenic 
mouse studies. Reports from the active immunization clinical trial indicated that, indeed, 
amyloid levels in brain were reduced.105 The performance of anti-Aβ antibodies in transgenic 
mouse models of AD showed they are delivered to the CNS, clearing Aβ plaques and protecting 
the mice from learning and age-related memory deficits.  
As immunotherapy is at the crossroads of immunology and the nervous system, a deeper 
understanding of the Aβ peptide clearance mechanism may lead to an optimized therapeutic 
approach to the treatment of AD. Antibodies generated with the first-generation vaccine might 
not have the desired therapeutic properties to target the "correct" mechanism, however, new 
immunological approaches are now under consideration.106 
 
Hyperphosphorylated tau protein and tau-based therapeutics 
Neurofibrillary tangles (NFT) in AD brain consist of paired helical filaments of 
hyperphosphorylated, conformationally altered tau (τ) proteins. Tau binds and stabilizes 
microtubules, while hyperphosphorylated τ from AD brain disrupt microtubule structure.107 The 
presence of NFT in AD and their correlation with cognitive status suggest an important role in 
dementia.108 Phosphorylation within the microtubule binding domain of τ protein results in its 
reduced ability to stabilize microtubules assembly, leading to the disruption of neuronal transport 
and eventually to faster synaptic loss and cell death. Dephosphorylation of τ protein isolated 
from NFT restores its ability to bind with neuronal microtubules, indicating that the mechanisms 
regulating phosphorylation/dephosphorylation kinetics are perturbed in AD. Reducing τ 
phosphorylation via inhibition of kinases is a major therapeutic strategy based on the presence of 
hyperphosphorylated τ in the brain. 
The nature of protein kinases, phosphatases, and τ sites involved in this lesion has recently 
been elucidated, suggesting that activation of phosphoseryl/phosphothreonyl protein 
phosphatase-2A (PP-2A) or inhibition of both glycogen synthase kinase-3β (GSK3β) and cyclin-
dependent protein kinase 5 (cdk5) might be required to inhibit AD neurofibrillary 
degeneration.109 In particular, recent data also suggest that GSK3β inhibition plays a significant 
role in synaptic plasticity, which may be involved in learning and memory. GSK3β inhibition 
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suppresses long term depression and consolidated long-term potentiation.110,111 Many small 
molecules acting as GSK3β inhibitors have been designed and one of those inhibitors, developed 
by Neuropharma, is in phase I clinical trials for AD.112,113,114 
Reduction in τ levels and increased catabolism of abnormal forms of τ are also therapeutic 
strategies for AD. Heat shock protein 90 (Hsp90) inhibitors were identified in a cellular screens 
for small molecule that decreases total τ levels.115 The Hsp90 inhibitors PU-DZ8 and EC102 
reduce phospho-τ but not total τ, in two tauopathy models.116,117 A useful therapeutic window for 
Hsp90 inhibitors in AD may be possible because EC102 binds higher affinity to AD brain tissue 
from affected areas.118 
Furthermore, the discovery that NFTs in AD brain are made up of the microtubule (MT)-
associated protein τ and the evidence that the toxic amyloid peptides in AD can lead to τ hyper-
phosphorylation and cytoskeletal dystrophy support the assertion that disruption of the MT 
network is an early signalling event in neurodegenerative cascades. Therefore, drugs that can 
moderate such signals through interactions with MTs would protect neurons against Aβ toxicity. 
Drugs targeted to MTs are currently used as anti-cancer agents, due to their blockade of cell 
proliferation and induction of cell death. However, it is accepted that low concentrations of 
compounds that help to stabilize MTs, do indeed protect post-mitotic neurons challenged with 
various toxic stimuli. Therefore cytoskeletal network actually serves as a sensor for the overall 
state of the neurons and a first-line transducer of stress signals. Drugs that can moderate 
initiation of such early signalling events do protect against disruption of the cytoskeleton and 
neuritic dystrophy in neuronal cell cultures. Moreover, microtubule stabilizing agents protect 
cultured neuron from Aβ42, chloroquine, and glutamate induced toxicity.119,120,121 Paclitaxel 
reverse deficit in fast axonal transport, increased microtubule numbers, and improved motor 
deficits in transgenic mice with tauopathy in the spinal cord.122 These observations suggest that 
drugs able to protect the integrity of the cytoskeletal network can have significant and novel 
effects on signalling events in specific cellular contexts.123 
 
1.1.3. Oxidative stress in AD 
 
Oxidative stress, perturbed calcium regulation and mitochondrial impairment are major 
alterations involved in functional and structural abnormalities in synapses and axons in AD. 
Oxidative damage is present within the brain of AD patients and is observed within every class 
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of biological macromolecules. Oxidative injury may develop secondary to excessive oxidative 
stress resulting from Aβ-induced free radicals, mitochondrial abnormalities, inadequate energy 
supply, inflammation, or altered antioxidant defences. Oxidative stress is thought to have a 
causative role in the pathogenesis of AD.124 Support for this hypothesis has also been provided 
by the current notion that, while AD is probably associated with multiple aetiologies and 
pathogenic phenomena, all these mechanisms seem to share oxidative stress as a unifying factor. 
Oxidative stress occurs when the oxidative balance is disturbed, that is, excessive production 
of ROS to cellular antioxidant defences. The brain is particularly vulnerable to oxidative stress 
because it is rich in unsaturated fatty acids, moreover it is a highly oxidative organ consuming 
20% of the body's oxygen despite accounting for only 2% of the total body weight. With normal 
ageing the brain accumulates metals ions such iron (Fe), zinc (Zn) and copper (Cu). 
Consequently the brain is abundant in antioxidants to control and prevent the detrimental 
formation of ROS generated via Fenton chemistry involving redox active metal ion reduction 
and activation of molecular oxygen.125 
The early involvement of oxidative stress in AD is demonstrated by oxidative modifications of 
lipids,126,127 proteins,128 and nucleic acids129 in brains from AD patients, and also in cellular and 
animal models of AD. Oxidative stress-modified molecules are detected not only in extracellular 
plaques, but also within cells. For example, elevated concentration of 4-hydroxynonenal (4-
HNE), a marker of lipid peroxidation, is found in Aβ.130 Oxidized RNA nucleoside 8-
hydroxyguanosine is significantly increased in neurons from the frontal cortex of familial AD 
with a mutation in presenilin-1 (PS-1) or APP gene.129 Moreover, the activity of a mitochondrial 
enzyme α-ketoglutarate dehydrogenase (KGDH) complex is reduced in brains of AD patients. 
KGDH complex is sensitive to various oxidants whether they are added to cells or generated 
internally in cells.131 
Together, these data support oxidative stress serving as an early event that leads to the 
development of cognitive disturbances and pathologic features observed in AD. The origin of 
these ROS is also critical to understanding how they might alter gene transcription. There are 
several major sites of ROS production in the cells, including mitochondria. The major source of 
radicals during unstressed conditions is not clear, but during pathologic conditions, mitochondria 
seem to be a major source and they represent the primary target of ROS. 
Among the pathways acting in generating ROS, the major role has played by the metal ions 
via activation of molecular oxygen. Besides this function in oxidative stress, copper, together 
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with other metal ions, influences the protein aggregation processes that are critical in most 
neurodegenerative diseases. For example, APP and Aβ are able to bind and reduce copper, which 
forms a high-affinity complex with Aβ, promoting its aggregation, and Aβ neurotoxicity 
depends on catalytically generated H2O2 by Aβ-copper complexes in vitro. Moreover, lipid 
peroxidation induced by Aβ, impairs the function of ion-motive ATPases, glucose and glutamate 
transporters, and also GTP-binding proteins as the result of covalent modification of the proteins 
by the 4-HNE. By disturbing cellular ion homeostasis and energy metabolism, relatively low 
levels of membrane-associated oxidative stress can render neurons vulnerable to excitotoxicity 
and apoptosis. The dysfunction and degeneration of synapses in AD may involve Aβ-induced 
oxidative stress, because exposure of synapses to Aβ impairs the function of membrane ion and 
glutamate transporters and compromises mitochondrial function by an oxidative-stress-mediated 
mechanism (Fig. 7). 
Oxidative modifications of τ by 4-HNE and other ROS can promote its aggregation and may 
thereby induce the formation of NFT. Aβ can also cause mitochondrial oxidative stress and 
dysregulation of Ca2+ homeostasis, resulting in impairment of the electron transport chain, 
increased production of superoxide anion radical and decreased production of ATP. Superoxide 
is converted to H2O2 by the activity of superoxide dismutases (SOD) and superoxide can also 
interact with nitric oxide (NO) via nitric oxide synthase (NOS) to produce peroxynitrite 
(ONOO⋅). Interaction of H2O2 with Fe2+ or Cu+ generates the hydroxyl radical (OH⋅), a highly 
reactive oxyradical and potent inducer of membrane-associated oxidative stress that contributes 
to the dysfunction of the endoplasmic reticulum. 132 
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Figure 7.The neurotoxic action of Aβ involves generation of ROS and disruption of cellular calcium 
homeostasis.132 
  
Therefore, therapeutic strategies preventing oxidative damage and stimulating mitochondria 
are currently pursued.133 The use of the peroxisome proliferator-activated receptor-γ (PPARγ) 
agonist rosiglitazone, an anti-diabetic drug, now in phase III clinical trials, is one potential 
method to stimulate mitochondrial metabolism.134,135 The metal ions accumulated in the amyloid 
deposits of AD brains could be partially disassembled by metal chelators.136 Some of them, such 
as clioquinol and desferrioxamine have had some success in altering the progression of AD 
symptoms.  
Potential antioxidants include mitoquinone,97 vitamin E, and natural polyphenols, such as 
extracts from Ginkgo biloba, green tea, wine, blueberries, and curcumin (phase II).137 
Nevertheless, clinical trials with vitamin E, Ginkgo biloba extract, and omega-3 fatty acids have 
not shown strong beneficial effects in AD patients.138,139,140 Since several antioxidant agents may 
be required for significant benefits for AD,137 clinical trials are in progress using a combination 
of vitamin E, vitamin C, α-lipoic acid, and coenzyme Q.141  
In particular, α-lipoic acid (LA) is a naturally occurring precursor of an essential cofactor for 
mitochondrial enzymes, including pyruvate dehydrogenase (PDH) and KGDH. LA has been 
shown to have a variety of properties which can interfere with pathogenic principles of AD.38 LA 
showed relevant antioxidant activities: LA chelates redox-active transition metals, thus inhibiting 
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the formation of hydroxyl radicals and also scavenges ROS, thereby increasing the levels of 
reduced glutathione. Via the same mechanisms, down-regulation redox-sensitive inflammatory 
processes is also achieved. Furthermore, LA can scavenge lipid peroxidation products such as 4-
HNE and acrolein. Besides these antioxidant, carbonyl scavenging and metal chelating activities, 
LA increases ACh production by activation of ChAT and increases glucose uptake, thus 
supplying more acetyl-CoA for the production of ACh. The reduced form of LA, dihydrolipoic 
acid (DHLA), is the active compound responsible for most of these beneficial effects. (R)-α-LA 
can be applied instead of DHLA, as it is reduced by mitochondrial lipoamide dehydrogenase, a 
part of the PDH complex. These multiple properties make LA suitable to be a promising tool in 
slowing AD progression. 
 
1.1.4. Neuroinflammation 
 
Neuroinflammation of CNS cells has been recognized as an invariable feature of all 
neurodegenerative disorders. In AD, among CNS cells, microglia have received special interest. 
Microglia are activated by Aβ to produce cytokines, chemokines, and neurotoxins that are 
potentially toxic and therefore may contribute to neuronal degeneration. However, recent 
findings suggest that microglia may play a neuroprotective role in AD. This highlights the 
potential risk of using the inhibition of monocyte/macrophage recruitment as a therapeutic 
strategy and argues for caution in the pursuit of this approach.142 
In this field, a cytokine modulator, VP-025 is developed and is now entering phase II clinical 
trials for AD.97 Rosiglitazone may have also anti-inflammatory effects and Aβ reducing 
properties.143 The lipid-lowering statins may also have some anti-inflammatory effects, and 
initial clinical results with atorvastatin have been promising.144 
Another approach involves stimulation of the neuronal cannabinoid receptor-1 (CB-1), which 
shows activity of neuroinflammation.145 In contrast, some data suggests that stimulation of the 
inflammatory response may be beneficial in AD.146,147 Although most inflammation in AD is 
usually associated with Aβ due to the localization of activated astrocytes and microglia with 
plaques, inflammation may also play a role in tau-mediated aspects of the disease. A role for tau-
mediated inflammation is suggested by recent work using an aggressive tauopathy model where 
inflammatory markers in microglia and neurons are increased prior to the development of 
tangles.148 
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Interestingly, modulation of inflammation is nowadays one of the most dynamic areas in the 
search for new therapeutic targets for AD and related neurodegenerative disorders.149 
 
1.2. β-Secretase (BACE1) 
 
Nowadays, β-Secretase (BACE1) is universally recognized as the first protease that processes 
APP in the pathway leading to the production of Aβ. This hypothesis has been carefully 
confirmed by scientific community during the last decade. Actually, from the initial discovery 
that Aβ was a normal proteolytic product of APP, it was supposed that two enzymes must exist 
to cleave small products (1-40/42 peptides) from its larger single transmembrane precursor 
protein. The unknown enzyme cleaving APP at the beginning of Aβ, prior to aminoacid 1, was 
called β-secretase. In 1992, the discovery that patients affected by a rare autosomal dominant 
forms of AD, show a Swedish APP (APPSWE) double mutation, located at -2 and -1 (Lys670 → 
Asn/Met671 → Leu) of the β-secretase site,150 drew attention to the possibility that this mutation 
could cause AD. Therefore, it was supposed APPSWE would have been more favourable to β-
secretase cleavage. This was strengthened in studies showing that APPSWE significantly 
enhanced the proteolytic activity of β-secretase causing a 10 fold increase in Aβ production.151 
Following an intensive search to identify β-secretase, an aspartic protease fitting all the 
requirements for β-secretase was identified in 1999 and 2000 by several groups.68,152,153,154,155 
This protease was named memapsin-2, and Asp-2 and is now more commonly referred to as 
BACE1 (β-site APP cleaving enzyme 1). Soon after the discovery of BACE1, a homologue was 
described and identified.156 The gene identified was named memapsin-1 and is also referred to as 
Asp-1, ALP-56, CDA-13, DRAP (Down’s region aspartic protease), but is now more commonly 
called BACE2. Both BACE1 and BACE2 can process APP at the β-site, but BACE2 has a 
preference to cleave between aminoacids 19 and 20 of the Aβ sequence, thus precluding Aβ 
formation. A number of studies provide strong evidence that BACE1 is the major β-secretase 
responsible for Aβ generation in the brain. Thus BACE1 cleaves at the β and also the β’ site 
(between aminoacid 10 and 11 of Aβ) of APP and has a higher preference to cleave 
APPSWE.68,152,153,154 BACE1 mRNA has highest expression levels in the mammalian brain,157 and 
is found in organelles of the secretory pathway displaying optimal activity at pH = 4.5,158 which 
is consistent with its detection in acidic organelles of the endosomes and trans-Golgi network 
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where Aβ is predominantly generated.151,159,160 The most interesting discovery was to assess that 
targeted deletion of BACE1 in APP transgenic mice completely abolishes the production and 
deposition of Aβ.83,161,162 
BACE1 and BACE2 are the newest described members of the A1 aspartic protease family, 
commonly known as the pepsin family. Human aspartic proteases of this family include pepsin, 
cathepsin-E, cathepsin-D, renin, pepsinogen-C and napsin. The BACE proteins represent a novel 
subgroup of this family, being the first reported aspartic proteases to contain a transmembrane 
domain and carboxyl terminal extension,157 and also possessing unique disulphide bridge 
distribution.163,164 The eight known functional human A1 aspartic proteases vary in genomic 
structure. 
Main features of A1 aspartic proteases are their bilobar structure, with an essential catalytic 
Asp dyad located at the interface of the homologous N- and C-terminal lobes, with maximal 
enzyme activity occurring in an acidic environment. These Asp residues activate water 
molecules to mediate nucleophilic attack on the substrate peptide bond,165 and mutation of the 
catalytic active site aspartic residues abolishes enzyme activity. For BACE1 the Asp dyad 
locates at aminoacids, 93-96 (D*TGS) and 289-292 (D*SGT). A1 aspartic proteases are usually 
synthesised as inactive pre-pro-enzymes (zymogens), where pro-domain removal is necessary for 
enzymatic activity. However, this is not the case for BACE1, which possesses enzymatic 
activity.166 BACE1 is synthesised with a pro-sequence that is rapidly removed during transit 
through the Golgi167 by the action of a furin-like convertase.168 BACE1 is highly glycosylated,169 
and its carbohydrate chains may favour interaction with its substrate or with glycoproteins that 
help regulate its activity. 
All A1-aspartic proteases have six conserved Cys residues which form three disulphide 
bridges. BACE1 disulphide bridges maintain correct folding and orientation of BACE, but are 
not vital to its enzymatic activity.163,164 In addition, the unique transmembrane regions of BACE1 
and BACE2 confer an evolutionary specialisation, allowing their sequestration to membranes of 
specific organelles and the plasma membrane. This serves to expose their catalytic lobes to the 
lumenal regions of vesicles such as endosomes or Golgi where the low pH environment sustains 
their optimal protease activity, while their C-termini are exposed to the cytoplasm, enabling post-
translational modification and protein-protein interaction. 
Although very short, the cytoplasmic domain of BACE1 plays an important role in orienting 
BACE1 cellular trafficking and compartmentalization. BACE1 resides in the trans-Golgi 
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network (TGN) and its endosomes, the main cellular sites of APP processing and Aβ 
production.170  
 
 
Figure 8. Intracellular trafficking of the BACE1 protein. 171 See text for discussion. 
 
As depicting in figure 8, after synthesis, BACE1 resides in the endoplasmic reticulum (1) and 
is transported to the TGN (2). From this compartment, BACE1 is transported to the plasma 
membrane (PM) (3) where a small proportion can undergo ectodomain compartment (EC) (5) 
where the acidic environment provides the optimal condition for the proteolysis of APP. From 
the endocytic compartments BACE1 can be recycled to directly back to the cell surface (6a), 
transit to lysosomes for degradation (6b) or retrogradely to the TGN (6c) from where it can be 
trafficked back to the PM (7). It is also possible that BACE1 can be transported directly from the 
TGN to endocytic compartments (8). 
Insight into the three-dimensional structure of BACE1 is vital to understanding how the 
enzyme works catalytically, and in developing inhibitors which block BACE1 activity as a 
therapy for AD. X-Ray crystallography of BACE1 has determined numerous structures of 
BACE1 complexes, and residues and regions that are important for substrate specificity and 
proteolysis.85,172,173,174,175,176 To date, there are over 70 known structures of BACE1 in complex 
with inhibitor, seven without inhibitor and one of BACE2 in the protein data bank.177 The 
number of crystal structures of BACE1 is an evidence to the variety of compounds being tested 
as β-secretase drug candidates (for review see following section 1.3.). The X-ray structure of 
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BACE1 protease domain was first determined to 1.9Å resolution, with BACE1 bound to an eight 
residue transition state analogue inhibitor OM99-2 (Fig. 9).85  
 
 
Figure 9. A ribbon model of the crystal structure of BACE1 complexed to inhibitor OM99-2. The N-lobe and C-
lobe are blue and yellow, respectively, except the insertion loops, designated A to G in the C-lobe are magenta and 
the COOH-terminal extension is green. The inhibitor bound between the lobes is shown in red.85 
 
OM99-2 (I) is a P4-P4’ peptide (P4-P3-P2-P1*-P1’-P2’-P3’-P4’) based on the aminoacid 
composition of APPSWE (Glu-Val-Asn-Leu*Ala-Ala-Glu-Phe) but incorporating a non-cleavable 
hydroxyethylene isostere (*) at P1 and P1’, blocking normal proteolytic BACE1 cleavage 
between the P1 and P1’ scissile bond (Fig. 10). 
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Figure 10. Chemical structure of BACE1 inhibitor OM99-2 with the constituent aminoacids and their subsite 
designations. The hydroxyethylene transition-state isostere is between P1 and P1'. 
 
Further enzyme subsites were identified for BACE1 with enzyme bound to other eight 
residue175 and longer transition state inhibitors,176 and the crystal structure of free BACE1 has 
been studied.172,174 These crystal structure studies show BACE1 has strong conservation with A1 
aspartic proteases, for which pepsin is prototypic, and also more recently with BACE2.178 
Ribbon diagrams of the 3D structure described for BACE1, BACE2 and pepsin, describing their 
major structural features, are shown in figure 11. 
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Figure 11. Structural features of BACE1 compared to pepsin and BACE2. The shown cartoon illustrations 
underneath the ribbon structures represent the surface structures of each protein and a possible orientation of 
BACE1 and BACE2 to the membrane. The N-terminal lobes of pepsin, BACE1 and BACE2 are coloured gold, 
magenta and blue, respectively, and the C-terminal catalytic lobes are coloured dark blue, dark grey and silver, 
respectively. The flap regions of pepsin, BACE1 and BACE2 are shown in their respective colours of purple, green 
and beige. The third-strands in BACE1 and BACE2 are shown adjacent to the flaps and coloured orange and beige, 
respectively. The active site aspartates of each enzyme are coloured in red space fill. The BACE1 and BACE2 
insertion loops are indicated with arrow heads and the BACE1 insertion helix is highlighted with a hatched circle. 
The dashed line in BACE2 represents a disordered region in the BACE2 crystal structure.171  
 
Regions of commonality include: the conformation and location of the catalytic Asp dyad in 
the middle of the active site cleft at the interface between N- and C terminal lobes, and the 
shielding of the active site by a flexible antiparallel hairpin-loop, known as a flap.85,178 Overall 
accommodation of the eight peptide substrate (P1-P4) residues occurs at enzyme subsites (S1-
S4) and P1’-P4’ at enzyme subsites S1’-S4’ in a similar way to other aspartic proteases. Thus, 
hydrogen bonds between the active site aspartates and 10 hydrogen bonds from different parts of 
the active site and flap bond to the substrate/inhibitor backbone in the active site cleft, with a 
high degree of conservation. There are key differences between the BACE1 crystal structure and 
other aspartic proteases that may be exploited in BACE inhibitor design. The most obvious 
difference is the larger molecular surface of BACE1, due to the presence of five insertions (four 
loops and one helix) all in the C-terminal lobe, in addition to the presence of a 35 residue C-
terminal extension, the latter being highly ordered in structure and possibly forming a stem with 
the transmembrane domain.85 
Introduction 
 29
In addition, although the general organisation of the active site subsites is similar to other 
aspartic proteases, their specificity and conformation display key differences.85,173,174,175, 
Moreover, the active site of BACE1 is larger, having additional subsites (S5-S7), and although it 
works well with the eight substrate residues as is normal for other aspartic proteases, it can also 
accommodate a greater number of substrate residues (11).176 The larger opening of the active site 
occurs due to structural differences near subsites, and the absence of a constricting pepsin helix 
loop across from the active site.85,173,174,175 The S1 and S3 subsites consist mostly of hydrophobic 
residues and their conformations are very different to pepsin. S4 and S2 are much more 
hydrophilic than these subsites in other aspartic proteases, where S2 in BACE1 and BACE2 
contains Arg (Arg296, Arg310, respectively), absent in other aspartic proteases and linked to 
more effective cleavage of APPSWE compared to normal APP.85,178,179 Subsites S5-S7 localise in 
the vicinity of the insertion helix, a region also absent in other A1 aspartyl proteases, and is 
believed to contribute to substrate recognition and transition state binding.176 
The flexible flaps which cover the active sites of all A1 aspartic protease contribute to 
hydrolytic specificity and substrate access, believed to open to allow substrate/inhibitor access, 
close when substrate/inhibitor is bound, and open to release hydrolytic products. However, the 
details of this mechanism are unclear. The BACE1 flap position can differ by 4.5Å-7Å at the tip 
when comparing free unbound enzyme (Apo) with enzyme bound to transition state 
inhibitor.174,180 A conserved aspartic protease Tyr71 residue in the tip of the flap forms hydrogen 
bonds with substrates/inhibitors at the P1 and P2’ positions of BACE1, thereby mechanistically 
sealing the flap shut.174 The open position is narrow and stabilised by intra-flap hydrogen bonds 
and a hydrogen bond with Tyr71 (Fig. 12). 
 
Figure 12. View of the difference in flap positions of free (red) and inhibitor-bound BACE1 (light gray). Three 
unique hydrogen bonds in the structure of the free BACE1 flap are shown in green dotted lines. Notice the 
differences between side-chain orientations of Tyr71, Lys75, and Glu77.174 
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A parallel side chain region in BACE1 (and also in BACE2), known as the third strand (see 
fig. 11), forms hydrogen bonds with residues in the flap and active site residues, thereby 
influencing and stabilising the open or closed state of the enzyme.174 Another region of 
flexibility shared between BACE1 and BACE2, most likely important in recognition and 
processing of APP substrate, is known as the 10s loop,178 which forms part of the hydrophobic 
S3 binding pocket (Fig 11). This region can also display flexible conformations in BACE1 when 
comparing Apo and inhibitor complexed structures,85,172,174 and displays subtle differences in 
aminoacid composition between BACE1 and BACE2 (Fig. 11) and may be involved in their 
substrate discrimination.178 Examination of the interaction of the P4-P4’ peptide inhibitor based 
on the mutant aminoacid composition of APPSWE (Glu-Val-Asn-Leu*Ala-Ala-Glu- Phe) with 
BACE1’s active site gives information about why this substrate displays a 60-fold increase in 
affinity of APPSWE over that of normal wild-type APP to cause AD.85 Firstly, mutant P1-Leu is 
closely packed against P3-Val and both have considerable hydrophobic contacts with BACE1, 
especially true for P1-Leu, part of which encompasses its interaction the Tyr71 at the flap tip. 
This hydrophobic interaction would likely be much more unfavourable with P1-Met in the 
normal APP substrate. Furthermore, the side-chain of mutant P2-Asn is H-bonded to P4-Glu and 
interacts strongly with Arg296 within the S2 subsite, both interactions would be much less 
favourable with the positively charged P2-Lys in normal APP. Together, the information gained 
on the unique structural features of BACE1 through investigating crystal structure is lending to 
the rational design of inhibitor drugs,181 incorporating such information on unique subsite-
inhibitor interaction and flap control.  
Definitely, crystal structures of BACE1 inhibitors complexes have revealed much about the 
nature of protein-ligand interactions, and information regarding the nature of binding sites 
obtained by this approach has been of critical importance in the design and development of 
inhibitors that will be effective drugs in treatment of AD. 
 
1.3. BACE1 inhibitors 
 
The availability of structural data from the extracellular domain of BACE1 has greatly 
enhanced the design of potential inhibitors. The conceptual basis of such a design elements has 
traditionally relied on mimicking the tetrahedral transition state of the enzyme-substrate complex 
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with a suitable surrogate. The first generation of BACE1 transition state inhibitors using 
peptidomimetics based on APPSWE with non-cleavable isosteres have been employed to 
determine the crystal structure of the enzyme, and to understand BACE1 substrate and inhibitor 
interactions at the active site. Although these inhibitors potently inhibit BACE1 activity and 
provide information for inhibitor design, they are unfortunately too large to penetrate the blood 
brain barrier (BBB) and to be functional as drug candidates. Thus, ideally β-secretase inhibitors 
should be 700 kDa or smaller, in addition to having high lipophilicity, in order to penetrate the 
BBB and to access neuronal membranes, in particular the membranes of subcellular organelles 
where BACE1 resides. Improvements in the design of the above inhibitors have reduced their 
mass and increased their specificity, but they remain ineffective in permeating cell membranes. 
Moreover, a certain selectivity towards other aspartic proteases has to be pursued, in particular 
towards BACE2, for its close specificity to β-secretase,182 and cathepsin D (CatD), for its 
ubiquitous presence in nearly all the cells.  
Definitely, in order to obtain a practical BACE1 inhibitor, we need to keep in mind that such a 
compound has to be directed to cells, and maintain the feature of permeating neuronal membrane 
and in particular the membranes of subcellular organelles where BACE1 resides. To this aim 
selective cell penetrable BACE1 inhibitors, non-peptidomimetic ligands or compounds bearing 
penetratin183 or carrier peptide184 sequences are being explored.  
Very recently, one of the most intriguing approach dealt with the inhibition of BACE1 by 
membrane targeting: specifically a transition state inhibitor was linked to a sterol moiety 
allowing to reach active BACE1 found in endosomes increasing its local membrane 
concentration.185 
The area of drug development for BACE1 inhibition has been addressed in several excellent 
recent reviews.186,187,188,189 
 
1.3.1. Transition-state analogues: from peptidomimetics to small-molecules 
inhibitors 
Substrate analogues have generally been used as starting point in the development of aspartic 
protease inhibitors and the search for BACE1 inhibitors has taken advantage of the efforts 
invested in the development of inhibitors for renin and HIV protease.190 The inhibitor is designed 
as structural analogue of the transition state occurring when an appropriate substrate is cleaved 
by the aspartic proteases. The non-hydrolysable isostere mimics the transition state avoiding to 
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be cleaved by aspartic protease and definitely inhibiting the enzyme. 
Statines 
Sinha et al.152 were the first to report the use of a peptidic inhibitor based on the APP 
sequence. This was the tetradecapeptide Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-LeuStatine-Val-Ala-
Glu-Phe-OH, (II) (known as STA-200) corresponding to APP residues 588-599 of the human 
APP695 sequence harbouring the Swedish mutation (Fig. 13). 
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Figure 13. Statine core and STA-200 inhibitor (Leu-Statine isostere is highlighted in dashed circle). 
STA-200 contained a modification at the cleavage site, with the introduction of a statine ((3S, 
4S)-4-amino-3-hydroxy-6-methylheptanoic), an unusual aminoacid that was found to behave as a 
transition state isostere in the inhibition of pepsin by the microbial aspartic protease inhibitors of 
the pepstatin family.191 The incorporation of statine increased binding affinity of the peptide for 
BACE1 by three order of magnitude. The residue Asp596 was also replaced by Val resulting in a 
30 nM inhibition of BACE1. The use of a bis-statine central core has further provided high 
affinity inhibitors for BACE1.192 From these seminal discoveries, medicinal chemistry 
development at Elan and Boehringer-Ingelheim created smaller statine-containing 
molecules.193,194 Recent results of the biological assays for the Boehringer inhibitors indicate in 
vitro IC50 < 30 µM.194 
 
Hydroxyethylene derivatives 
As already cited, Tang and Ghosh and researchers at the Oklahoma Medical Research 
foundation used homostatine (or hydroxyethylene, HE) as an isostere to design the octapeptide 
analogue Glu-Val-Asn-Leu*Ala Ala Glu-Phe, OM99-2 (Fig. 10), in which the cleavable bond 
Leu-Asp (BACE1 cleavage site) is replaced with HE isostere, to create a transition state mimic. 
This peptide inhibits BACE1 with Ki = 1.6 nM. In fact, a hydroxyethylene isostere in the 
backbone of the synthetic protease inhibitor has performed an admirable role in the design of a 
potential inhibitor. Starting from this crystal structure of a BACE1-OM99-2 complex (Fig. 9), 
reported by the Tang and Ghosh85 groups in 2000, valuable insights gleaned from this structural 
information led to the design and synthesis of several other types of both BACE1 inhibitors. 
Structure refinements provided OM00-3 (III) (Glu-Leu-Asp-Leu*Ala-Val- Glu-Phe) with Ki = 
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0.3 nM195 (Fig.14). 
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Figure 14. Hydroxyethylene core and OM00-3 inhibitor (HE isostere is highlighted in dashed circle). 
Conformationally restricted peptidomimetic BACE1 inhibitors have been reported by several 
groups. Hanessian and Novartis researchers accomplished some functional modification and 
appropriate truncation of a synthetic OM99-2 of BACE1 leading to a series of constrained 
carbocyclic or heterocyclic analogues.196 The representative compound IV displayed an IC50 = 
10 nM in enzymatic assays. 
AcHN
N
H
H
N
O
O
SMe
N
H
H
N
OH
HH
O
O
Bu
O(IV) (V)
N
H
H
N N
H
N
H
Bu
O
OH
O
O
S
S
 
Despite the character of these compounds remains still peptidic, the above structural 
modifications have produced potent BACE1 inhibitors endowed with excellent potential for 
selectivity over CatD. Moreover, a series of macroheterocyclic analogues were synthesized in 
order to establish by macrocyclization the bioactive conformation of these transition state mimic 
inhibitors, giving a representative compound V endowed with an IC50 = 184 nM in enzymatic 
assays.197 The protease inhibitors are designed to mimic essential features of peptides in β-strand 
conformation because protease substrates have to adopt such extended conformation to be 
recognized and cleaved by the enzyme. In this topic, macrocyclization has been applied 
successfully for a number of proteases with the final purpose to improve activity, 
pharmacokinetic properties and proteolytic stability in comparison to the open chain analogues. 
Other examples by Lilly198 (compound VI, IC50 = 80 nM) and Oklahoma / Zapaq199 (compound 
VII, IC50 = 25 nM) gave good results in term of enzymatic inhibitory activity. The high 
resolution X-ray crystal structures of the Novartis and Lilly macrocycles providing further 
insights into interactions with enzyme. 
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Although peptidomimetics inhibitors are very potent in vitro, their large size and their peptidic 
structure seriously impair their use in vivo. Chang et al.184 conjugated such HE inhibitor to a 
carrier peptide, to improve BBB permeability.  
In order to overcome their limited druggability, researchers at Elan Pharm. Inc. developed 
hydroxyethylene based drug by replacing the statin moiety with the HE core which represents a 
dipeptide isostere.200 
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Therefore, a variety of compounds bearing the optimal isophthalamide N-terminus of the statin 
series and different C termini at the P1’ substituent were synthesized. The HEs were more cell 
permeable than the statins. The representative compound VIII (BACE1 IC50 = 0.03 µM) was 
less potent than the best statin analogue toward BACE1, but demonstrated a ratio of cell to 
enzyme activity (EC50/IC50) of 100, (EC50 = 3 µM in HEK-293 cells). 
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Modification carried out onto original peptidomimetic inhibitor OM99-2 gave interesting 
results. Size reduction of this inhibitor revealed that the removal of the four outside residues P4, 
P3, P3’ and P4’ resulted in greatly reduced potency.201 A representative inhibitor is compound 
IX, which, despite well-optimized side chains, has a Ki value almost 1000 times higher 
compared to OM99-2. The inclusion of P3 Val, combined with the optimization of P2 and C-
terminal blocking group, brought the Ki back to the nanomolar level, as represented by 
compound X. Evidence from these studies suggested that, from the structural template derived 
from OM99-2, high potency could be attained by inhibitors with five subsites, from P3 to P2’, 
resulting in a molecular size of approximately 700 Da. 
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In search of selectivity towards CatD, researchers in Ghosh group designed a selective 
inhibitor XI with a Ki of 0.3 nM against BACE1; it displayed 1186-fold selectivity over BACE2 
and 436-fold selectivity over CatD. Subsequently, they designed inhibitor XII, which has 
demonstrated a Ki of 0.12 nM against β-secretase but with Ki values for BACE2 and CatD 
greater than 3800-fold and 2500-fold, respectively. The structural basis of selectivity versus 
BACE2 resides mainly in P3-oxazole, which affected a local conformational change better 
accommodated in BACE1, compared to BACE2.202 The P2-sulfone group in compound XII also 
provides a hydrogen-bonded network in β-secretase that cannot be accommodated in CatD, thus 
differentiating inhibition potency. 
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In order to investigate different means to restrain the conformational freedom of the inhibitors, 
macrocyclic compound were designed. Cyclization of the N-terminal portion of the previous 
inhibitors guided by structure-based design produced cycloamide-urethane derivatives with 
improved biological properties. A series of (14 to 16)-membered macrocyclic inhibitors were 
reported199 resulting in good potency in vitro and improved cell penetration. A representative 
inhibitor XIII, (Ki = 14 nM) suggests that introduction of rings to constrain the backbone 
freedom may be pursued. 
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Further evolution of the inhibitor structures along this line gave rise to compound XIV, which 
contains a substituted isophthalamide ring at P2 and optimized side chains from structure-based 
design and energy minimization. This inhibitor is potent (Ki = 1.1 nM), and has moderately good 
selectivity (Ki values of 31 nM and 41 nM versus BACE2 and CatD, respectively). At 648 Da, it 
penetrated the cell membrane well and inhibited Aβ production in cultured cell with an IC50 of 
39 nM. Recently Ghosh and co-workers reported that XIV is active in vivo, showing 30% 
reduction of Aβ40 production in Tg2576 transgenic mice after a single intraperitoneal 
administration (8 mg/kg).203 
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Hydroxymethylcarbonyl derivatives 
The group of Kiso at Kyoto Pharmaceutical University has used norstatine 
(hydroxymethylcarbonyl, HMC) (Fig. 15) as alternative isostere to develop potent BACE1 
inhibitors. Similarly, they started by designing octapeptide analogues and reported that KMI-008 
(XV) had an IC50 = 413 nM in the in vivo assay and that could decrease by 38% the secretion of 
sAPPβ from COS-7 cells overexpressing APP.204 
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Figure 15. Hydroxymethylcarbonyl core and Kyoto Pharmaceutical University inhibitors (HMC isostere is 
highlighted in dashed circle). 
Norstatine was then replaced with phenylnorstatine205 and introduction of a tetrazole carbonyl 
in the P4 position provided KMI-429 (XVI), with in vitro IC50 = 3.9 nM.206 Biological assays 
revealed that XVI was effective in cells and in animals.207 An IC50 value of 42.8 nM was 
obtained in a cell assay measuring APPβ release from BACE1 overexpressing human embrionic 
kidney (HEK293) cells. Injection of 2.5 nM of KMI-429 (XVI) into the hippocampus of Tg2576 
transgenic mice caused a 20% decrease of sAPPβ. Recent further modification to those 
compounds include the introduction of carboxylic acid bioisosteres at P1’ position, resulting in 
IC50 as low as 1-5 nM208 and elongation of the side chain at P1 position by changing the 
phenylnorstatine to phenylthionorstatine.209 Further optimization was carried out replacing the 
acidic moiety of KMI-429 with non acidic hydrogen bonding groups, to give KMI-758 (XVII) 
(IC50 = 14 nM).210 In order to improve cellular inhibitory activity, a series of BACE1 inhibitors 
possessing a heterocyclic ring at the P2 position and a 5-membered ring at the P3 position, were 
designed. The authors found novel small-molecule and non-peptidic chelidonic BACE1 inhibitor 
KMI-1027 (XVIII) (IC50 = 50 nM).211 
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Hydroxyethylamine derivatives 
However, the scaffold, which provided the majority of active compounds is the 
hydroxyethylene (HEA). The HEA transition-state analogue inhibits aspartic proteases, with both 
the secondary amine and the secondary alcohol interacting with the two catalytic aspartates. The 
hydroxyethyl secondary amine isostere was an alternative of HE because of the strict preference 
of BACE for acyclic residues at the S1’ subsite, and considering that the majority of CNS drugs 
contain a basic amine.212 This was extensively exploited by Elan-Pharmacia who had claimed 
some hydroxyalkylamine derivatives as BACE1 inhibitors.213 Compound XX (BACE1, IC50 = 
0.13 µM; HEK-293, EC50 = 0.23 µM; EC50/IC50 = 1.8) was a potent cellular inhibitor of Aβ 
production, Compound XXI bearing a C-terminal meta-iodo benzyl amine exhibited nanomolar 
both enzymatic and cellular BACE1 enzyme inhibitory activity (BACE1, IC50 = 5 nM; HEK-
293, EC50 = 3 nM; EC50/IC50 = 0.6). 
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For compound XXII, some in vivo studies showed it reduced Aβ levels by 17% in brain cortex 
and by 47% in plasma, when administered at 100 mg/Kg.214 A drawback for this class of 
compounds was the predicted poor metabolic stability due to microsomal N-debenzylation and 
N-depropylation.215 By replacing the isophthalate N-terminus by acyclic sulfones, the racemic 
carbobenzyloxy-derivative compound XXIII was designed, representing a lead compound 
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endowed with good enzymatic activity, but more potent inhibitory activity against CatD (IC50 = 
67 nM).216 
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Further structure based drug design gave the derivative XXIV, with highly improved 
enzymatic inhibitory activity (IC50 = 2 nM) and cellular potency (IC50 = 1 nM). The X-ray 
crystal structure of compound XXIV-bound to BACE1 highlighted a close association between 
the pyridyl nitrogen and the Arg235 in the S2 site. The authors suggest that, because CatD S2 
pocket is more lipophilic, and consequently is less tolerant of the introduction of polar groups 
with respect to BACE1, the pyridyl moiety of compound XXIV is also the main determinant of 
improved selectivity versus CatD enzyme (IC50 = 474 nM).217 Inhibitor XXV (GSK188909) was 
described as the first orally bioavailable BACE1 inhibitor capable of lowering brain Aβ in APP 
transgenic mice,218 and the studies leading to the discovery of this orally active HEA isostere-
based inhibitor have been reported.219 GSK188909 inhibited BACE1 activity with an IC50 of 5 
nM and also showed good selectivity with respect to BACE2, renin, and CatD. It caused a 
decrease in Aβ40 and Aβ42 production in cell-based assays expressing both wild-type and 
Swedish-variant APP sequences (IC50 = 5 and 30 nM, respectively). When orally administered to 
TASTPM mice, along with a P-glycoprotein (P-gp) inhibitor, GSK188909 (250 mg/kg) 
displayed a 68% and 55% decrease in Aβ40 and Aβ42, respectively. Further optimization led to 
discover inhibitor XXVI incorporating a tricyclic nonprime side and a truncated prime side 
residues, which showed nanomolar potency in a cell-based assay (IC50 = 19 nM). Moreover, this 
compound is endowed with good oral bioavailability.220 
Another interesting example is compound GRL-8234 (XXVII),221 that contains a HEA 
isostere with a P1-phenylmethyl side chain, a functionalized P2-isophthalamide ligand, and a 
P2’-hydrophobic benzyl derivative. The inhibitor exhibited a BACE1 Ki = 1.8 nM. Most 
Introduction 
 39
strikingly, it has shown a BACE1 cellular IC50 = 1 nM. This impressive cellular activity is in 
marked contrast to inhibitors with hydroxyethylene isosteres. The P1-leucine side chain 
containing inhibitor XXVIII (Ki = 916 nM) was significantly less potent. 
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Inhibitor XXIX (Ki = 425 nM) with a P2’-isopropyl group is also less potent than inhibitor 
GRL-8234 with a P2’-methoxybenzyl derivative. Similarly, replacement of P3-phenylmethyl 
derivative gave inhibitor XXX which resulted in marked attenuation of activity (Ki = 552 nM). 
The remarkable cellular activity of GRL-8234 may be due to the balance of its lipophilic and 
basic amine properties. The X-ray crystallographic analysis of protein–ligand structure of GRL-
8234 shows that both the hydroxyl group and the secondary amine group form a network of tight 
hydrogen bonding with the active site aspartic acid residues Asp32 and Asp228. The P2-
sulfonamide derivative fits well into the S2-site and makes extensive hydrogen bonding with β-
secretase. Inhibitor GRL-8234 has shown good selectivity over other aspartic proteases (39-fold 
selective over BACE2 and 23-fold selective over CatD) and very relevant in vivo properties in 
transgenic mice. Administration of compound (8 mg/kg i.p.) to Tg2576 mice resulted in up to 
65% reduction of Aβ40 production after 3 h.  
Very recently, researchers at Novartis discovered some macrocycles-based BACE1 inhibitor 
NB-544 (XXXI, IC50 = 27 nM; cellular-CHO, IC50 = 45 nM) exchanging the HE to HEA 
transition state core. Variation of the P’ moiety resulted in the macrocyclic inhibitor NB-533 
(XXXII, IC50 = 2 nM; cellular-CHO, IC50 = 24 nM). Both macrocycles not only are highly 
potent and selective, but show inhibition of BACE1 in the brain of APP51/16 transgenic mice, 
NB-544 after intravenous and NB-533 after oral application.222 
Chapter 1 
40 
N
N
H
N
H
O
OH
NB-544 (XXXI)
O
N
N
H
N
H
O
OHO
O
NB-533 (XXXII)
 
Other isosteres 
Sunesis and Merck researchers investigated the effect of introducing an aminoethylene (AE) 
isostere group as a central scaffold. Crystallization data indicated the amino group can interact 
with BACE1 active sites aspartates. Furthermore, following a macrocyclization approach, to 
improve affinity and selectivity, a series of inhibitors were designed based on an isophthalamide 
scaffold coupled to a reduced amide isostere.223 The compound XXXIII displayed an enzymatic 
IC50 = 4 nM, a cellular IC50 = 76 nM, and, most important, an improved membrane permeability 
and reduced P-gp susceptibility. When administered in mouse at a dose of 100 mg/kg i.v., it 
produced a 25% decrease in Aβ40 levels in brain extracts. Merck researchers have also 
discovered a series of 2,6-diamino-isonicotinamide inhibitors, which bind to S1-S3 pocket of 
BACE1 active site in conjunction with a primary amine or alcohol group. These are highly 
potent and selective for BACE1 over CatD. The truncated reduced amino isostere as the 
aspartate binding element224,225 is exemplified by compound XXXIV, displaying cellular IC50 of 
49 nM and in vivo activity in transgenic mice expressing human wild-type APP. After 
intravenous administration of a 50 mg/kg dose of inhibitor XXXIV, a maximal reduction of 
Aβ40 (34%) at 3 h from dosing was observed, and the concentration of drug in the brain was 1.9 
= µM.225 
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1.3.2. Non-transition-state-derived small molecules 
In 2001, Takeda Chem. Ind. reported the first novel non-transition-state-derived ligands 
disclosing new avenues to non-peptidomimetic BACE1 inhibitors.226,227 Derivative XXXV was 
found, at that time, the most potent inhibitor among a series of tetralines, and showed IC50 = 
0.349 µM as determined by a fluorescence assay.  
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Neurologic, Inc. described non-peptidomimetic phosphinylmethyl and phosphorylmethyl 
succinic and glutaric acid analogues along with some phosphorous-containing 
tetrapeptides.228,229 Noteworthy, the BACE1 inhibitory activity of the phospho analogues was 
indirectly associated through measurements of the compounds ability to increase sAPPα (it was 
expected to increase the pool of non-amyloidogenic derivatives). The activity of XXXVI on 
sAPPα secretion was dose proportional at > 1 nM concentration. 
Vertex, in 2002, disclosed hundreds of different heterocycle compounds,230 whose activity was 
around micromolar range. Vertex researchers proposed a 3D pharmacophore map of BACE to 
guide the design of new inhibitors. The compounds described in the invention showed hydrogen-
bonding moiety interactions (HB) with the active site and other key residues of BACE, and 
hydrophobic interactions (HPB) with BACE subsites. Different BACE/inhibitor binding modes 
were hypothesized involving, for instance, seven features of the inhibitor as shown in figure 16. 
 
Figure 16. Seven features binding modes with BACE1 
One of the most intriguing small-molecule inhibitors deriving from HEA drug design was first 
disclosed by Merck. In particular, the discovery and optimization of tertiary carbinamine-derived 
inhibitors231 represented novel non-transition-state-derived ligands incorporating a single 
primary amine to interact with the catalytic aspartates of the target enzyme. Optimization of this 
series provided inhibitors with intrinsic and functional potency comparable to evolved transition 
state isostere derived inhibitors of BACE1. Their optimized inhibitor (XXXVII) showed high 
potency in enzymatic and cellular assays (IC50 = 12 and 65 nM, respectively) and good 
selectivity toward both renin and CatD, but only moderate selectivity toward the high homolog 
BACE2 (IC50 = 620 nM). 
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Macrocyclization of this series of inhibitors led to lactone XXXVIII, which displayed 
increased potency versus BACE1 (IC50 = 2 nM). Both series of compounds, however, suffer 
from poor brain penetration, mostly due to high efflux of P-gp.232 
Strategies to discover non-peptidomimetic small-molecule hits, to be optimized as BACE1 
inhibitors, mostly involved screening of multimillion libraries of compounds. Wyeth drug 
discovery team has identified W-25105 (XXXIX) as low micromolar BACE1 inhibitor through 
screening of drug libraries in a high throughput screening (HTS) in vitro assay, endowed with 
activity in cells at 20 µM. This acylguanidine compound interacts through hydrogen bonding via 
catalytic aspartates and stabilizes the flap in an open position conformation whereas the polar 
functionality of the guanidine N-substituent extends into the S1’ pocket, forming hydrogen-
bonding interactions through bridging water molecules.233 Optimization of the hit using 
structure-based design led to the design of compound XL which displayed a BACE1 inhibition 
IC50 of 110 nM. 
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Preliminary structure–activity relationship (SAR) investigations234,235 resulted in moderate 
improvement of BACE1 inhibitory potency, but poor selectivity for BACE2 enzyme and poor 
permeability, as assessed in a Caco-2 drug transport model, remain major drawbacks of this class 
of compounds. The poor cellular permeability of the acylguanidine inhibitors could be due to the 
guanidinyl functionality, and bioisosteric replacement of this group is currently under 
evaluation.235 
In this regard, a series of bioisosteric 2-amino-3,4-dihydropyrido[3,4-d]pyrimidines showed Ki 
values in the submicromolar range of concentration.236 Johnson & Johnson Pharm. focused SAR 
development on 2-amino-3,4-dihydroquinazoline XLI (BACE1 Ki = 900 nM). An X-ray 
structure of BACE1/XLI obtained in collaboration with Astex Ther. showed that the side chain 
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bent back onto itself in a hairpin turn orientation, allowing the N-cyclohexyl substituent to 
occupy the S1 binding pocket, while the flap region of the protein adopted an ‘‘open’’ structure.  
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Compound XLI formed H-bonds with the catalytic aspartates as shown in Fig. 17. Compound 
XLII incorporates a 1,3-disubstituted phenyl ring in the side chain and 6-phenoxy substituent 
instead of the 6-benzoyl group, was six fold more potent than parent compound XLI (BACE1 Ki 
= 158 nM). To fill the S1’ pocket a cyclohexyl was introduced on the (R)-α-carbon of the side 
chain. The (S) enantiomer XLI inhibited BACE1 with Ki = 11 nM (racemate Ki = 30 nM). 
Compound XLIII displayed modest selectivity for BACE1 over renin and CatD as well as the 
hERG channel. Compound XLIII exhibited excellent potency in a cellular assay, which 
measures the inhibition of Aβ40 secretion in CHO cells transfected with the Swedish familial 
AD mutant APP. Additionally, XLIII lowered Aβ40 in plasma by 40–70% in rats after oral 
administration (30 mg/kg), 3 hr post-dosing.237 
 
 
Figure 17. Left: the 2-amino-3,4-dihydroquinazoline fragment of XLI and the Asp32 and Asp228 sidechains of 
BACE1, with H-bond distances in Å. Right: the X-ray structure of XLIII  bound into the enzyme, showing the R-
cyclohexyl moiety filling the S1’ pocket.237 
 
Astex Ther. used the Pyramid fragment screening methodology to BACE1 to identify by X-
ray crystallography three distinct chemotypes (amino-heterocycle, piperidine and aliphatic 
hydroxyl group) binding to the catalytic aspartates. The fragment hits were endowed with weak 
BACE1 inhibitory activity but most of them displayed relatively good ligand efficiency. Virtual 
screening around the aminoheterocycle recognition motif identified an amino-pyridine with 
increased potency. By means of Pyramid, non-peptidic fragments were identified useful for the 
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design of new (non-peptidic) BACE1 inhibitor.238 Structure-based design approaches have led to 
identification of low micromolar lead compounds that retain these interactions and additionally 
occupy adjacent hydrophobic pockets of the active site. From this novel medicinal chemistry 
approach a representative lead XLIV (IC50 = 690 nM) was identified. 
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1.4 Alternative therapeutic approaches to targeting β-secretase 
 
Most of the effort in the area of targeting BACE1 has been directed toward the development of 
inhibitors of this protease. Despite significant progress, very few examples of inhibitor drug 
candidates have been disclosed due to their limited capability to penetrate the blood brain barrier. 
Therefore, the late generation inhibitors are, as already described, small molecules. For some of 
them, such as GRL-8234, the ability to penetrate membranes and to inhibit Aβ production is well 
demonstrated in transgenic mice.181 In 2007, a compound named CTS-21166, belonging to small 
molecule transition-state analogues, began Phase I of clinical trials handled by CoMentis. 
However, many of the BACE1 inhibitors developed so far inhibit APP binding to the active site, 
but underestimate the fact that in vivo action of BACE1 on APP hydrolysis would require the 
participation of many other cellular components and would thus provide alternative opportunities 
for therapeutic intervention. 
However, few therapeutic approaches outside of BACE1 inhibitors have so far been reported.  
Chang et al.239 explored the idea that neutralizing antibodies against BACE1, generated from the 
immunization with the protease itself, may be enlisted to reduce Aβ production. Immunization of 
BACE1 produce polyclonal anti BACE1 antibodies in peripheral system such as plasma. Certain 
percentage of antibodies penetrates BBB and binds to BACE1 on surface of brain cells. Rapid 
endocytosis on neuron membrane carries surface molecules to endosome with an optimal pH 
(4.5) for BACE1 activity. Because enzymatic site of BACE1 is masked by antibodies, BACE1 
hydrolysis on APP is prevented. Therefore, production of Aβ is reduced improving the cognitive 
performance of AD mice (Fig. 18). 
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Figure 18. Schematic representation of mechanism for proposed BACE1 immunization.239 
 
The antibodies in this approach serve as inhibitors for BACE1 activity and thus do not require 
the participation of immune cells for Aβ reduction. This may indeed lower the risk of 
autoimmune response as observed in Aβ immunization. A conceptually related approach is 
immunization using peptides derived from the BACE1 cleavage site in APP. A study with AD 
mice using this approach has shown promise.240  
Other strong evidences to deal with are the intracellular trafficking of BACE1 allowing to 
perform its function of APP hydrolysis and consider endosome as the main location of enzyme 
activity. Considering this issue might explain the poor results obtained with some inhibitors in 
cellular assays.241 
In fact, although ubiquitously expressed, BACE1 mRNA has the highest expression levels in 
the mammalian brain, and is found in acidic organelles of the endosomes and trans-Golgi 
network. This is consistent with the discovery that BACE1 cleavage of APP occurs 
predominantly in endosomes, and that endocytosis of APP and BACE1 is essential for Aβ 
production. BACE1 activity and access to substrates is regulated by the composition of lipid raft 
domains in the membrane bilayer. Endosomes have high lipid raft and cholesterol content, 
critical in regulating APP endocytosis with increased amyloidogenic processing. In order to 
overcome this crucial issue, an innovative approach was recently reported, consisting of targeting 
inhibition to the subcellular compartment where the enzyme is active. A membrane anchored 
BACE1 transition state inhibitor was synthesized by coupling via a polyglycol linker the 
inhibitor to a sterol moiety (Figure 19).185 
BACE1 Immunize 
with 
BACE1 
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Figure 19. Illustration of sterol-linked BACE1 inhibitor targeting endosome. 
 
This inhibitor efficiently targeted BACE1 in endosomes via endocytosis, significantly 
enhancing the inhibitor efficacy, both in cell culture and in fly and mouse models of AD. 
Although it is too early to say whether this approach will lead to a functional drug therapy, the 
authors postulate that this membrane-tethering strategy might also be useful for designing 
inhibitors against other disease-associated membrane proteins. 
 
1.5. Multi Target Directed Ligands to combat AD 
 
AD is currently recognized as a complex neurodegenerative disorder with a multifaceted 
pathogenesis. This may explain why the currently available drugs, developed according to the 
reductionist paradigm of "one-molecule-one-target," have turned out to be palliative rather than 
curative.  
Different pharmacological approaches offer possible ways of overcoming the problems that 
arise from the use of such drugs.242 When a single medicine is not sufficient to effectively treat a 
disease, a multiple-medication therapy (MMT) (also referred to as a “cocktail” or “combination 
of drugs”) may be used. Usually, an MMT is composed of two or three different drugs that 
combine different therapeutic mechanisms. But this approach might be disadvantageous for 
patients with compliance problems. A second approach might be the use of a multiple-compound 
medication (MCM) (also referred to as a “single-pill drug combination”), which implies the 
incorporation of different drugs into the same formulation in order to simplify dosing regimens 
and improve patient compliance. Finally, a third strategy is now emerging on the basis of the 
assumption that a single compound may be able to hit multiple targets. Clearly, therapy with a 
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single drug that has multiple biological properties would have inherent advantages over MMT or 
MCM. It would obviate the challenge of administering multiple single-drug entities, which could 
have different bioavailability, pharmacokinetics, and metabolism. Indeed, if a single molecular 
species can show a complex ADMET profile, an MMT/MCM approach might be untenable. 
Furthermore, in terms of pharmacokinetic and ADMET optimization, the clinical development of 
a drug able to hit multiple targets should not, in principle, be different from the development of 
any other single lead molecule. It thus offers a much simpler approach than MMT/MCM. In 
addition, the risk of possible drug-drug interactions would be avoided and the therapeutic 
regimen greatly simplified in relation to MMT. In light of this, drug combinations that can act at 
different levels of the neurotoxic cascade offer new hopes toward curing AD and other 
neurodegenerative diseases.243 All these considerations are of particular relevance, as one of the 
major contributions to the attrition rate in drug development continues to be the drug candidate’s 
pharmacokinetic profiling.244 There is, therefore, a strong indication that the development of 
compounds able to hit multiple targets might disclose new avenues for the treatment of, for 
example, major neurodegenerative diseases, for which an effective cure is an urgent need and an 
unmet goal. 
Morphy and Rankovic elegantly discuss in recent articles242,245,246 “designed multiple ligands” 
approach to describe compounds whose multiple biological profile is rationally designed to 
address a particular disease. In parallel, this new paradigm in medicinal chemistry, recently 
termed by Melchiorre and co-workers7 as "multi-target-directed ligand" (MTDL) design strategy 
(Fig. 20) has been successfully exploited at both academic and industrial levels in the fields of 
AD247 and similarly complex diseases.248,249  
 
Figure 20. Pathways leading to the discovery of new medications: (a) Target-driven drug discovery approach, 
that is, the application of the current one-molecule-one-target paradigm. Although this approach has led to many 
effective drugs able to hit a single target, it is now well-documented that these drugs may represent the exception 
rather than the rule. (b) MTDLs approach to drug discovery. A drug, could recognize (in principle, with comparable 
affinities) different targets involved in the cascade of pathological events leading to a given disease. Thus, such a 
medication would be highly effective for treating multifactorial diseases. The design of such a drug may not be easy 
because it could also bind targets that are not involved with the disease and could be responsible (although not 
necessarily) for side effects. With MTDLs, the one-medication-one-disease paradigm finds a practical application. 
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To obtain novel Multi-Target-Directed Ligands (MTDLs) a design strategy is usually applied 
in which distinct pharmacophores of different drugs are combined in the same structure to afford 
hybrid molecules. In principle, each pharmacophore of these new drugs should retain the ability 
to interact with its specific site(s) on the target and, consequently, to produce specific 
pharmacological responses that, taken together, should slow or block the neurodegenerative 
process. One of the most widely adopted approaches in the field has been to modify the 
molecular structure of an AChEI in order to provide it with additional biological properties 
useful for treating AD. 
However, the selection of a therapeutic target (to seek either a single- or a multi-target-directed 
ligand) is one of the biggest challenges in designing new molecules for this multifactorial 
disease.250 Clearly, MTDLs should be targeted against the most important pathophysiological 
processes. Obviously, better understanding of the complexity of the signalling pathways in which 
targets are involved is needed. Moreover, it is important to develop new approaches with which 
to unravel the mechanisms underlying the neurodegenerative process. Knowing that BACE1 is 
now recognized as one of the most intriguing target in the pathogenesis of AD, conferring to a 
given molecule an additional property such as BACE1 inhibition could be a useful strategy to 
seek a multi-target-directed ligand for the treatment of AD.  
However, more clues regarding the target seek come from the system biology approach251 
which may help in addressing how ‘networking’ (collective arrangement, connections, and 
interactions) of targets influences the final properties of the MTDLs against a given pathological 
event.252,253 
The main criticism to MTDL drug discovery paradigm is that this approach is resource hungry, 
because the rational design of MTDLs has to deal with the critical issues of affinity balancing 
and pharmacokinetics. However, as proof of principle, and to support the view that MTDLs are 
destined to become the mainstream of AD therapeutics in the years to come, could be useful to 
discuss the biological profile of ladostigil (TV-3326), an MTDL developed by Youdim and co-
workers,254 which is currently in phase II clinical trials for AD. 
The design of MTDLs is based on the combination of two or more pharmacophores acting on 
different AD targets. In particular, ladostigil was designed by merging the structures of 
rivastigmine, an AChEI, and rasagiline, a selective MAO-B inhibitor (Fig. 21). 
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Figure 21. The design strategy leading to the anti-Alzheimer MTDL ladostigil. 
 
Thanks to these chemical features, ladostigil showed the ability to inhibit both cholinesterases 
(AChE and BChE) and brain monoamine oxidases (MAO-A and -B). The block of MAOs avoids 
hydrogen peroxide generation, thus preventing the Fenton reaction and the formation of 
neurotoxic free radical species. In addition, MAO inhibition confers potential antidepressant 
activity by increasing the levels of dopamine, noradrenaline, and serotonin in the central nervous 
system.255 Interestingly, in addition to its ability to inhibit MAOs and AChE, ladostigil also 
showed other supplementary neuroprotective actions, such as APP processing regulation via 
mitogen-activated protein kinase-signalling pathways, and mitochondrial membrane potential 
stabilization.256,257 Furthermore, ladostigil was a protective agent against oxidative stress-induced 
neuronal apoptosis, increasing the antioxidant enzymes’ expression and catalase activity.258 
Ladostigil increased the brain-derived nerve factor (BDNF) mRNA expression, leading to an 
improved production of BDNF and to a consequent enhanced neuroprotective activity.259 Thanks 
to this wide MTDL profile, ladostigil can be considered a very promising drug for the treatment 
of AD. 
Definitely, in view of the complexity of AD and the involvement of multiple and 
interconnected pathological pathways, a combination of therapeutic properties may result in a 
more effective strategy to address this unmet medical need and to slow or perhaps even halt the 
course of the disease. 
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The aspartic protease BACE1 (β-secretase) is recognized as one of the most promising targets 
in the treatment of Alzheimer’s disease (AD). The accumulation of β-amyloid peptide (Aβ) in the 
brain is a major factor in the pathogenesis of AD. Aβ is formed by initial cleavage of β-amyloid 
precursor protein (APP) by BACE1, therefore its inhibition represents one of the therapeutic 
approach to control progression of AD, by preventing the abnormal generation of Aβ. For this 
reason, in the last decade, many research efforts have focused at the identification of new 
BACE1 inhibitors as drug candidates. Generally, BACE1 inhibitors are grouped into two 
families: substrate-based inhibitors, designed as peptidomimetic inhibitors, and non-
peptidomimetic ones. The research on non-peptidomimetic small-molecule BACE1 inhibitors 
remains the most interesting approach, since these compounds hold an improved bioavailability 
after systemic administration, due to good blood-brain barrier permeability in comparison to 
peptidomimetic inhibitors.  
 
2.1 Design of heterocycles-based BACE1 inhibitors. 
Very recently, our research group discovered a new promising lead compound for the 
treatment of AD, named lipocrine (6), a hybrid compound between lipoic acid and the AChEI 
tacrine, characterized by a tetrahydroacridinic moiety. Lipocrine was one of the first compounds 
able to inhibit the catalytic activity of AChE and AChE-induced Aβ aggregation and to protect 
against reactive oxygen species (See Fig.1).1 Lipocrine represents one of the best example of 
Multi-Target-Directed-Ligands (MTDLs) by acting simultaneously on different targets involved 
in AD pathogenesis. Therefore it emerged as valuable pharmacological tool to investigate AD 
and as a promising lead compound for new anti-AD drugs. 
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Figure 1. Multi-target profile of lipocrine. 
 
In view of the complexity of AD and the involvement of multiple and interconnected 
pathological pathways, a new therapeutic approach based on the development of multifunctional 
molecule able to inhibit BACE1 and to interfere with other pathological event, could be a new 
paradigm to address this unmet medical need and to slow, or perhaps even halt, the course of the 
disease.  
In view of discover new Multi-Target-Directed-Ligands (MTDLs), lipocrine was also 
evaluated for BACE1 inhibitory activity, resulting in a potent and selective BACE1 inhibitor 
(IC50 = 57 nM). Due to its interesting profile, we investigated new scaffold modifications based 
on this compound in order to obtain useful chemical entities as potent BACE1 inhibitors. 
An important structural feature of lipocrine for the optimal inhibition of BACE1 was thought 
being the dithiolane group; therefore, to confirm this hypothesis the tiophene analogue 7 was 
designed and synthesised. To evaluate the optimal distance for the inhibitory activity between the 
tetrahydroacridine moiety and dithiolane fragment, different polimethylene spacers were 
interposed affording derivatives 1-5 (Fig.2). 
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Figure 2. Design strategy of compounds 1-5 and 7 
 
With the aim to obtaining multifunctional compounds able to inhibit not only BACE1 but also 
the classical targets of AD pathogenesis (i.e. AChE and AChE-mediated Aβ aggregation 
inhibition), new ligands bearing lipoic acid as key structure were synthesised. The hybrid 
derivatives 8 and 9 retain lipoic acid fragment of lipocrine and the aromatic moiety of 
rivastigmine, a known AChEI used in AD therapy. In particular 8 include the free tertiary amino 
groups on meta-position of the aromatic ring, whereas 9 displays the methoxy group. These key 
features are coupled to lipoic acid in two different ways to evaluate the interaction with the 
enzyme (Fig. 3). 
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Figure 3. Design strategy of compounds 8 and 9. 
 
Moreover, derivative 10 represents a hybrid compound incorporating the caproctamine 
pharmacophore and lipoic acid fragment. Caproctamine was the prototype of the polyamine-
based structure AChEIs developed by Melchiorre and co-workers in a study aimed to generate 
novel polyamine ligands having simultaneously affinity for both AChE active and peripheral 
sites and for muscarinic M2 autoreceptors.2 Its structure has been discovered applying the 
universal template approach to AChE, which is a polyamine backbone can recognize different 
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biological targets through its policationic structure and its selectivity can be achieved by 
modulating the distance between the amine functions and by inserting appropriate residues on a 
polyamine backbone. We designed compound 10 by coupling the caproctamine pharmacophore 
to lipoic acid residue, with the aim to evaluate the potential inhibitory activity towards AD 
different targets, such as AChE, Aβ-aggregation and BACE1 (Fig. 4). 
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Figure 4. Design strategy of compounds 10. 
 
To investigate the importance of tetrahydroacridinic moiety of lipocrine for BACE1 inhibitory 
activity, we applied the concept of molecular simplification as drug design strategy, to synthesise 
novel heterocyclic compounds. Thus, we designed and synthesized new ligands by replacing the 
tetrahydroacridine moiety of lipocrine with 4-amino-quinazoline. 
In the meanwhile of our investigation on new suitable small molecules for BACE1 inhibition, 
a work published in 2007 by Johnson & Johnson researchers revealed that 2-amino-3,4-
dihydroquinazoline ring is an appropriate moiety for the inhibition of BACE1.3 This fragment 
was identified by high-throughput screening, and X-ray crystallography of the inhibitor XLIII 
co-crystallized with the enzyme revealed that the 2-amino-3,4-dihydroquinazolines adopted a 
compact structure bearing a hairpin turn of side chain and the exocyclic amino group participated 
in a hydrogen bonding array with the two catalytic aspartic acids of BACE1 (Fig. 5) 
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Figure 5. Schematic representation of hydrogen bonding of inhibitor XLIII with two Asp and crystal structure of 
inhibitor co-crystallised with BACE1 (the two Asp residues are also displayed). 
 
For this reason it was worthwhile to following our investigation upon 2-chloro-4-amino-6,7-
dimethoxy-quinazoline in view of chemical similarity to 2-amino-3,4-dihydroquinazoline ring. 
Therefore, in order to evaluate modifications of the tetrahydroacridinic moiety of lipocrine with 
a 2-chloro-4-amino-6,7-dimethoxy-quinazoline residue, compound 11 was synthesised revealing 
an enhanced BACE1 inhibitory activity, compared to lipocrine (IC50 = 18 nM). Thus, in order to 
establish structure-activity relationships for BACE1 inhibition, different modifications were 
carried out on the new prototype. Firstly, we studied the importance of the 2-Cl replacement by 
inserting different substituents like -H, -CH3, -NH2, obtaining compounds 12-14, respectively 
(Fig. 7). In addition, structure-activity relationships studies made on the lateral chain allowed 
exploring the importance of the lipoic acid residue. In view of conferring to the new chemical 
entity the additional antioxidant property, we replaced the antioxidant moiety of trans-ferulic 
acid in exchange of the dithiolane residue of lipoic acid obtaining compound 15. Meanwhile, the 
replacement with acrylic acid led to compounds 16 and 17 which could have the ability to 
interact to a potential cysteine residue of the enzyme blocking the enzyme in an irreversible 
mode. 
In order to evaluate the effect of changing the position of the lateral chain on inhibitory 
activity and taking advantage of the interesting activity profile displayed by compound XLIII 
which bears a guanidinic group in its structure, we chose to shift the lateral chain from the 4-
position of quinazoline moiety to 2-position, obtaining compound 20 and 21 holding a lipoic acid 
and trans-ferulic acid fragment, respectively (Fig. 7). These compounds bore in their structure a 
guanidinic moiety that has shown, by X-ray data, to be a key fragment for strong interactions 
with the catalytic aspartates as displayed by the very potent inhibitors XL and XLV shown in 
figure 6.4,5 
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Figure 6. Example of potent BACE1 inhibitors bearing a guanidine moiety (dashed circle). 
 
Knowing that the phenoxy group in 6-position led to an improved activity profile among 
dihydroquinazoline derivatives,3 we decided to apply such a modification by replacing the 6-
methoxy of  compound 20 with 6-phenoxy group, obtaining compound 22. 
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Figure 7. Design strategy of quinazoline compounds 11-17  and 20-22 (LA = lipoic acid, tFA = trans-ferulic 
acid, AA = acrylic acid). 
 
Finally, the concept of molecular simplification was applied to synthesise further heterocyclic 
compounds related to lipocrine. Compounds bearing the 4-quinoline moiety were synthesised by 
replacement of the 6-chloro-tetrahydrocridine residue with 7-chloro-quinoline-2,3-dicarboxylic 
acid dimethyl ester providing compound 19. With the aim to maintain AChE inhibitory activity, 
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the new scaffold was coupled to 6-chlorotacrine fragment through a propandiamine spacer 
affording compound 18 (Fig. 8). 
N
CO2Me
CO2Me
NH
Cl
N
H
O
S S
N
CO2Me
CO2Me
NH
Cl
N
H
N
Cl
18
19
N
NH
Cl
N
H
O
S S
Lipocrine
 
Figure 8. Design strategy of compounds 18 and 19. 
 
2.2 Design of δ-aminocyclohexane carboxylic acid based BACE1 inhibitors 
 
A side project related to the synthesis of novel enzymatic inhibitors of BACE1 in order to 
explore the pseudopeptidic transition-state isosteres chemistry was carried out during a research 
stage at Université de Montréal (Canada) in Hanessian's group.  
The availability of structural data from the extracellular domain of BACE1 has greatly 
enhanced the design of potential inhibitors. The conceptual basis of such a design element has 
traditionally relied on mimicking the tetrahedral transition state of the enzyme-substrate complex 
with a suitable surrogate. In fact, a hydroxyethylene isostere in the backbone of the synthetic 
protease inhibitor has performed an admirable role. Indeed, the first crystal structure of a 
BACE1-OM99-2 (A) complex (Fig. 9), was reported by the Tang and Ghosh6 groups in 2000. 
Valuable insights gleaned from this structural information led to the design and synthesis of 
several other types of BACE1 inhibitors. 
In previous work, Hanessian’s group reported on the structure-based design, synthesis, and X-
ray crystallographic studies of carbocyclic7 and heterocyclic8,9 P1/P1' truncated variants of the 
Tang and Ghosh original 1nM BACE1 inhibitor A (Fig. 9). Further refinement of these 
prototypical inhibitors led to consider unnatural, minimally peptidic molecules in which the 
traditional P2/P3 dipeptide subunit in the Tang and Ghosh inhibitor was replaced by a 
cyclohexane spacer unit. Preliminary results with a prototypical molecule B (Fig. 9), resulted in 
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low µM inhibitory activity against BACE1. In spite of the weak activity, a crystal structure of B 
in complex with BACE1 showed that it was indeed bound in the active site, although the 
orientation of the N-acetyl group was changed. In an effort to study the effect of the nature of 
steric environment near the N-acetyl group, we considered the synthesis of carbocyclic 
aminoacids represented by the generic structure C shown in figure 9. 
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Figure 9. Tang-Ghosh inhibitor OM99-2 (A), truncated peptidomimetics bearing carbocyclic aminoacids core B-
C. 
 
Such carbocyclic δ-aminoacids with stereochemically defined substitution are not known in 
the context of peptidomimetic design. In this regard, the aim of the project was to the incorporate 
such a constrained carbocyclic aminoacids in a potential inhibitors of BACE1 endowed with 
reduced peptidic character. This target structure was synthesized previously in Hanessian's lab 
using a well-know multistep synthesis, starting from the chiral aminoacid as depicted in an 
exemplar retrosynthetic analysis (Fig.10).10 
Pr
NBn2H CO2MeH Pr
NBn2
CO2Me
Pr
NBn2
CO2Me Pr
NBn2
CO2Et Pr CO2H
NH2
L-norvaline
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Figure 10. Retrosynthetic analysis of δ-aminocyclohexane carboxylic acid motif C starting from a chiral 
aminoacid (L-norvaline). 
 
The aim of our work has been the synthesis of the δ-aminocyclohexane carboxylic acid motif 
by a novel asymmetric approach. In particular, we envisioned an alternative route based on an 
organocatalytic asymmetric conjugate addition of nitroalkanes to cyclohexenone. The obtained 
3-(α-nitroalkyl)-cyclohexanones were further functionalized to give the corresponding δ-
nitroalkyl cyclohexane carboxylic acids. These intermediates were elaborated to the target 
structures 3-(α-aminoalkyl)-1-cyclohexane carboxylic acids in a new readily accessible way. 
The Michael addition reactions of enolates are some of the most fundamental C-C bond-
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forming reactions. Therefore, their catalytic asymmetric versions have been studied 
extensively.11 Stereoselective Michael additions to α,β-unsaturated ketones represents a 
challenging objective in asymmetric catalysis. The activation as an iminium ion can in principle 
constitute a suitable and general method for accomplishing highly stereoselective 
transformations of enones. However, the inherent problems of forming highly substituted 
iminium ions from ketones, along with the issue associated with a more difficult control over the 
configuration of the iminium ion, have complicated the development of an efficient chiral 
organocatalyst for ketones.  
However, the first organocatalyzed addition of 2-nitropropane to cyclohexenone, reported by 
Yamaguchi and co-workers in 1993,12 was based on proline catalysis. Using rubidium L-
prolinate, they achieved an ee of 59% for cyclohexenone. In 2000, Hanessian and co-workers 
reported on a substantial improvement in the addition of 2-nitropropane to cyclohexenone in the 
presence of 10 mol% of L-proline, in conjunction with 2,6-dimethylpiperazine as an additive. 
The reaction profile exhibited an unusual non-linear effect, before reaching ee values ranging 89-
93%.13 Since then, the enantioselectivity of this reaction has been extended with trans-4,5-
methano-L-proline to 99% ee.14 
Applying the organocatalyzed reaction we were able to obtain a separable mixture of isomers: 
the less polar (S,S)-propyl syn-isomer (89% ee), and the more polar (S,R)-propyl anti-isomer 
(74% ee) that were each separated and characterized. The individual enantiomeric purities were 
determined by HPLC analysis on a chiral column, using racemic mixtures as controls. A similar 
protocol with 1-nitrobutane gave the less polar syn-(S,S)-butyl isomer (89% ee) and the more 
polar anti-(S,R)-isomer butyl (71% ee) in a ratio of 1:2 , respectively (see Chemistry section 3.2). 
Synthetic manipulations to the obtaining nitroketone D will be accomplished to reach to the 
target compound exemplified by motif C as depicting in retrosynthetic analysis in figure 11. In 
particular, the individual nitroketones D were each transformed to the corresponding ketene 
dithioacetals. Successive methanolysis gave the methyl esters that were subjected to reduction 
and N-acetylation.  
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Figure 11. Retrosynthetic analysis of δ-aminocyclohexane carboxylic acid motif C featuring the organocatalyzed 
Michael addition 
 
In the context of the peptidomimetics BACE1 program, this alternative route will represent a 
practical, shorter and asymmetric approach to the target compound using the enantioselective 
reaction as synthetic key step. 
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Chapter 3 
 
Chemistry 
 
3.1 Synthesis of heterocycles-based BACE1 inhibitors. 
 
Synthesis of compounds 1-7 
Nucleophilic aromatic substitution of the tetrahydroacridines 30 or 31 with the opportune 
chain length diamines, in n-pentanol, gave intermediates 23 and 32-36 (Scheme 1). Coupling 
reaction of tetrahydroacridine intermediates 32-36 with lipoic acid (LA) in the presence of 1-(3-
dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl), gave compounds 1-5, 
respectively. 
Compound 6 and 7 were obtained following the same coupling conditions by condensation of 
the tetrahydroacridinamine 23 with LA and 5-(thiophen-2-yl)pentanoic acid, respectively 
(Scheme1).  
 
Synthesis of compounds 8-10 
The starting material 1-(3-hydroxyphenyl)ethanone was functionalised under standard 
reductive amination to the dimethylamine derivative 371. The following alkylation with tert-
butyl 3-chloropropylcarbamate in DMF gave intermediate 38 which was N-deprotected and 
coupled under standard conditions with LA to give compound 8 (Scheme 2).  
Ketone 40 was converted to the known 1-(3-methoxyphenyl)-N-methylethanamine 412 
through reductive amination with methylamine and NaBH4 under H2 atmosphere. The following 
alkylation with tert-butyl 3-chloropropylcarbamate in DMF, and N-deprotection gave 
intermediate 43 which was coupled with LA under standard conditions to give compound 9 
(Scheme 3). 
Compound 10 was obtained by coupling the known N1-ethyl-N1-(2-methoxybenzyl)hexane-
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1,6-diamine 443 with LA under the same conditions (Scheme 4). 
 
Synthesis of compounds 11-15 
The readily available 2,4-dichloro-6,7-dimethoxyquinazoline 45 and 4-chloro-6,7-
dimethoxyquinazoline 464 were converted to intermediates 26 and 48 under nucleophilic 
aromatic substitution with N-Boc-1,3-propandiamine, followed by N-deprotection (Scheme 5). 
The substitution of 4-chloro-6,7-dimethoxy-2-methylquinazoline 474 with free 1,3-
propandiamine gave the key intermediate 49. In order to obtain the 2-amino-quinazoline 
analogue 51, an ethanolic solution of the intermediate 24 was heated in autoclave at 140 °C 
under NH3 pressure to obtain the analogue 50. The successive N-deprotection afforded 51 as a 
title compound. The coupling reaction of 26, 48, 49 and 51 with LA using EDCI⋅HCl gave 
compounds 11-14, respectively, whereas the amidation of compound 26 with trans-ferulic acid in 
the presence of propylphosphonic anhydride5 afforded 15 in moderate yield (Scheme 5). 
 
Synthesis of compounds 16-17 
The 4-substitution of dichloroquinazoline 45 with N-Boc-1,3-propandiamine or N-Boc-1,6-
hexandiamine gave intermediate 24 and 52, respectively. After deprotection, the resulting amine 
derivatives 26 and 53 were acylated with acryloyl chloride in CH2Cl2 in good yield to give 
acrylamide derivatives 16 and 17, respectively (Scheme 6). 
 
Synthesis of compounds 18-19 
The cyclization of methyl 2-amino-4-chlorobenzoate and dimethyl acetylenedicarboxylate in 
refluxing t-butanol afforded quinolinol 54 that was converted into the chloro analogue 55 in 
refluxing POCl3. The substitution with tetrahydroacridinamine 23 gave compound 18, whereas 
nucleophilic substitution of 55 with N-Boc-1,3-propandiamine gave intermediate 56. After N-
deprotection, the resulting amine 57 was coupled with LA under standard conditions to afford 
compound 19 (Scheme 7). 
 
Synthesis of compounds 20-21 
The commercially available dichloroquinazoline 45 was converted to 4-dimethylamino 
derivative 58. The following 2-substitution with N-Boc-1,3-propandiamine followed by N-
deprotection afforded amine 60. The coupling reaction with LA using EDCI⋅HCl gave compound 
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20, whereas the condensation with trans-ferulic acid in the presence of propylphosphonic 
anhydride gave compound 21 (Scheme 8). 
 
Synthesis of compound 22 
The intermediate 616 was obtained following the Williamson synthesis by coupling phenol and 
methyl-5-chloro-2-nitrobenzoate in N-methyl-2-pyrrolidone, under basic conditions. The alkaline 
hydrolysis of the resulting benzoate 61 gave the corresponding acid 62 which was reduced under 
catalytic hydrogenation to obtain the amino-benzoic acid 63 that was subjected to cyclization in 
presence of potassium cyanate under basic condition to afford quinazolindiol 64. Refluxing this 
intermediate in phosphorous oxychloride gave 2,4-dichloro-6-phenoxyquinazoline 65 that was 
converted to 4-dimethylamino derivative 66 with dimethylamine. Following the same procedure 
carried out for compound 20, the intermediate 66 was converted into amine 68 that was coupled 
with LA to afford compound 22 (Scheme 9). 
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Scheme 1 
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Scheme 6 
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Scheme 7 
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Scheme 8 
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Scheme 9 
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3.2 Synthesis of δ-aminocyclohexane carboxylic acid-based BACE1 
inhibitors 
 
The approach followed to get the δ-aminocyclohexane carboxylic acid motif A (Fig.1) was 
based on an organocatalytic asymmetric conjugate addition of nitroalkanes to cyclohexenone.  
OH
ONH2
H H
R 13' 3
A
 
Figure 1. δ-Aminocyclohexane carboxylic acid motif A 
Addition of 1-nitropropane and 1-nitrobutane to cyclohexenone 69 in the presence of 10 mol 
% equivalent of D-proline and a stoichiometric amount of trans-2,5-dimethylpiperazine in 
reagent grade CHCl3 for 48 hours gave, in each case, a separable mixture of isomers in 85-97% 
combined yield (Scheme 10, Table 1). The less polar (S,S)-propyl syn-isomer 70 (89% ee), and 
the more polar (S,R)-propyl anti-isomer 71 (74% ee), (1:2.2 ratio by 1H NMR and HPLC, 
respectively), were each separated and characterized. A similar protocol with 1-nitrobutane gave 
the less polar syn-(S,S)-butyl isomer 72 (89% ee) and the more polar anti-(S,R)-isomer butyl 73 
(71% ee) in a ratio of 1:2 , respectively (Table 1). 
Table 1. Catalytic enantioselective addition of nitroalkane to cyclohexenone catalyzed by D-proline 
O
69
+
R NO2
less polar
syn-isomer
70 R = Et
72 R = Pr
more polar
anti -isomer
71 R = Et
73 R = Pr
D-proline (10 mol% cat),
trans-2,5-dimethylpiperazine,
CHCl3, rt, 48 h
R
NO2
H O
R
NO2
H O
 
R 
Yield 
(%) 
dra 
(syn:anti)  ee (%)
b
 
   
syn anti 
Ethyl 84 1 : 2.2  89  74 
Propyl 97 1 : 2.0  89  71  
a
 obtained by RP Chiral HPLC and 1H-NMR at 700 MHz 
b
 obtained by RP Chiral HPLC (see Experimental Section) 
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The individual enantiomeric purities were determined by HPLC analysis on a chiral column, 
using racemic mixtures as controls. An example of HPLC traces of enantioenriched mixture of 
compounds 70 is shown in figure 2 (see Experimental Section for details of all isomers). 
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Figure 2. HPLC profiles of the less polar syn-isomer (S)-3-((S)-1-Nitropropyl)cyclohexanone 70 
(enantioenriched in the left side, racemic in the right side). Enantiomeric excesses were determined by RP-HPLC 
analysis with CHIRALPAK AD-RH column (∅ 0.46 cm × 15 cm) eluting in isocratic mode with 0.1 % Formic acid 
in CH3CN / 0.1 % Formic acid in H2O (30:70), flow = 0.5 mL/min, retention times minor: 34.90 min, major: 39.02 
min. 
 
The definitive stereochemical identity of the desired 3S,3'S-diastereomer was established by 
correlation with authentic samples obtained from a previous established route starting with the 
chiral aminoacids as well as from available X-ray structures. 
The individual nitroketone less polar syn-isomers 70 and 72 were each transformed to the 
corresponding ketene dithioacetals 74 and 75 (Scheme 10). Methanolysis of 74 and 75 in the 
presence of HgCl2 gave the methyl esters 76, 77, and 78, 79, respectively.  Attempts to 
equilibrate the (S,R)-isomers 77 and 79 to the desired 1,3-cis-(S,S)-isomers 76 and 78 without 
affecting the stereochemistry of the carbon centre containing the nitro group were unsuccessful. 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 34.90 2500539.25 5.39 
2 39.02 43910696.00 94.61 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 34.76 25787958.00 53.57 
2 39.86 22348432.00 46.43 
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In order to establish definitive configurational identity for the desired (S,S)-compounds 77 and 
78, they were each subjected to reduction in the presence of 10% Pd/C and ammonium formate, 
and the resulting amines were N-acetylated to give 80 and 81, respectively. The alkaline 
hydrolysis of ester and following coupling with the hydroxyethylene based amine gave final 
compounds 28 and 29. 
The individual more polar anti-nitroketone isomers 71 and 73, as well as their conversion to 
ketene dithioacetals and methyl esters were also achieved, although these "undesired" 
diastereomeric nitro alkyl esters were not pursued further in the context of the present 
peptidomimetic BACE1 project. 
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Scheme 10 
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Biology 
 
All the compounds were tested for in vitro BACE1 inhibitory activity in different protocols of 
FRET (fluorescence resonance energy transfer) enzymatic assays, varying the nature of 
substrates and enzyme origin, in order to assess the optimal conditions for a reliable enzymatic 
test. Moreover, the most active compounds of the series were evaluated also towards cathepsin D 
(CatD) in order to test their selectivity.  
In view of MTDLs drug design approach, the majority of compounds were also evaluated 
towards the AChE and BChE inhibitory activity, and some of them were investigated in the Aβ 
aggregation inhibition test induced by AChE. 
In addition, lipocrine (6) and hybrid compounds 8-10 were the subjects of an in vivo 
pharmacological investigation in AD mice model. 
4.1. BACE1 inhibition 
BACE1 activity was measured with a FRET analysis method using a multi well 
spectrofluorimeter. The peptide substrate of the analyses mimes the APP protein which is the 
natural substrate of BACE1. The synthetic substrate contains two fluorogenic groups: a group 
that donates fluorescence (D) and a group that quenches fluorescence (A) as depicted in figure 1. 
The weakly fluorescent substrate becomes highly fluorescent upon enzymatic cleavage; the 
increase in fluorescence is linearly related to the rate of proteolysis.  
 
Figure 1. Schematic representation of a FRET-based enzymatic assay. 
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4.1.1. Method A: Panvera substrate and Invitrogen enzyme 
The inhibitory potency against recombinant human BACE1 for compounds 1-10 was 
evaluated by method (A) based on FRET assay using Rhodamine-Glu-Val-Asn-Leu-Asp-Ala-
Glu-Phe-Lys-quencher as fluorogenic substrate (Panvera peptide harbouring rhodamine as 
donating fluorescent group (Fig. 2)). 
O N
H3C
CH3
N
CH3
CH3
CO2H
Cl-
 
Figure 2. Rhodamine as fluorescence donating group 
Purified Baculovirus-expressed BACE1 and rhodamine derivative substrate were purchased 
from Panvera (Madison, WI, U.S.).  
The inhibitory potency of compounds was expressed as IC50 values or as a certain % of 
enzyme inhibition, which represent the concentration of inhibitor required to decrease the 
maximum enzymatic activity by 50%. Enzyme activity was determined reading the fluorescence 
emitted by rhodamine at λ = 590 nm. 
Assays were done with a blank containing all components except BACE1 in order to account 
for non enzymatic reaction. The reaction rates were compared and the percent inhibition due to 
the presence of test compounds was calculated. Each concentration was analyzed in triplicate. 
The percent inhibition of the enzyme activity due to the presence of increasing test compound 
concentration was calculated by the following expression: 100-(vi/vo × 100), where vi is the 
initial rate calculated in the presence of inhibitor and vo is the enzyme activity. To demonstrate 
inhibition of BACE1 activity, a statine-derived inhibitor was serially diluted into the reactions’ 
wells (IC50 = 18  ± 1 nM) or inhibitor IV (Calbiochem, Darmstadt, Germany) was used as 
reference inhibitor (IC50 = 12.89 nM) (Fig. 3). 
Ph
H
N
H
N
H
N
OH
Ph
NS
O O
O O
inhibitor IV
H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[Statine(3S,4S)]-
-Val-Ala-Glu-Phe-OH
Statine derivative
 
Figure 3. Reference compounds inhibitor IV and statine derivative. 
4.1.2. Method B: Casein-FITC substrate and Invitrogen enzyme1 
The inhibitory potency against recombinant human BACE1 for compounds 6, 11-19, 22 and 
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24-27 was evaluated by a modified method (B) employing bovine casein labelled with 
Fluorescein isothiocyanate (Casein-FITC) as a fluorogenic substrate (Fig.4). The enzyme 
BACE1 was purchased from Panvera (Madison, WI, U.S). 
OO OH
HO2C
N
CS
 
Figure 4. Fluorescein isothiocyanate (FITC) as fluorescence donating group. 
The inhibitory potency of compounds was expressed as IC50 values or as a certain % of 
enzyme inhibition. Enzyme activity was determined reading the fluorescence emitted by FITC at 
λ = 538 nm. 
Assays were done as in method A. To demonstrate inhibition of BACE1 activity donepezil was 
used as reference inhibitor (IC50 = 586 nM) (Fig. 5). 
O
O
O
N
 
Figure 5. Reference inhibitor: donepezil. 
 
4.1.3. Method C: M-2420 substrate and Sigma enzyme 
The inhibitory potency against recombinant human BACE1 for compounds 6, 11, 13, 15, 20-
22 was evaluated by a third method (C) based on MCA-SEVNLDAEFK(DNP)-CONH2 (Fig.6) 
as fluorogenic substrate called M-2420 that was purchased from Bachem (Torrance, CA, United 
States). Human recombinant BACE1 was purchased from Sigma Aldrich (Milan, Italy). 
O
O
CO2H
H3CO
NO2
NO2
HO
MCA DNP
 
Figure 6. Fluorogenic residues of substrate M-2420 
The inhibitory potency of compounds was expressed as IC50 values or as a certain % of 
enzyme inhibition. Enzyme activity was determined reading the fluorescence emitted by the 
fluorophore at  λ = 405 nm. Assays were done as in method A. To demonstrate inhibition of 
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BACE1 activity, inhibitor IV (Calbiochem, Darmstadt, Germany) (Fig. 3) was used as reference 
inhibitor (IC50  = 13.61 nM). 
 
4.1.4. BACE1 fluorogenic substrate evaluation 
The kinetic parameters for the three enzymatic assays were evaluated in order to assess the 
most reliable assay. Specificity constants (kcat/KM) were determined under pseudo-first-order 
conditions, via the “progress curve method”2 using a substrate concentration (0.04 or 0.05 µM) 
far below KM, and a final enzyme concentration of 10 or 34 nM (E0). The {time; fluorescence} 
data pairs were fitted to equation (F(t) = ΛF [1-exp(-kobs ·  t)] + Finit), and the apparent first-order 
rate constant (kobs) was calculated. The second-order rate constant, kcat/KM values were calculated 
according to the following equation: kcat/KM = kobs/[E0]. Quenching efficiency was determined 
according to the equation: q.e.(%) = (1-F0/F1) × 100, were F0 = Finit-Fbuffer and F1 = Fmax- Fbuffer. 
 
4.2. Cathepsin D inhibition 
Cathepsin D (CatD) activity was measured with a FRET analysis method using a multi well 
spectrofluorimeter. The inhibitory potency against recombinant for compounds 11, 14 and 15 
was evaluated by a modified B method employing bovine casein labelled with Fluorescein 
isothiocyanate (Casein-FITC) as a fluorogenic substrate. The inhibitory potency of compounds 
was expressed as IC50 values or as a certain % of enzyme inhibition. Enzyme activity was 
determined reading the fluorescence emitted by FITC at λ = 538 nm. Assays were done as in 
method A. To demonstrate inhibition of CatD activity, pepstatin A was used as a reference 
inhibitor (IC50 = 0.011 ± 0.002 µM) . 
 
4.3. AChE and BChE inhibition  
The inhibitory potency against recombinant human AChE and isolated serum BChE for 
compounds 1-10, 11, 13, 15-19, 24 and 25 was evaluated by studying the hydrolysis of 
acetylthiocholine (ATCh) following the colorimetric method of Ellman.3 The inhibitory potency 
of compounds was expressed as pIC50 values, which represent negative logarithm of the 
Biology 
 95
concentration of inhibitor required to decrease the maximum enzymatic activity by 50%. 
Enzyme activity was determined through the revelation of the formation of an anionic coloured 
molecular species (2-nitro-4-thiobenzoate, λmax = 412 nm), which is obtained from the reaction 
of thiocholine, a product of the enzymatic hydrolysis of acetylthiocholine (substrate of AChE) or 
butyrylthiocholine (substrate of BChE), and 5,5’-dithio-bis-nitrobenzoic acid (Ellman’s reactive). 
The variation of absorbance at λ = 412 nm (that is the variation of the absorbance of 2-nitro-4-
thiobenzoate per minute, ∆A/min, enzymatic speed) depends on the substrate concentration, and 
on the enzymatic activity of AChE or BChE, according to the Michaelis-Menten kinetic.  
The nature of AChE inhibition caused by the synthesized compounds was investigated by the 
graphical analysis of steady-state human AChE inhibition data of 5. Information regarding the 
ligand-enzyme interaction was obtained through the determination of Ki,4 which describes the 
state of equilibrium between the free enzyme, the inhibitor, and the enzyme-inhibitor complex.  
4.4. Inhibition of AChE-induced Aβ aggregation 
Anti-aggregation action of compounds 6-10 and 23 was determined in comparison with well-
known AChEIs, through a fluorimetric method adapted from Inestrosa.5,6 This assay is able to 
highlight the ability of AChE (recombining human, EC 3.1.1.7) to promote the formation of Aβ 
fibrils. Thioflavin-T interacts selectively with amyloid peptide in the β conformation forming a 
fluorescent complex (λem = 490 nm). A compound able to interfere with Aβ fibrils formation 
would reduce the fluorescent signal, and this signal is directly proportional to the log of the 
concentration of the tested compound. The anti-aggregation action is expressed as the inhibitor 
concentration able to reduce the fluorescent signal of 50%. 
 
4.5. Animal studies  
In order to check the efficacy of 6, 8-10 and 23 in improving the degeneration due to AD, 
these compounds were administered to anti-NGF mice. Recovery of cholinergic neurons and 
blockade of tau hyperphosphorylation were studied as anti-AD properties. 
This animal model (anti-NGF)7 presents a phenotype highly similar to AD in man. In 
particular, the model consists of a transgenic mouse which expresses antibodies for the nervous 
growth factor (NGF), and consequently shows an extensive loss of neurones in the cortex, 
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formation of Aβ plaques and of intracellular neurofibrillary tangles, as well as behavioural 
dysfunctions. In particular, in order to produce anti-NGF transgenic mice (AD11), the variable 
regions in the light and heavy chains of the anti-NGF monoclonal antibody αD11 were linked to 
the constant human region κ and γ1, to give the man/rat chimeric antibody αD11, and they were 
then placed under the transcriptional control of the promoter of the precocious region of the 
human cytomegalovirus (CMV). Mice expressing functional anti-NGF antibodies (AD11 mice) 
were obtained by crossing mice that expressed the heavy chain (CMV-VH αD11). 
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Chapter 5 
 
Results and discussion 
 
In order to search new chemical entities able to inhibit BACE1, we designed and synthesised 
novel heterocyclic compounds related to lipocrine, one of the first examples of MTDLs for AD.1 
 
5.1. Biological evaluation of tetrahydroacridine-, rivastigmine- and caproctamine–
based compounds (1-10) 
Modifying the chain length between the two nitrogen atoms bearing tetrahydroacridine moiety 
and lipoic acid of lipocrine led to compounds 1-5 and 7, respectively. Modifications to the 
tetrahydroacridine moiety afforded hybrid compounds 8 and 9, bearing the structural features of 
rivastigmine and lipoic acid, and compound 10 incorporating caproctamine and lipoic acid 
fragments. All of them were evaluated as BACE1 inhibitors in a FRET (fluorescence resonance 
energy transfer) enzymatic assay (Method A, for details see Section 4.1.1) and as AChE and 
BChE inhibitors. Moreover, some of them were evaluated as Aβ anti-aggregating compounds 
and were the subjects of an in vivo pharmacological investigation in AD mice model. 
As shown in Table 1, among the tetrahydroacridine-based compounds 1-6, derivatives 1 and 2, 
bearing a diaminoethylene and diaminopropilene spacer, are endowed with an inhibitory activity 
in submicromolar range towards BACE1, whereas longer spacers are detrimental for activity. 
The insertion of a chlorine atom into the acrydine system, affording lipocrine (6), led to a very 
good profile of inhibitory activity towards BACE1, quantified as a 15-fold increase relative to its 
analogue 2. In order to define whether the dithiolane group is fundamental for BACE1 activity, 
the intermediates tacrine and 23 were also evaluated, displaying a total absence of activity. 
Moreover, the substitution of dithiolane residue with tiophene led to compound 7 which lacked 
affinity for the enzyme, strengthened the hypothesis that lipoic acid is a key fragment for BACE1 
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inhibition. As already published,1 given that the tetrahydroacridine-based derivatives 1-5 and 7 
bear the tacrine pharmacophore, are endowed with a good activity profile towards AChE and 
BChE. To allow comparison of the results shown in Table 1, 23, tacrine, and LA were used as 
reference compounds. It is evident that all compounds were effective inhibitors of AChE and 
BChE, significantly more potent than prototype tacrine. Among compounds 1-5, optimum 
inhibition of AChE was observed for 2, having propylene chain unit. As expected for AChE 
inhibition,2 the insertion of a chlorine atom into the acrydine moiety, as in lipocrine (6), 
produced an 85-, 1676-, and 28-fold increase in AChE inhibition relative to 23, tacrine, and 2, 
respectively. 
As one would expect, LA did not inhibit neither AChE nor BACE1 enzyme. On the other 
hand, the hybrid compounds between rivastigmine and LA 8 and 9, respectively, displayed a 
micromolar range of AChE inhibitory activity and a submicromolar range of BACE1 inhibitory 
activity. The caproctamine-based compound 10 displayed a modest AChE inhibition and a 
submicromolar BACE1 inhibition (Table 1). 
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Table 1. AChE, BChE, and BACE1 inhibitory activities of derivative 1-10 and reference compounds. 
 
N
HN N
H
1: n = 2
2: n = 3
3: n = 4
4: n = 5
5: n = 6
O
n
O
7
O
N
N
H
O
8
9
O
N
H
N
O
N
H
N
O
10
Cl N
HN NH2
Cl N
HN N
H
23
4
4
44
4
O
4
SS
SS S
SS
S
S
O
6 Lipocrine
Cl N
HN N
H 4
SS
 
Compound   IC50 ± SEM (nM) 
 n R AChE BChE BACE1a 
1 2 H 97.0 ± 3.6 47.5 ± 1.8 772.3 ± 20.7 
2 3 H 6.96 ± 0.45 12.0 ± 0.6 867.7 ± 11.2 
3 4 H 35.2 ± 2.2 5.04 ± 0.32 > 2000 
4 5 H 38.4 ± 2.3 1.48 ± 0.35 > 2000 
5 6 H 30.1 ± 1.5 3.24 ± 0.29 > 2000 
6  
(Lipocrine) 3 Cl 0.253 ± 0.016 10.8 ± 2.5 IC50 = 57.0 ± 12.0 
7   2.66 ± 0.23 30.6 ± 0.7 > 2000 
8   25200 ± 1700 82400 ± 6500  
9   74100 ± 3700 398 ± 24 846.5 ± 53.9 
10   256 ± 8 2490 ± 110 929.1 ± 28.7 
23   21.5 ± 0.8 2580 ± 60 > 3500 
Tacrine   424 ± 21 45.8 ± 3.0 inactive at 4000 
b
 
Lipoic acid   >1000000 >1000000 > 500 
a
 = IC50 values obtained by FRET assay following Method A. (for details See Section 4.1.1) 
b
 = maximum solubility concentration to perform the analysis 
 
Furthermore, as already cited, lipocrine inhibited both the active site and a second distal site of 
the enzyme. Once verified that lipocrine may interact also with PAS of AChE, it was verified 
whether there is a concomitant inhibition of Aβ aggregation induced by AChE. As shown in 
Table 2, it turned out that tacrine and LA, i.e., the pharmacophoric moieties combined in 
lipocrine, were not able to inhibit at 100 µM the Aβ aggregation induced by AChE, whereas 
compound 23 at 100 µM caused only a 25 ± 5% inhibition. In contrast, lipocrine was only 3-fold 
less potent than propidium, used as reference compound being the most potent inhibitor of 
AChE-induced Aβ aggregation so far available, as revealed by their IC50 values. Furthermore, 
lipocrine was significantly more potent than all the other AChE inhibitors ever tested.3 Clearly, 
this finding, together with the results observed for 23, tacrine, and LA separately, is relevant 
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because an association of 100 µM tacrine and 100 µM LA or 100 µM 23 and 100 µM LA 
produced only a weak inhibition of AChE-induced Aβ aggregation, suggesting that marked Aβ 
aggregation inhibition may be achieved only when the two prototypes are combined into the 
same structure, as in lipocrine. 
Lipocrine turned out to be the most potent Aβ anti-aggregating compound of the series, 
exhibiting IC50 value around 45 µM . Compounds 7 and 11 exhibited lower, but still significant, 
Aβ anti-aggregating effects, while the derivatives bearing methoxybenzylamino groups 8-10 in 
replacement of the tacrine unit, were weak inhibitors of the AChE-induced Aβ aggregation. 
 
Table 2. Inhibition of Aβ40-aggregation induced by AChE. 
 
Compound [ ] 100 µM 
 
Inhibition % 
± SEM 
Tacrine < 5 
Lipoic acid < 5 
Lipoic acid + Tacrine 15 ± 6 
23 25 ± 5 
Lipoic acid + 23 30 ± 7 
6 (lipocrine) 61.8 ± 0.8 (IC50 = 45.0 ± 14.6 µM) 
propidium (IC50 = 12.5 ± 0.5 µM) 
7 24.1 ± 5.7 
8 9.0 ± 6.6 
9 15.6 ± 7.8 
10 16.8 ± 2.2 
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Animal Studies 
As already cited, some selected compounds of the series were the subject of a preliminary in 
vivo pharmacological investigation in AD mice model (For details see Section 4.5). In order to 
check the efficacy of 6, 8-10 and 23 in improving the degeneration due to AD, these compounds 
were administered to anti-NGF mice. Recovery of cholinergic neurons and blockade of tau 
hyperphosphorylation were studied as anti-AD properties. 
The dosage (expressed in mM of solution) was chosen in order to demonstrate that the efficacy 
of these compounds is better than that the efficacy of the compounds from which they are 
derived. For this reason Memoquin4, which is known for improving all the phenotypic markers 
in anti-NGF (AD11), was administered in a dose which, based on previous studies, was expected 
to give only a partial recovery of the phenotype. Moreover, to assess the direct contribution of 
lipoic acid (LA) alone, in comparison with that of the conjugate of lipoic acid, and to exclude 
that the effect observed might be due to LA, this compound was administered to the anti-NGF 
mice as well. The treatment pattern is shown on Experimental section (See Section 6.2.5). 
In particular, the administration of LA, tacrine, lipocrine, 8, rivastigmine and Memoquin did 
not allow the complete recovery of the cholinergic deficit of the anti-NGF mice. The only 
compound that allowed a significant recovery, from a statistical point of view, of a number of 
cholinergic neurones in the basal forebrain was caproctamine-based derivative 10 (P < 0.05, Fig. 
1). All the compounds administered recovered the phospho-tau phenotype, with the exception of 
23 (Figure 2). 
 
Figure 1. Recovery of cholinergic neurons in AD mice [WT = wild type mice, PL = AD11 mice + placebo, R = 
AD11 mice + rivastigmine (0.5 mg/Kg/die), 8 = AD11 mice + compound 8 (0.52 mg/Kg/die), 9 = AD11 mice + 
compound 9 (0.52 mg/Kg/die), 23 = AD11 mice + compound 23 (0.1 mg/Kg/die), 6 = AD11 mice + compound 6 
(0.165 mg/Kg/die), Mq = AD11 mice + Memoquin (3.5 mg/Kg/die), 10 = AD11 mice + compound 10 (3.5 
mg/Kg/die), LAa = AD11 mice + LA (0.254 mg/Kg/die), LAb = AD11 mice + LA (0.114 mg/Kg/die)] 
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Figure 2 . Recovery of phosphotau phenotype in AD mice [WT = wild type mice, PL = AD11 mice + placebo, R 
= AD11 mice + rivastigmine (0.5 mg/Kg/die), 8 = AD11 mice + compound 8 (0.52 mg/Kg/die), 9 = AD11 mice + 
compound 9 (0.52 mg/Kg/die), 23 = AD11 mice + compound 23 (0.1 mg/Kg/die), 6 = AD11 mice + compound 6 
(0.165 mg/Kg/die), Mq = AD11 mice + Memoquin (3.5 mg/Kg/die), 10 = AD11 mice + compound 10 (3.5 
mg/Kg/die), LAa = AD11 mice + LA (0.254 mg/Kg/die), LAb = AD11 mice + LA (0.114 mg/Kg/die)] 
 
5.2. Biological evaluation of 4-amino-quinoline- and 4-amino-quinazoline–based 
compounds (11-27) 
 
Modification accomplished to the heterocyclic core of lipocrine gave a series of compounds 
bearing 2-substituted-4-amino-6,7-dimethoxyquinazoline 11-19 and 24-27 (Table 3), that were 
assayed in modified FRET method (Method B) employing bovine casein labelled with 
fluorescein isothiocyanate (Casein-FITC) as a fluorogenic substrate. Casein-FITC was selected 
as new potential substrate of BACE1 because it is already known to be a selective substrate for 
proteases, it is easily available and it is convenient and versatile for the activity of other aspartic 
proteases, such as CatD.5 Fluorescein isothiocyanate is a good label for proteins because it is 
highly fluorescent, and it reacts with the amino groups of most proteins in a simple reaction that 
yields the fluorescein thiocarbamoyl derivative. 
The activity profiles obtained referring to this new method (Method B)6 guided the 
modifications carried out in the quinazoline-based compounds. In addition, inhibitory activity 
towards CatD was also evaluated for the most potent compounds. 
As shown in Table 3, the replacement of the tetrahydroacridinic moiety of lipocrine with 2-
chloro-4-amino-6,7-dimethoxyquinazoline residue led to a more potent compound (11). Since 
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this new lead structure exhibited an enhanced BACE1 inhibitory activity relative to lipocrine and 
a moderate selectivity over CatD (IC50 = 78 nM), it was chosen for further structure-activity 
relationship studies. 
The replacement of the 2-chloro substituent of 11 with H, CH3, and NH2 groups gave 
compounds 12-14, respectively, endowed with a lower BACE1 inhibitory activity. In addition, 
structural modifications on the lateral chain confirmed the importance of the lipoic acid residue, 
as its replacement with acrylic acid or tert-butylcarbonic acid led to less potent analogues (16, 
17, 24 and 25). The amine intermediates 26 and 27 did not exert a remarkable inhibition 
revealing the importance of lateral chain. Finally, the most intriguing result was the disclosure 
that the insertion of a different antioxidant residue, such as trans-ferulic acid in place of lipoic 
acid, led to compound 15 with a 9-fold increased selectivity over CatD while retaining a 
nanomolar BACE1 activity compared to prototype 11 (Table 3). 
The replacement of the lipoic acid residue of lipocrine with the 7-chloroquinoline-2,3-
dicarboxylic acid dimethyl ester gave compound 18 endowed with a very poor BACE1 
inhibitory activity, whereas the substitution of tetrahydroacridinic ring of lipocrine with the same 
moiety (7-chloroquinoline-2,3-dicarboxylic acid dimethyl ester) provided a less potent analogue 
19.  
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Table 3. BACE1 and CatD inhibitory activity in different assays by compounds 11-19, 24-27, lipocrine and 
reference inhibitors (statine derivative and inhibitor IV) 
N
N
HN
O
O
N
H
R
11: R = Cl
12: R = H
13: R = CH3
14: R = NH2
24: X = Boc, R = Cl
25: X = Boc, R = H
26: X = H, R = Cl
N
N
HN
O
O
N
H
Cl
O
O
OH
O
4
SS
N
N
NH2
O
O
Cl
27
N
N
NH NH
O
O Cl
O
n
16: n = 3
17: n = 6
N
N
HN
O
O
N
H
R
X
15
Ph
H
N
H
N
H
N
OH
Ph
NS
O O
O O
inhibitor IV
O
Cl N CO2Me
CO2Me
HN NH
SS
19
Cl N CO2Me
CO2Me
HN NH
18
N
Cl
4
 
Compound BACE1 inhibition CatD inhibition 
 
Method A 
Rhodamine Invitrogen 
substrate 
Method B 
Casein-FITC substrate 
 
 
Casein-FITC 
subtrate 
11 IC50  = 17.9 ± 3.9 nM IC50 = 18 nM  78 nM 
12 nd 26 % at 500 nM   
13 no inhibition at 1.13 
µM no inhibition at 18 nM   
14 nd 30 % at 18 nM  18 % at 70 nM 
15 10.8 % at 1.05 µM 
no inhibition at 18 nM IC50 = 18 nM  154 nM 
16 nd 45 % at 500 nM   
17 nd 20 % at 500 nM   
18 nd 9.04% at 0.493 µM   
19 nd IC50 = 490 nM   
24 nd 30 % at 500 nM   
25 nd 22 % at 500 nM   
26 nd no inhibition at 116 nM   
27 nd no inhibition at 116 nM   
6 
(lipocrine) IC50 = 57.0 ± 12.0 nM IC50 = 57 nM   
Inhibitor 
IV IC50 = 12.89 nM IC50 = 48.86 nM   
Statine 
derivativea IC50 = 18.0 ± 1.0 nM IC50 = 61 ± 2.0 nM   
nd = not detected 
a
 = (H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[Statine(3S,4S)]-Val-Ala-Glu-Phe-OH) 
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Some selected compounds were also evaluated towards AChE, in view of the fact that such 
compounds could be seen as molecular simplifications of lipocrine and the results are reported in 
Table 4. All the quinazoline-based derivatives do not show interesting AChE activity profiles, 
except the tacrine-based compound 18. As expected, only compound 18, bearing the 6-
chlorotacrine residue, maintained a strong affinity for AChE, revealing only a 25-fold reduced 
potency compared to lipocrine, and a good selectivity towards BChE (Table 4). 
 
Table 4. AChE inhibitory activities by 4-amino-quinazoline (11, 13, 15-17, 24 and 25) and 4-amino-quinoline 
derivatives (18 and 19)and reference compound lipocrine 
 
N
N
HN
O
O
N
H
R
11: R = Cl
13: R = CH3
24: X = Boc, R = Cl
25: X = Boc, R = H
N
N
HN
O
O
N
H
Cl
O
O
OH
O
4
SS
N
N
NH NH
O
O Cl
O
n
16: n = 3
17: n = 6
N
N
HN
O
O
N
H
R
X
15
HN NH
NCl
COOCH3
COOCH3
O
4
SS
19
HN NH
NCl
COOCH3
COOCH3
18
N
Cl
 
Compound IC50 AChE M IC50 BChE M 
11 (1.92 ± 0.25) 10-4  
13 (6.21 ± 0.10)10-5  
15 1.10 10-3  
16 (6.94 ± 0.14)10-4  
17 (3.14 ± 0.55)10-4  
18 (6.41 ± 0.14)10-9 (3.70 ± 0.14)10-6 
19 (1.91 ± 0.02)10-5  
24 (5.70 ± 0.45)10-4  
25 (3.75 ± 0.58)10-4  
6 
(lipocrine) (2.53 ± 0.16) 10
-10
 (1.08 ± 0.25) 10-8 
 
In order to evaluate the effect of changing the lateral chain position on BACE1 inhibitory 
activity and taking advantage of the interesting activity profile displayed by BACE1 inhibitors 
bearing a dihydroquinazoline moiety,7 we designed and synthesised compounds 20 and 21 (Table 
5). They bear a lipoic acid and trans-ferulic acid fragment, respectively, linked to an 
aminopropilene spacer in the 2-position of the quinazoline ring. They show in their structure a 
guanidinic moiety that has shown, by X-ray data, to be a key fragment for strong interactions 
with the catalytic aspartates. Knowing that the phenoxy group in the 6-position led to an 
Chapter 5 
108 
improved activity profile in dihydroquinazoline-based BACE1 inhibitors, we decided to replace 
6-methoxy substituent by 6-phenoxy group, obtaining compound 22.  
Meanwhile, with the aim of confirming the results of synthesised ligands, the most potent 
compounds were screened in a well established FRET assay,8 prior to be test in a cellular assay. 
The different FRET tests were studied varying the nature of substrate and of the enzyme origin, 
in order to evaluate the consistency of results and assess the versatility of the assays. 
To this aim, the compounds 6, 11, 13 and 15, together with the 2-amino-quinazoline 
derivatives 20-22 were evaluated by a new method (Method C, for details see Section 4.1.3.) 
based on MCA-SEVNLDAEFK(DNP)-CONH2 as fluorogenic substrate called M-2420. 
As shown in Table 5, even though the results on reference inhibitors (Inhibitor IV and statine 
derivative) displayed a good superimposition, in A, B, and C assays, defining their potency in 
nanomolar range, surprisingly, the data on behalf of the lead compounds lipocrine and 11, 
obtained following the new FRET assay C, led to different results that were not comparable to 
the previous ones. 
While A and B assays seemed to reproduce data for the first lead compounds 6 and 11, that 
bear in their structure very similar moiety (i.e. lipoic acid in the lateral chain coupled to 
tetrahydroacridine and quinazoline, respectively), is not the case for compound 15 that showed a 
different fragment on lateral chain in the structure (i.e. trans-ferulic acid). Very surprisingly, the 
C assay does not confirm the nanomolar activity profile found with method B for the most 
promising derivative 15, which seemed to display a modest inhibitory BACE1 activity.  
Within the designed 2-amino-quinazoline compounds 20-22, only derivative 21, that bears the 
trans-ferulic acid residue on lateral chain, showed a submicromolar inhibitory BACE1 activity. 
This data seems to be quite comparable for B and C assays, whereas they are not strengthened by 
A assay. 
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Table 5. BACE1 inhibitory activities in different assays by selected compounds 6, 11, 13, 15, 20-22 and reference 
inhibitors (statine derivative and inhibitor IV). 
N
N
HN
O
O
N
H
R
11: R = Cl
13: R = CH3 N
N
HN
O
O
N
H
Cl
O
O
OH
O
4
SS
15
Ph
H
N
H
N
H
N
OH
Ph
NS
O O
O O
inhibitor IV
N
N
N
O
O
N
H
N
H
O
N
N
N
O
O
N
H
N
H
O
O
OH
4
SS
20
21 22
N
N
N
O
N
H
N
H
O
4
SS
 
Compound BACE1 inhibition 
 
Method A 
Rhodamine 
Invitrogen substrate 
Method B 
Casein-FITC 
substrate 
Method C 
M-2420 substrate 
(MCA-DNP labelled) 
6 
(lipocrine) 
IC50 = 57.0 ± 12.0 
nM IC50 = 57 nM 2.0% at 9.4 µM 
11 IC50  = 17.9 ± 3.9 
nM IC50 = 18 nM 15.2% at 10.8 µM 
13 no inhibition 
at 1.13 µM 
no inhibition 
at 18 nM 
no inhibition at 10.6 
µM 
15 10.8 % at 1.05 µM 
n.i at 18 nM IC50 = 18 nM 8.27 % at 9.82 µM 
20 36.03% at 3 µM 10.82% at 1 µM nd 
19.17% at 3 µM 
17.78% at 1 µM 
21 
6.81% at 3 µM 
no inhibition at 1 
µM 
IC50 = 0.51 µM 
IC50 = 0.80 ± 0.41 
µM 
22 10.68% at 3 µM 5.00% at 1 µM nd 
37.53% at 3 µM 
21.29% at 1 µM 
Inhibitor 
IV IC50 = 12.89 nM 
IC50 = 48.86 
nM IC50 = 13.61 nM 
Statine 
derivativea 
IC50 = 18.0 ± 1.0 
nM 
IC50 = 61 ± 2.0 
nM IC50 = 30.8 ± 0.7 nM 
nd = not detected; n.i. = no inhibition 
a
 = (H-Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-[Statine(3S,4S)]-Val-Ala-Glu-Phe-OH) 
 
In this regard, it is well known that FRET assays have some disadvantages in term of 
interference rates that are strongly dependent on compound properties. For example, FRET 
rhodamine substrate (Method A) has shown to give a 10 times higher rate of potential “false 
negative” compounds. Subsequent validation assays could be performed in a kinetic mode in 
order to define with guarantee the correct classification of “false positives” and “false 
negatives”.9 For this reason, BACE1 fluorogenic substrate evaluation assay were carried out to 
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measure the kinetic parameters and quenching efficiency leading to assess the best conditions for 
each FRET assay (Table 6). It is well-known that KM (the Michaelis constant) is often associated 
with the affinity of the enzyme for substrate, or more accurately is a measure of the substrate 
concentration required for effective catalysis to occur. On the other hand, Kcat gives a direct 
measure of the catalytic production of product under optimum conditions (saturated enzyme). 
Consequently, the Kcat/KM ratio is often thought of as a measure of enzyme efficiency. So the 
higher values for assay C revealed a good specificity and enzymatic efficiency. Moreover the 
good quenching efficiency, shown in table 6, confirms the correlation between catalytic activity 
and fluorogenic quenching. 
 
Table 6. Specificity constants for substrates A-C and relative quenching efficiencies 
 
Substrate 
 
Kcat/KM Q.E. (%) 
Invitrogen Peptide (Method A) 1286.13 M-1 s-1 98.77 
Casein-FITC (Method B) 3298.23 M-1 s-1 83.55 
M-2420 (Method C) 6221.61 M-1 s-1 91.38 
 
Definitely, in search of a FRET assays for the most reliable BACE1 inhibition test, we have 
investigated on the variability of the results depending on the substrate nature, on changed 
fluorophores and on different enzyme origin. Among the three FRET evaluated methods, the A 
assay suffers from a low predictivity but boast a good selective wavelength for fluorescence 
measure, so the majority of compounds, also intrinsically coloured, could be evaluated. In 
addition, even though B assay shows modest predictivity, it has been used for a fast screen of 
inhibitors because it is cheap and versatile for other aspartic proteases, such as CatD. Finally, the 
C assay has shown to be the most predictive test even though is not suitable for any kind of 
inhibitors due to its non selective wavelength for the fluorescence measure. 
In conclusion, for a preliminary evaluation of compounds is not sufficient to perform 
experiments only by one specific method because each one has some advantages and 
disadvantages. The most active compound will have to be investigated on parallel studies with 
all substrates, prior to cellular assays. Regarding the specific FRET employed assays, we need to 
exclude that a specific inhibitor could establish some certain interactions with substrate, and 
compete with the sites where the different fluorophores reside during enzymatic substrate 
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cleavage. This consideration reflects the variability of emitted fluorescence, and consequently, of 
the evaluated activity profile. 
So far, results variability does not allow us to define which the best assay to be trusted is. 
Surely, a couple of different assays could give a good consistency of the result, in order to guide 
structure activity relationship on lead modification, and to select a good candidates for cellular 
BACE1 inhibition test. 
For this reason, we decide to test on cellular assays our first promising candidate, lipocrine. 
Preliminary data confirmed a micromolar activity on cellular assay (EC50 = 3.7 µM) 
strengthening the idea to find a small molecule non-peptidomimetic compound as BACE1 
inhibitor. Moreover, after deep investigation on lead modification and validation assay reliability, 
promising results obtained from compound 22, seemed to disclose new avenues for the 
developing a new quinazoline-based BACE1 inhibitor. Definitely 2-amino-quinazoline 
compounds could represent the starting point for further studies on lead optimization, with the 
aim of discovery a more potent chemical entity able to inhibit the key enzyme in AD 
pathogenesis. 
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5.3 Synthesis of δ-aminocyclohexane carboxylic acid-based BACE1 
inhibitors 
 
Carbocyclic δ-aminoacids (Fig. 3) with stereochemically defined substitution are not known in 
the context of peptidomimetic design. In this regard, the aim of the project was to incorporate 
such a constrained carbocyclic aminoacids in a potential inhibitors of BACE1 endowed with 
reduced peptidic character.  
OH
ONH2
H H
R 13' 3
A
 
Figure 3. δ-Aminocyclohexane carboxylic acid motif A. 
 
The target structure A was previously synthesized in Hanessian's lab using a well-known 
multistep synthesis, starting from a chiral aminoacid as depicted in the retrosynthetic analysis 
exemplified in figure 4. 
Pr
NBn2H CO2Me
H
Pr
NBn2
CO2Me
Pr
NBn2
CO2Me Pr
NBn2
CO2Et Pr CO2H
NH2
L-norvaline
A
 
Figure 4. Retrosynthetic analysis of δ-aminocyclohexane carboxylic acid motif A starting from a chiral 
aminoacid (L-norvaline). 
 
The alternative approach to get the δ-aminocyclohexane carboxylic acid motif A was based on 
a novel asymmetric synthesis. In particular, it was envisioned an organocatalytic asymmetric 
conjugate addition of nitroalkanes to cyclohexenone. The resulting 3-(α-nitroalkyl)-
cyclohexanones were further functionalized to give the corresponding δ-nitroalkyl cyclohexane 
carboxylic acids that were elaborated to the target structures 3-(α-aminoalkyl)-1-cyclohexane 
carboxylic acids exemplified by A (Figure 3) in a new readily accessible way. 
The first proline-catalyzed addition of 2-nitropropane to cyclohexenone was reported by 
Yamaguchi and co-workers in 1993.10 Using rubidium L-prolinate, they achieved an ee of 59% 
for cyclohexenone. In 2000, Hanessian and co-workers reported on a substantial improvement in 
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the addition of 2-nitropropane to cyclohexenone in the presence of 10% mol of L-proline, in 
conjunction with 2,6-dimethylpiperazine as an additive. The reaction profile exhibited an 
unusual non-linear effect, before reaching ee values ranging 89-93%.11 Since then, the 
enantioselectivity of this reaction has been extended with trans-4,5-methano-L-proline to 99% 
ee.12 
Particularly, in this project we explored the feasibility of 1-nitroalkane additions to 2-
cyclohexenones and further functionalisation of the resulting 3-(α-nitroalkyl)-cyclohexanones. 
These intermediate were elaborated to the corresponding δ-nitroalkyl cyclohexane carboxylic 
acids as an alternative approach to the target strucures 3-(α-aminoalkyl)-1-cyclohexane 
carboxylic acids exemplified by A (Fig. 3). Based on our previous experience,12 it was expected 
that the addition of a 1-nitroalkane to 1-cyclohexenone would lead to a diastereomer in which the 
stereogenic centre at C3 of the resulting cyclohexanone would be fixed as a result of the 
stereodifferentiating event during the approach of the nitronate anion at the azadienium 
carboxylate stage (Fig. 5).  
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Figure 5. Proposed intermediates in the organocatalytic 1-nitroalkane addition to 2-cyclohexenone in the 
presence of D-Proline. 
 
However, the stereochemical fate of the carbon atom bearing the C3' residing 1-nitro alkyl 
appendage would be difficult to predict, since it could undergo proton-abstraction and 
reprotonation after the initial attack. This appears to be no stereochemical bias to favour one 
diastereomer over another (Fig. 5). However, the results show that there is a stereochemical 
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preference for the less polar, minor (R,S)-diastereomers in the case of the propyl and butyl chains 
in 70 and 72, respectively as evidenced by the higher ee values (Table 5).  
 
Table 5 Catalytic enantioselective addition of nitroalkane to cyclohexenone catalyzed by D-proline 
O
69
+
R NO2
less polar
syn-isomer
70 R = Et
72 R = Pr
more polar
anti -isomer
71 R = Et
73 R = Pr
D-proline (10 mol% cat),
trans-2,5-dimethylpiperazine,
CHCl3, rt, 48 h
R
NO2
H O
R
NO2
H O
 
R 
Yield 
(%) 
dra 
(syn:anti) 
ee (%)b 
   Syn anti 
Ethyl 84 1 : 2.2 89 74 
Propyl 97 1 : 2.0 89 71 
a
 obtained by RP Chiral HPLC and 1H-NMR at 700 MHz 
b
 obtained by RP Chiral HPLC (see Experimental Section) 
 
The iminium ion A initially formed from 1-cyclohexenone with the 1-nitroalkane provides the 
necessary bias for a Si-face attack by the nitronate anion with its associated bulky conjugate base 
leading to the corresponding enamines B1 and B2 (Fig. 5). Release of the D-proline by the 
hydrolysis of iminium ions C1 and C2 leads to the observed products 70 and 72, respectively, 
and the catalytic cycle continues. 
In 2000, Hanessian and coworkers11 showed that the conjugate addition of 1-nitropropane to 2-
cyclohexenone in the presence of 10 mol% of L-proline and trans-1,5-dimethylpiperazine as 
additive in CHCl3 afforded a 80% yield of a 1:2 mixture of ent.70 and ent.71. The diastereomeric 
excesses determined by 13C NMR analysis of the corresponding ketals with (2R,3R)-2,3-
butanediol, were 85% and 72% for ent.70 and ent.71, respectively. In the presence of trans-4,5-
methano-L-proline as a catalyst, there was a measurable improvement in diastereoselectivity to 
91% and 74%, respectively. 
In the present study, these results were independently confirmed by HPLC analysis on chiral 
columns. Furthermore, the stereochemical identity of the less polar syn-isomers 70 and 72 were 
definitively confirmed by comparison with conversion to compounds 80 and 81 prepared from 
the aminoacid route. 
A priori, it is difficult to rationalize the preponderance of the more polar anti-isomers 71 and 
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73 by a ratio of 2:1 over the less polar syn-counterparts 70 and 72, respectively. The ratio appears 
to be a thermodynamic one under the reaction conditions. Nevertheless, it is interesting that the 
desired syn-isomers 70 and 72 in the context of our intended carbocyclic aminoacid motif A 
(Fig. 3), was produced in an enriched form corresponding to an enantiomeric ratio of 
approximately 95:5. In this regard, the modest enantiomeric excesses of the anti-(3S,3'R) isomers 
71 and 73 (74% and 71%, respectively), were significantly better than the corresponding isomers 
with Mauroka's N-spiro chiral quaternary ammonium bromide phase transfer catalyst, where an 
ee of 57% was reported.13 However, the ratios of diastereomers in Maruoka’s study were highly 
in favour of the enantioenriched syn-isomer 70 (syn/anti 96:4, 91% and 57% ee, respectively). 
In conclusion, proline catalysis has shown an efficient tool to obtain highly enantiopure 
addition product from nitroalkanes and cyclohexenone. Further straightforward elaboration of 
nitro alkanes intermediate led us to build an alternative organocatalytic route to access 
cyclohexane carboxylic δ-aminoacid. In the context of the peptidomimetics BACE1 program, 
this new asymmetric route was compared to a previous substrate-controlled route resulting in a 
shorter, asymmetric, and more elegant way to access the δ-aminocyclohexane carboxylic core.  
During this thesis drafting, we do not have biological evaluation on behalf of the presented 
compounds available yet. In the context of the peptidomimetics BACE1 program we are waiting 
to know activity profiles and selectivity tests of designed ligands in order to guide future work 
on the δ-aminocyclohexane carboxylic core as structural motif for new small size BACE1 
inhibitors. 
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Chapter 6 
 
Experimental Section 
 
6.1 Chemistry 
Anhydrous solvents were transferred under a positive pressure of Ar from a solvent dispensing 
system or obtained from commercial suppliers. All commercially available reagents were used 
without further purification. Melting points were taken in glass capillary tubes on a Büchi SMP-
20 apparatus and are uncorrected. Optical rotations were recorded in a 1 dm cell at ambient 
temperature with a sodium lamp (wavelength of 589 nm) using a 100 mm cell with a 1 mL 
capacity and are given in units of 10-1 deg cm2 g-1.  
1H NMR, 13C NMR, gHSQC and COSY experiments were recorded on Mercury 400 and 
Varian VXR 200 and 300 instruments (Università di Bologna) or Bruker AMX-300, ARX-400, 
AV-400 spectrometers (Université de Montréal). Chemical shifts are reported in parts per million 
(ppm) relative to tetramethylsilane (TMS), and spin multiplicities are given as s (singlet), d 
(doublet), dd (double doublet), t (triplet), br t (broad triplet), q (quartet) or m (multiplet) and 
coupling constants (J) were reported in Hertz. When the IR spectra data are not included 
(because of the lack of unusual features), they were obtained for all compounds reported and 
were consistent with the assigned structures. The elemental compositions of the compounds 
agreed to within ± 0.4% of the calculated value. When the elemental analysis is not included, 
crude compounds were used in the next step without further purification. 
Analytical thin-layer chromatography was performed on 60F254 pre-coated silica gel plates. 
Visualization was achieved using ultraviolet light and/or staining in a iodine chamber, or with 
ceric ammonium molybdate, potassium permanganate, ethanolic solution of anisaldehyde or 
ninhydrin. Flash chromatography was performed on a column of 230-400 mesh silica gel or 
Kieselgel 40, 0.040-0.063 mm; (Merck) with the indicated solvent system. Gravity column were 
performed with Kieselgel 60, 0.063-0.200 mm; (Merck). Compounds were named following 
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IUPAC rules as applied by ChemBioDraw Ultra 11.0, a PC integrated software package for 
systematic names in organic chemistry. 
IR, electron impact (EI) and direct infusion ESI-MS analyses performed by Department of 
Organic Chemistry “A. Mangini” (Università di Bologna) were obtained on Perkin-Elmer 297, 
VG 7070E, and Waters ZQ 4000 apparatus, respectively. Low and high resolution mass analyses 
performed by Centre Régional de Spectroscopie de l’Université de Montréal were obtained on 
AEI-MS 902, MS-50 or LC-MSD-TOF spectrometers using ES or FAB techniques. Either 
protonated molecular ions [M+H]+ or sodium adducts [M+Na]+ were used for empirical ion 
confirmation. LC-MS analyses were performed on LC-Gilson apparatus (autoinjector model 234, 
pump 322), Thermo Finnigan LCQ Advantage MS and TSP UV6000 interface. 
 
General procedure for the synthesis of compounds 1-6 and 8-10. (Procedure A) 
A solution of the appropriate amine (1 eq, 0.1 M) and (±)-lipoic acid (1.5 eq) in dry DMF (5 
mL), under N2 was cooled to 0 °C and then treated with 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCI·HCl) (1.2 eq): the mixture was stirred at 0 °C for further 
15 min and then at rt for 2 h in the dark. Solvent was then removed under vacuum, avoiding 
heating up the reaction mixture, affording an oily residue that was purified by gravity column. 
 
General procedure for the synthesis of compounds 11-13, 19-20 and 22 (Procedure B) 
To a solution of the appropriate amine (1 eq, 0.05 M) in anhydrous THF, NEt3 (1 eq) and (±)-
lipoic acid (1 eq), under N2 were added. The reaction mixture was cooled to 0 °C and then 
treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI·HCl) (1 eq): 
the mixture was stirred at 0 °C for 20 min and then was allowed to reach rt overnight in the dark. 
Solvent was then removed under vacuum, avoiding heating up the reaction mixture, affording an 
oily residue that was purified by column chromatography. 
 
N
HN
H
N
O
SS
1
 
5-(1,2-dithiolan-3-yl)-N-(2-(1,2,3,4-tetrahydroacridin-9-ylamino)ethyl)pentanamide (1). It 
was synthesized from N1-(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine 321 (140 mg) 
following the procedure A. Elution with petroleum ether/CH2Cl2/MeOH/aqueous 30% ammonia 
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(6:3:1:0.055) afforded 1 as a foam solid: 35% yield; 1H NMR (300 MHz, CD3OD) δ 8.12 (d, J = 
8.8 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.58, (t, J = 8.2 Hz, 1H), 7.39 (t, J = 8.2 Hz, 1H), 3.70 (t, J 
= 6.3 Hz, 2H), 3.28-3.39 (m, 3H), 2.93-3.15 (m, 4H), 2.71-2.79 (m, 2H), 2.26-2.40 (m, 1H), 2.15 
(t, J = 8.6 Hz, 2H), 1.64-1.93 (m, 5H), 1.30-1.61 (m, 6H); MS (ESI+) m/z 430 [M+1]+. Calcd. for 
C23H31N3OS2: C, 64.30; H, 7.27; N, 9.78; found C, 64.41; H, 7.28; N, 9.75. 
 
N
HN N
H
O
S
S
2
 
5-(1,2-dithiolan-3-yl)-N-(3-(1,2,3,4-tetrahydroacridin-9-ylamino)propyl)pentanamide (2). 
It was synthesized following the procedure A, from N1-(1,2,3,4-tetrahydroacridin-9-yl)propane-
1,3-diamine 33 (100 mg), obtained from 9-chloro-1,2,3,4-tetrahydroacridine and propane-1,3-
diamine following the procedure described in Carlier et al.2, and purified by flash 
chromatography with a step gradient system of CH2Cl2/MeOH/aqueous 30% ammonia 
(9.5:0.5:0.0 to 7:3:0.1): 65% yield, 1H NMR (200 MHz, CD3OD) δ 8.08 (d, J = 8.8 Hz, 1H), 7.78 
(d, J = 8.7 Hz, 1H), 7.53, (t, J = 8.3 Hz, 1H), 7.32 (t, J = 8.3 Hz, 1H), 3.54 (t, J = 6.7 Hz, 2H), 
2.87-2.98 (m, 2H), 2.65 (t, J = 7.5 Hz, 4H), 1.64-1.93 (m, 6H). Elution with petroleum 
ether/CH2Cl2/MeOH/aqueous 30% ammonia (5:4:1:0.05) afforded 2 as a foam solid: 35% yield; 
1H NMR (200 MHz, CD3OD) δ 8.15 (d, J = 8.8 Hz, 1H), 7.78 (d, J =8.8 Hz, 1H), 7.56-7.64 (m, 
1H), 7.37-7.44 (m, 1H), 3.69 (t, J = 6.6 Hz, 2H), 3.40-3.52 (m, 1H), 3.23-3.36 (t, J = 6.6 Hz, 
2H), 2.92-3.18 (m, 4H), 2.74-2.83 (m, 2H), 2.28-2.43 (m, 1H), 2.19 (t, J = 7.1 Hz, 2H), 1.73-
1.95 (m, 7H), 1.22-1.68 (m, 6H). MS (ESI+) m/z 444 [M+1]+. Calcd. for C24H33N3OS2: C, 64.97; 
H, 7.50; N, 9.47; found C, 65.18; H, 7.52; N, 9.44. 
 
N
HN
H
N
O
SS
3
 
5-(1,2-dithiolan-3-yl)-N-(4-(1,2,3,4-tetrahydroacridin-9-ylamino)butyl)pentanamide (3). 
It was synthesized from N1-(1,2,3,4-tetrahydroacridin-9-yl)butane-1,4-diamine 342 (290 mg) 
following the procedure A. Elution with petroleum ether/CH2Cl2/MeOH/aqueous 30% ammonia 
(6:3:1:0.06) afforded 3 as a foam solid: 38% yield; 1H NMR (200 MHz, CD3OD) δ 8.12 (d, J = 
8.6 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.52-7.62 (m, 1H), 7.32-7.43 (m, 1H), 3.41-3.60 (m, 3H), 
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2.90-3.21 (m, 6H), 2.68-2.77 (m, 2H), 2.31-2.46 (m, 1H), 2.17 (t, J = 6.9 Hz, 2H), 1.38-1.95 (m, 
15H); MS (ESI+) m/z 458 [M+1]+. Calcd. for C25H35N3OS2: C, 65.60; H, 7.71; N, 9.18; found C, 
65.67; H, 7.69; N, 9.15. 
 
N
HN N
H
O
S
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5-(1,2-dithiolan-3-yl)-N-(5-(1,2,3,4-tetrahydroacridin-9-ylamino)pentyl)pentanamide (4). 
It was synthesized from N1-(1,2,3,4-tetrahydroacridin-9-yl)pentane-1,5-diamine 352 (480 mg) 
following the procedure A. Elution with petroleum ether/CH2Cl2/MeOH/aqueous 30% ammonia 
(6:3:1:0.055) afforded 4 as a foam solid: 40% yield; 1H NMR (200 MHz, CD3OD) δ 8.09 (d, J = 
8.6 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.52-7.60 (m, 1H), 7.33-7.41 (m, 1H), 3.40-3.57 (m, 3H), 
2.87-3.18 (m, 6H), 2.63-2.75 (m, 2H), 2.25-2.43 (m, 1H), 2.17 (t, J = 6.8 Hz, 2H), 1.35-1.95 (m, 
17H); MS (ESI+) m/z 472 [M+1]+. Calcd. for C26H37N3OS2: C, 66.20; H, 7.91; N, 8.91; found C, 
66.41; H, 7.89; N, 8.88. 
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H
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5-(1,2-dithiolan-3-yl)-N-(6-(1,2,3,4-tetrahydroacridin-9-ylamino)hexyl)pentanamide (5). 
It was synthesized from N1-(1,2,3,4-tetrahydroacridin-9-yl)hexane-1,6-diamine 362 (370 mg) 
following the procedure A. Elution with petroleum ether/CH2Cl2/MeOH/aqueous 30% ammonia 
(6:3:1:0.05) afforded 5 as a foam solid: 30% yield; 1H NMR (200 MHz, CDCl3) δ 7.83 (apparent 
t, J = 9.3 Hz, 2H), 7.47-7.56 (m, 1H), 7.28-7.37 (m, 1H), 5.89 (t, J = 3.2 Hz, 1H, exchangeable 
with D2O), 4.15 (br s, 2H, exchangeable with D2O), 3.40-3.57 (m, 3H), 3.01-3.23 (m, 6H), 2.60-
2.75 (m, 2H), 2.31-2.48 (m, 1H), 2.15 (t, J = 7.3 Hz, 2H), 1.35-1.96 (m, 19H); MS (ESI+) m/z 
486 [M+1]+. Calcd. for C27H39N3OS2: C, 66.76; H, 8.09; N, 8.65; C, 66.87; H, 8.12; N, 8.62. 
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N-(3-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)propyl)-5-(1,2-dithiolan-3-
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yl)pentanamide (6). It was synthesized following the procedure A, from N1-(6-chloro-1,2,3,4-
tetrahydroacridin-9-yl)propane-1,3-diamine 23 (180 mg), obtained from 6,9-dichloro-1,2,3,4-
tetrahydroacridine and propane-1,3-diamine following the procedure described in Carlier et al.,2 
and purified by flash chromatography with a step gradient system of CH2Cl2/MeOH/aqueous 
30% ammonia (9.5:0.5:0.0 to 8:2:0.03): 70% yield, 1H NMR (200 MHz, CDCl3) δ 7.93 (d, J = 
9.1 Hz, 1H), 7.86 (d, J = 2.4 Hz, 1H), 7.22 (dd, J = 9.0, 2.3 Hz, 1H), 3.62 (t, J = 6.8 Hz, 2H), 
2.88-3.05 (m, 4H), 2.60-2.68 (m, 2H), 1.71-1.95 (m, 6H). Elution with petroleum 
ether/CH2Cl2/EtOH/aqueous 30% ammonia (7:2:1:0.03) afforded 6 as a foam solid: 35% yield; 
1H NMR (200 MHz, CD3OD) δ 8.08 (d, J = 8.9 Hz, 1H), 7.72 (d, J = 2.1 Hz, 1H), 7.28 (dd, J = 
8.9, 2.1 Hz, 1H), 3.42-3.58 (m, 3H), 3.27 (t, J = 6.5 Hz, 2H), 2.89-3.17 (m, 4H), 2.65-2.77 (m, 
2H), 2.27-2.43 (m, 1H), 2.19 (t, J = 7.2 Hz, 2H), 1.73-1.91 (m, 7H), 1.31-1.65 (m, 6H); MS 
(ESI+) m/z 478 [M+1]+. Calcd. for C24H32ClN3OS2: C, 60.29; H, 6.75; N, 8.79; found C, 60.45; 
H, 6.74; N, 8.77. 
 
NCl
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H
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N-(3-(6-chloro-1,2,3,4-tetrahydroacridin-9-ylamino)propyl)-5-(thiophen-2-
yl)pentanamide (7). It was synthesized from N1-(6-chloro-1,2,3,4-tetrahydroacridin-9-
yl)propane-1,3-diamine 23 (0.350 g, 1.21 mmol), 5-(thiophen-2-yl)pentanoic acid (0.334 g, 1.82 
mmol) and EDCI·HCl (0.278 g, 1.45 mmol) following the procedure A. Purification by flash 
chromatography (petroleum ether/CH2Cl2/MeOH/aqueous 30% ammonia, 6.0:3.5:0.5:0.007) 
afforded 7 (0.441 g, 80 %) as a yellowish wax. 1H NMR (CDCl3, 200 MHz) δ 8.70 (br t, 1H, 
exchangeable with D2O) 7.96 (d, 1H, J = 8.8 Hz), 7.88 (d, 1H, J = 2.2 Hz), 7.23 (d, 1H, J = 1.8 
Hz), 7.09-7.01 (m, 1H), 6.91 (t, 1H, J = 3.6 Hz), 6.76-6.78 (m, 1H), 6.05 (br t, 1H, exchangeable 
with D2O), 3.48-3.52 (m, 4H), 3.02-3.05 (m, 2H), 2.85 (t, 2H, J = 6.6 Hz), 2.71-2.76 (m, 2H), 
2.25 (t, 2H, J = 6.6 Hz), 1.71-1.90 (m, 10H).  MS (ESI+) : m/z  456 [M+1]+. 
 
O
N
NHBoc
38
 
tert-Butyl 3-(3-(1-(dimethylamino)ethyl)phenoxy)propylcarbamate (38). A solution of 
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compound 37 was synthesised following the procedure described for the corresponding (R,S)-3-
(1-(Di-(2H3)methylamino)ethyl)phenol in Ciszewska et al.3 (0.350 g, 2.17 mmol), tert-butyl 3-
chloropropylcarbamate (0.420 g, 2.17 mmol) and K2CO3 (0.300 g, 2.17 mmol) in DMF (10 mL) 
was stirred under reflux conditions for 24 h. Evaporation of the solvent afforded a residue which 
was purified by gravity column. Elution with CHCl3/MeOH/aqueous 30% ammonia (9:1:0.02) 
afforded 38 (0.454 g, 65 %) as an oil. 1H NMR (CDCl3, 200 MHz) δ 7.20 (t, J = 8.0 Hz, 1H), 
6.79-6.89 (m, 3H), 4.92 (br s, 1H, exchangeable with D2O), 4.02 (t, J = 6.4 Hz, 2H), 3.20-3.33 
(m, 3H), 2.20 (s, 6H), 1.93-1.99 (m, 2H), 1.44 (s, 9H), 1.35 (d, J = 6.6 Hz, 3H). 
 
O
N
39
NH2
 
3-(3-(1-(Dimethylamino)ethyl)phenoxy)propan-1-amine (39). To a solution of 38 (0.200 g, 
0.62 mmol) in CH2Cl2 (5 mL) trifluoroacetic acid (1.5 mL) was added. The reaction mixture was 
stirred at rt for 2 hr and evaporated in vacuum. The obtained residue was dissolved in water, 
made basic by adding 2N NaOH and then extracted with CHCl3 (3 × 20 mL). Evaporation of the 
dried solvent afforded 39 (0.137 g, quantitative). 1H NMR (CDCl3, 200 MHz) δ 7.20 (t, J = 8.0 
Hz, 1H), 6.72-6.88 (m, 3H), 4.04 (t, J = 6.2 Hz, 2H), 3.12-3.22 (m, 1H), 2.91 (t, J = 6.6 Hz, 2H),  
2.19 (s, 6H), 1.88-1.95 (m, 2H), 1.43 (br s, 2H, exchangeable with D2O), 1.34 (d, J = 6.6 Hz, 
3H). 
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N-(3-(3-(1-(Dimethylamino)ethyl)phenoxy)propyl)-5-(1,2-dithiolan-3-yl)pentanamide (8). 
It was synthesized from 39 (0.150 g, 0.67 mmol) and (±)-lipoic acid (0.210 g, 1.02 mmol) 
following the procedure A. Elution with petroleum ether/toluene/CH2Cl2/MeOH/aqueous 30% 
ammonia (6:1:1.5:1.5:0.01) afforded 8 (0.080 g, 30 %) as a waxy solid. 1H NMR (CDCl3, 200 
MHz)  δ 7.27 (t, J = 8.2 Hz, 1H), 6.98-6.78 (m, 3H), 5.99 (br t, 1H), 4.09 (t, J = 6.0 Hz, 2H), 
3.62-3.21 (m, 5H), 3.19-3.05 (m, 3H), 2.53-2.40 (m, 1H), 2.32 (s, 6H), 2.22 (t, J = 7.2 Hz, 2H),  
1.99-1.81 (m, 3H), 1.73-1.65 (m, 4H), 1.47 (d, J = 6.6 Hz, 3H). MS (ESI+) : m/z  411 [M+1]+. 
Calcd for C21H34N2O2S2: C, 61.42; H, 8.35; N, 6.82. found: C, 61.62; H, 8.36, N, 6.80. 
Experimental Section 
 123
 
42
O
N NHBoc
 
tert-Butyl 3-((1-(3-methoxyphenyl)ethyl)(methyl)amino)propylcarbamate (42). A solution 
of 1-(3-methoxyphenyl)-N-methylethanamine 414 (0.320 g, 1.9 mmol), tert-butyl 3-
chloropropylcarbamate (0.370 g, 1.9 mmol) and K2CO3 (0.260 g, 1.9 mmol) and a catalytic 
amount of KI in DMF (10 mL) was stirred under reflux conditions for 24 h. Evaporation of the 
solvent afforded a residue which was purified by gravity column. Elution with CHCl3/MeOH/ 
aqueous 30% ammonia (9:1:0.005) afforded 42 (0.245 g, 40 %) as an oil. 1H NMR (CDCl3, 200 
MHz) δ 7.20 (t, J = 8.0 Hz, 1H), 6.95-6.74 (m, 3H), 5.38 (br s, 1H, exchangeable with D2O), 
3.80 (s, 3H), 3.50 (q, J = 7.0 Hz, 1H), 3.13 (q, J = 6.2 Hz, 2H), 2.52-2.30 (m, 2H), 2.19 (s, 3H), 
1.68-1.54 (m, 2H), 1.44 (s, 9H), 1.35 (d, J = 6.6 Hz, 3H). 
 
43
O
N NH2
 
N1-(1-(3-Methoxyphenyl)ethyl)-N1-methylpropane-1,3-diamine (43). It was obtained as an 
oil from 42 (0.230 g, 0.62 mmol) and trifluoroacetic acid (1.5 mL) in CH2Cl2 (5 mL) following 
the procedure described for 39; (0.137 g, quantitative yield). 1H NMR (CDCl3, 200 MHz) δ 7.27 
(t, J = 8.0 Hz, 1H), 6.97-6.80 (m, 3H), 3.85 (s, 3H), 3.54 (q, J = 6.6 Hz, 1H), 2.74 (t, J = 6.6 Hz, 
2H), 2.58-2.30 (m, 2H), 2.25 (s, 3H), 1.67-1.55 (m, 2H+2H exchangeable with D2O), 1.39 (d, J = 
7.0 Hz, 3H). 
 
9
O
N
H
N
O
SS
 
5-(1,2-Dithiolan-3-yl)- N-(3-((1-(3-methoxyphenyl)ethyl)(methyl)amino) 
propyl)pentanamide (9). It was synthesised from 43 (0.130 g, 0.59 mmol) and (±)-lipoic acid 
(0.240 g, 1.47 mmol) following the procedure A, and purified by gravity column 
chromatography. Elution with petroleum ether/CH2Cl2/EtOH/aqueous 30% ammonia 
(5.5:3.5:1:0.015) afforded 9 (0.133 g, 55 %) as a waxy solid. 1H NMR (CDCl3, 200 MHz)  δ 7.23 
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(t, J = 7.8 Hz, 1H), 6.90-6.75 (m, 3H), 6.56 (br s, 1H, exchangeable with D2O), 3.79 (s, 3H), 
3.58-3.47 (m, 2H), 3.25-3.05 (m, 4H), 2.45-2.37 (m, 3H), 2.20 (s, 3H), 2.03 (t, J = 7.2 Hz, 2H),  
1.97-1.82 (m, 1H), 1.73-1.38 (m, 8H), 1.34 (d, J = 6.4 Hz, 3H). MS (ESI+) : m/z 411 [M+1]+. 
Calcd for C21H34N2O2S2: C, 61.42; H, 8.35; N, 6.82. Found: C, 61.65; H, 8.36, N, 6.81. 
 
H
N
O
SS
N
O
10
 
5-(1,2-dithiolan-3-yl)-N-(6-(ethyl(2-methoxybenzyl)amino)hexyl)pentanamide (10). It was 
synthesized from N1-ethyl-N1-(2-methoxybenzyl)hexane-1,6-diamine 445 (0.300 g, 1.13 mmol) 
and lipoic acid (0.350 g, 1.70 mmol) following the procedure A, and purified by gravity column 
chromatography. Elution with a gradient of mobile phase petroleum 
ether/toluene/CH2Cl2/EtOH/aqueous 30% ammonia (7:2:1:1:0.05 to 7:1:1:1:0.05) afforded 10 
(0.219 g, 43 %) as a waxy solid. 1H NMR (CDCl3, 200 MHz) δ 7.48-7.42 (m, 1H), 7.26-7.18 (m, 
1H), 6.99-6.85 (m, 2H), 5.43 (br s, 1H, exchangeable with D2O), 3.84 (s, 3H), 3.64-3.53 (m, 1H 
+ s, 2H), 3.27-3.08 (m, 4H), 2.57-2.43 (m, 5H), 2.17 (t, J = 7.4 Hz, 2H), 2.00-1.82 (m, 1H), 1.73-
1.29 (m, 14H), 1.07 (t, J = 7.0 Hz, 3H). MS (ESI+) : m/z  453 [M+1]+. Calcd for C24H40N2O2S2: 
C, 63.67; H, 8.91; N, 6.19. Found: C, 63.79; H, 8.93, N, 6.17. 
 
24
O
O N
N
HN NHBoc
Cl
 
tert-Butyl 3-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)propylcarbamate (24). To a 
stirred solution of 2,4-dichloro-6,7-dimethoxyquinazoline 45 (1.00 g, 3.86 mmol) in anhydrous 
DMF (15 mL) was added a solution of tert-butyl 3-aminopropylcarbamate (1.01 g, 5.79 mmol) 
in DMF and NEt3 (0.54 mL, 3.86 mmol). The resulting mixture was stirred at rt overnight, then 
was poured in ice-water and extracted with CH2Cl2 (2 × 100 mL), washed with water. The 
organic phase was dried over Na2SO4 and concentrated. Diethyl ether was added to the residue 
and the obtained suspension was stirred to remove DMF traces from solid, then filtered and dried 
to obtain 24 (1.33 g, 86 %) as a crystalline white solid. 1H NMR (CDCl3, 200 MHz) δ 7.63 (br s, 
1H, exchangeable with D2O), 7.32 (s, 1H), 7.14 (s, 1H), 4.89 (br t, 1H, exchangeable with D2O), 
4.05 (s, 3H), 4.00 (s, 3H), 3.77 (q, J = 5.4 Hz, 2H), 3.36 (q, J = 6.2 Hz, 2H), 1.79 (m, J = 4.6 Hz, 
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2H), 1.50 (m, 9H). MS (ESI+) : m/z 397 [M+1]+. 
 
26
N
N
HN
O
O Cl
NH2
 
N1-(2-chloro-6,7-dimethoxyquinazolin-4-yl)propane-1,3-diamine (26). To a stirred solution 
of 24 (0.18 g, 0.45 mmol) in MeOH (3 mL) was added 3 N HCl solution (6 mL) and was allowed 
to stir at rt overnight. The reaction mixture was diluted with  40% NaOH aq. solution and 
extracted with CH2Cl2 (5 × 50 mL). The organic layer was dried over Na2SO4 and concentrated 
to obtain the free amine 26 (0.103 g, 77%) as a off-white solid. Mp = 210°-215 °C (dec.). 1H 
NMR (CDCl3, 200 MHz) δ 8.53 (br s, 1H, exchangeable with D2O) 7.13 (s, 1H), 6.98 (s, 1H), 
3.99 (s, 3H), 3.96 (s, 3H), 3.80 (q, J = 4.4 Hz, 2H), 3.10 (t, J = 5.6 Hz, 2H), 1.87 (m, 2H), 1.64 
(br s, 2H, exchangeable with D2O).  MS (ESI+) : m/z 297 [M+1]+. 
 
O
O
HN N
H
O
S S
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N
N
Cl
 
N-(3-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide (11). It was synthesised from 26 (0.15 g, 0.505 mmol), NEt3 (70 µL, 0.505 
mmol), (±)-lipoic acid (0.104 g, 0.505 mmol) and EDCI·HCl (0.097 g, 0.505 mmol) following 
the procedure B. Purification by gravity column chromatography (petroleum 
ether/CH2Cl2/EtOH/aqueous 30% ammonia, 5:4.5:0.5:0.01) afforded 11 (0.110 g, 45 %) as a 
yellowish oil. 1H NMR (CDCl3, 300 MHz) δ 7.46 ( br t, J = 5.8 Hz, 1H, exchangeable with D2O), 
7.34 (s, 1H), 7.14 (s, 1H), 6.22 (t, 1H, exchangeable with D2O), 4.06 (s, 3H), 4.00 (s, 3H), 3.73 
(q, J = 4.8 Hz, 2H), 3.58 (m, J = 6.3 Hz, 1H), 3.45 (q, J = 6.0 Hz, 2H), 3.24-2.91 (m, 2H), 2.53-
2.42 (m, 1H), 2.32 (t, J = 7.5 Hz, 2H), 2.30-1.61 (m, 7H), 1.60-1.47 (m, 2H). 13C-NMR (CDCl3, 
75 MHz) δ 174.52, 160.58, 157.02, 155.07, 149.27, 147.93, 107.54, 107.22, 101.08, 56.63, 
56.57, 56.47, 40.52, 38.74, 37.34, 36.78, 36.21, 34.86, 29.69, 29.13, 25.75. MS (ESI+) : m/z 486 
[M+1]+. 
 
Chapter 6 
126 
O
O N
N
HN NHBoc
25
 
tert-Butyl 3-(6,7-dimethoxyquinazolin-4-ylamino)propylcarbamate (25). To a stirred 
solution of 466 (0.15 g, 0.67 mmol) in 2-propanol (20 mL) was added a solution of tert-butyl 3-
aminopropylcarbamate (0.12 g, 0.67 mmol) in 2-propanol. The resulting mixture was refluxed 
for 8 hr. After adding further amount of amine (0.04 g, 0.23 mmol) and refluxing another 16 hr 
the reaction mixture was allowed to cool to rt. The solvent was removed under reduced pressure, 
then diethyl ether was added, and the obtained suspension was stirred for a while. The 
precipitated formed was filtered under vacuum allowing to collect the title compound 25 (0.19 g, 
78 %) as  a white solid. 1H NMR (CDCl3, 200 MHz) δ 8.52 (s, 1H), 8.13 (br s, 1H, exchangeable 
with D2O), 7.49 (s, 1H), 7.36 (s, 1H) 5.10 (br s, 1H, exchangeable with D2O), 4.07 (s, 3H), 4.04 
(s, 3H), 3.80 (q, J = 5.6 Hz, 2H), 3.35 (q, J = 5.6 Hz, 2H), 1.82 (m, J = 4.6 Hz, 2H), 1.48 (m, 
9H). 
 
O
O N
N
HN NH2
48
 
N1-(6,7-Dimethoxyquinazolin-4-yl)propane-1,3-diamine (48). To a stirred solution of 25 
(0.18 g, 0.50 mmol) in MeOH (3 mL) was added 3 N HCl solution (7 mL) and was allowed to 
stir at rt overnight. The reaction mixture was diluted with  40% NaOH aq. solution and extracted 
with CH2Cl2 (5 × 50 mL). The organic layer was dried over Na2SO4 and concentrated to obtain 
the free amine 48 (0.10 g, 77%) as a colourless oil. 1H NMR (CDCl3, 300 MHz) δ 8.57 (s, 1H), 
7.83 (br s, 1H, exchangeable with D2O) 7.21 (s, 1H), 7.04 (s, 1H), 4.04 (s, 3H), 4.00 (s, 3H), 3.81 
(q, J = 3.9 Hz, 2H), 3.08 (q, J = 5.4 Hz, 2H), 1.99 (m, 2H), 1.80 (br s, 2H, exchangeable with 
D2O). MS (ESI+) : m/z 263 [M+1]+. 
 
O
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N
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N-(3-(6,7-Dimethoxyquinazolin-4-ylamino)propyl)-5-(1,2-dithiolan-3-yl)pentanamide 
(12). It was synthesised from 48 (0.08 g, 0.30 mmol), NEt3 (42 µL, 0.30 mmol), (±)-lipoic acid 
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(0.063 mg, 0.30 mmol) and EDCI·HCl (0.058 g, 0.30 mmol) following the procedure B. 
Purification by flash chromatography (CH2Cl2/MeOH 9.8:0.2) gave 12 (0.060 g, 44 %) as a 
yellowish oil. 1H NMR (CDCl3, 300 MHz) δ 8.51 (s, 1H), 7.57 (br s, 1H, exchangeable with 
D2O), 7.45 (s, 1H), 7.20 (s, 1H), 6.57 (t, J = 6.3 Hz, 1H, exchangeable with D2O), 4.05 (s, 3H), 
4.01 (s, 3H), 3.72 (q, J = 5.4 Hz, 2H), 3.56 (m, 1H), 3.47-3.25 (m, 3H), 3.22-3.07 (m, 2H), 2.46 
(m, 1H), 2.29 (t, J = 7.3 Hz, 2H), 2.00-1.40 (m, 8H). 13C-NMR (CDCl3, 50 MHz) δ 174.24, 
158.92, 154.53, 153.43, 149.21, 145.01, 108.20, 106.66, 101.08, 56.47, 56.29, 43.41, 40.33, 
38.56, 37.26, 36.62, 36.21, 34.69, 29.40, 28.97, 25.56. MS (ESI+) : m/z 451 [M+1]+. 
 
O
O N
N
HN NH2
49
CH3
 
N1-(6,7-dimethoxy-2-methylquinazolin-4-yl)propane-1,3-diamine (49). Following the 
procedure described in Millen et al.7, to a solution of 476 (0.60 g, 2.51 mmol) in anhydrous THF 
(20 mL) was added propane-1,3-diamine (420 µL, 5.03 mmol). Within 10 min the hydrochloric 
salt of diamine began precipitating out of the mixture. After stirring overnight at rt the solvent 
was removed in vacuo. The resulting crude was purified by flash column chromatography 
(CH2Cl2/MeOH 9.8:0.2) to obtain 49 (0.27 g, 40%) as an off-white solid. Mp = 110°-112 °C. 1H 
NMR (CDCl3, 200 MHz) δ 7.53 (s, 1H, exchangeable with D2O), 7.15 (s, 1H), 6.96 (s, 1H), 4.00 
(s, 3H), 3.97 (s, 3H), 3.82 (q, J = 5.4 Hz, 2H,), 3.04 (t, J = 6.0 Hz, 2H,), 2.62 (s, 3H), 1.87 (m, J 
= 6.0 Hz, 2H), 1.64 (br s, 2H, exchangeable with D2O).  
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N-(3-(6,7-Dimethoxy-2-methylquinazolin-4-ylamino)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide (13). It was synthesised from 49 (0.24 g, 0.87 mmol), NEt3 (121 µL, 0.87 
mmol), (±)-lipoic acid (0.179 g, 0.87 mmol) and EDCI·HCl (0.167 g, 0.87 mmol) following the 
procedure B. Purification by flash chromatography (CH2Cl2/MeOH 9.3:0.7) afforded 13 (0.170 
g, 42 %) as a yellowish oil. 1H NMR (CDCl3, 200 MHz) δ 7.30 (s, 1H), 7.13 (s, 1H), 7.05 (t, J = 
5.8 Hz, 1H, exchangeable with D2O), 6.57 (t, J = 5.8 Hz, 1H, exchangeable with D2O), 4.01 (s, 
3H), 3.97 (s, 3H), 3.73 (q, J = 6.0 Hz, 2H), 3.52 (m, 1H), 3.40 (q, J = 5.8 Hz, 2H), 3.25-3.03 (m, 
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2H), 2.60 (s, 3H), 2.52-2.23 (m, 5H), 1.97-1.45 (m, 7H). 13C-NMR (CDCl3, 50 MHz) δ 173.89, 
162.46, 159.09, 154.41, 151.08, 148.51, 106.84, 106.62, 100.81, 56.48, 56.36, 56.21, 40.33, 
38.55, 37.05, 36.68, 36.03, 34.70, 29.72, 28.98, 26.34, 25.60. MS (ESI+) : m/z 465 [M+1]+. 
 
N
N
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O
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tert-Butyl 3-(2-amino-6,7-dimethoxyquinazolin-4-ylamino)propylcarbamate (50). 
Following the procedure described in Ife et al.8, the chloroquinazoline 24 (0.45 g, 1.13 mmol) 
was dissolved in ethanolic ammonia (8 %) and heated in a sealed reactor at 140 °C for 24 hr. 
After cooling, solvent was evaporated off under vacuum and the obtained crude was purified by 
gravity column chromatography (CH2Cl2/MeOH/aqueous 30% ammonia, 9.5:0.5:0.07) to obtain 
the title compound 50 (160 mg, 37%) as a white solid. Mp = 105°-108 °C. 1H NMR (CDCl3, 300 
MHz) δ 7.15 (s, 1H), 6.87 (s, 1H), 6.85 (br s, 1H, exchangeable with D2O), 5.31 (br s, 1H, 
exchangeable with D2O), 4.76 (br s, 2H, exchangeable with D2O), 3.98 (s, 3H), 3.96 (s, 3H),  
3.70 (q, J = 5.8 Hz, 2H), 3.30 (q, J = 5.8 Hz, 2H), 1.77 (m, J = 6.0 Hz, 2H), 1.49 (s, 9H). MS 
(ESI+) : m/z 378 [M+1]+. 
 
N
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O
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N4-(3-aminopropyl)-6,7-dimethoxyquinazoline-2,4-diamine (51). To a stirred solution of 50 
(0.20 g, 0.529 mmol) in MeOH (2 mL) was added 3 N HCl solution (6 mL) and was allowed to 
stir at rt overnight. Concentration of the mixture under vacuum, using EtOH for the azeotropic 
removal of water, allowed to obtain the hydrochloride amine salt 51 (0.170 g, 91%) as a white 
solid. Mp = 280°-285 °C (dec.).1H NMR (CD3OD, 200 MHz) δ 7.63 (s, 1H), 6.92 (s, 1H), 3.99 
(s, 3H), 3.96 (s, 3H), 3.80 (t, J = 7.0 Hz, 2H), 3.07 (t, J = 7.4 Hz, 2H), 2.11 (m, J = 7.4 Hz, 2H). 
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N-(3-(2-amino-6,7-dimethoxyquinazolin-4-ylamino)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide (14). Following the procedure described in Karamanska et al.,9 to a stirred 
suspension of 51 hydrochloride (0.170 g, 0.485 mmol) in anhydrous DMF (15 mL) at 0 °C was 
added NEt3 (27 µL, 1.94 mmol), (±)-lipoic acid (0.100 g, 0.485 mmol) and EDCI·HCl (0.093 g, 
0.485 mmol) under nitrogen atmosphere. After stirring at 0 °C for 20 min, the resulting mixture 
was allowing to reach rt overnight in the dark. After adding a further amount of NEt3 (100 µL, 
7.18 mmol) and EDCI·HCl (0.050 g, 0.260 mmol)  and stirring at rt for  8 hr, solvent was 
removed under vacuum, avoiding heating up the reaction mixture. The residue was taken up in 
CH2Cl2 and washed with water (2 × 20 mL). The aqueous phase was re-extracted with CHCl3 to 
recover 80 mg of starting amine whereas the organic phase was dried (Na2SO4), dried and 
concentrated to afford a crude that was purified by gravity chromatography 
(CH2Cl2/MeOH/aqueous 30% ammonia, 9.2:0.8:0.03) to obtain 14 (0.050 g, 22 %, 46 % borsm) 
as a yellowish oil. 1H NMR (CDCl3, 300 MHz) δ 7.25 (s, 1H), 7.10 (br s, 1H, exchangeable with 
D2O), 6.89 (s, 1H), 5.98 (br t, J = 6.6 Hz, 1H, exchangeable with D2O), 4.96 (br s, 2H, 
exchangeable with D2O), 4.02 (s, 3H), 3.98 (s, 3H), 3.67 (q, J = 6.0 Hz, 2H), 3.57 (t, J = 6.3 Hz, 
1H), 3.45 (q, J = 6.0 Hz, 2H), 3.25-3.11 (m, 3H), 2.48 (m, 1H), 2.27 (t, J = 8.4 Hz, 2H), 2.00-
1.40 (m, 8H). MS (ESI+) : m/z 466 [M+1]+. 
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(E)-N-(3-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)propyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylamide (15). To a stirred solution of 26 (0.18 g, 0.607 mmol), trans-ferulic 
acid (0.118 g, 0.607 mmol) and NEt3 (254 µL, 1.82 mmol) in CH2Cl2 (50 mL), a 50% solution of  
propylphosphonic anhydride10 in DMF (0.464 mL, 0.728 mmol) was added. The resulting 
mixture was allowed to stir at rt for 8 hr, then was quenched with water, diluted with CH2Cl2 and 
washed with water (3 × 20 mL). The organic phase was dried over Na2SO4 and concentrated to 
obtain a crude that was purified by gravity column chromatography (CH2Cl2/MeOH 9.6:0.4) to 
obtain 15 (0.150 g, 53 %) as a white solid. Mp = 185°-188 °C.  1H NMR (CDCl3, 400 MHz) δ 
7.56 (d, J = 15.6 Hz, 1H), 7.44 (br t, 1H, exchangeable with D2O), 7.35 (s, 1H), 7.12 (s, 1H), 
7.08 (dd, J = 8.4, 1.5 Hz, 1H), 7.00 (d, J = 1.5 Hz. 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.39 (d, J = 
15.6 Hz, 1H), 6.28 (br t, 1H, exchangeable with D2O), 5.83 (br s, 1H, exchangeable with D2O), 
Chapter 6 
130 
4.09 (s, 3H), 3.98 (s, 3H), 3.93 (s, 3H), 3.75 (q, J = 4.8 Hz, 2H), 3.54 (q, J = 6.0 Hz, 2H), 1.87 
(m, 2H). 13C-NMR (CDCl3, 100 MHz) δ 166.70, 159.60, 158.80, 155.70, 151.50, 151.30, 147.30, 
144.90, 141.92, 128.80, 120.10, 118.80, 118.03, 109.63, 115.00, 111.92, 101.05, 56.59, 56.43, 
56.20, 37.31, 36.35, 29.71. MS (ESI-) : m/z  471 [M-1]-. 
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N-(3-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)propyl)acrylamide (16). To a stirred 
solution of 26 (0.10 g, 0.337 mmol) in  CH2Cl2 (15 mL) at 0 °C was added NEt3 (70 µL, 0.505 
mmol) and acryloyl chloride (40 µL, 0.50 mmol). After stirring at 0 °C for 20 min, the resulting 
mixture was allowing to reach rt in 6 hr. The reaction was quenched with water, diluted with 
CH2Cl2 and washed with water (3 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated to obtain a crude that was subjected to gravity column purification (CH2Cl2/MeOH 
9.5:0.5) to obtain 16 (0.080 g, 68 %) as a white solid. 1H NMR ((CD3)2SO, 200 MHz) δ 8.35 (br 
t, 1H, exchangeable with D2O), 8.19 (br t, 1H, exchangeable with D2O), 7.62 (s, 1H), 7.07 (s, 
1H), 6.30-6.17 (dd, J = 16.0, 10.0 Hz, 1H), 6.12-6.02 (dd, J = 16.0, 3.0 Hz, 1H), 5.62-5.55 (dd, J 
= 10.0, 3.0 Hz, 1H), 3.89 (s, 6H), 3.52 (q, J = 5.4 Hz, 2H), 3.25 (q, J = 5.4 Hz, 2H), 1.83 (m, 
2H). MS (ESI+) : m/z 351 [M+1]+. 
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tert-Butyl 6-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)hexylcarbamate (52). To a 
stirred solution of 2,4-dichloro-6,7-dimethoxyquinazoline 45 (0.20 g, 0.77 mmol) in anhydrous 
DMF (10 mL) was added tert-butyl 6-aminohexylcarbamate (0.519 mL, 2.32 mmol). The 
resulting mixture was stirred at rt for 2 hr. To the reaction mixture ice water was added until a 
suspension could be seen. The solid was filtered out and the filtrate was extracted with CH2Cl2 (2 
× 20 mL). The organic phase were dried over Na2SO4, concentrated and joined to the filtered 
solid. The overall residue was purified by flash column chromatography (petroleum 
ether/EtOAc, gradient from 8.8 :1.2 to 100% EtOAc) to obtain 52 (0.20 g, 60 %) as a white 
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solid. 1H NMR (CDCl3, 300 MHz) δ 7.29 (s, 1H), 7.12 (s, 1H), 6.78 (br s, 1H, exchangeable with 
D2O), 4.65 (br s, 1H, exchangeable with D2O), 3.96 (s, 6H), 3.63 (q, J = 6.0 Hz, 2H), 3.18 (q, J = 
6.0 Hz, 2H), 1.70 (t, J = 6.6 Hz, 2H), 1.49-1.33 (m, 15H). 13C NMR (CDCl3, 50 MHz) δ 160.32, 
156.67, 156.36, 154.75, 148.93, 147.73, 107.33, 106.83, 101.14, 79.41, 56.31, 56.18, 40.52, 
39.66, 30.12 (2C), 28.51 (3C), 25.46, 25.15.  MS (ESI+) : m/z 461 [M+23]+. 
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N1-(2-chloro-6,7-dimethoxyquinazolin-4-yl)hexane-1,6-diamine (53). To a stirred solution 
of 52 (0.070 g, 0.159 mmol) in MeOH (5 mL) was added 3 N HCl solution (5 mL) and was 
allowed to stir at rt overnight. MeOH was evaporated off under vacuum, then diluted and 
extracted with CH2Cl2 (3 × 10 mL). The organic layer was dried over Na2SO4 and concentrated 
to obtain the hydrochloride amine salt 53 (0.040 g, 75%) as a white solid. 1H NMR (CDCl3, 200 
MHz) δ 7.10 (s, 1H), 7.05 (s, 1H), 6.42 (t, 1H, exchangeable with D2O), 3.91 (s, 3H), 3.90 (s, 
3H), 3.60 (q, J = 6.2 Hz, 2H), 2.66 (t, J = 6.2 Hz, 2H), 1.91 (br s, 3H, exchangeable with D2O), 
1.70 (m, 2H), 1.40-1.20 (m, 6H).  MS (ESI+) : m/z 263 [M+1]+. 
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N-(6-(2-chloro-6,7-dimethoxyquinazolin-4-ylamino)hexyl)acrylamide (17). To a stirred 
solution of 53 (0.30 g, 0.885 mmol) in CH2Cl2 (30 mL) at 0 °C was added NEt3 (72 µL, 1.33 
mmol) and acryloyl chloride (72 µL, 0.885 mmol). After stirring at 0 °C for 20 min, the resulting 
mixture was allowing to reach rt in 3 hr. The reaction was quenched with water, diluted with 
CH2Cl2 and washed with water (3 × 20 mL). The organic phase was dried over Na2SO4 and 
concentrated to obtain a crude that was subjected to gravity column purification (CH2Cl2/MeOH 
9.5:0.5) to obtain 17 (0.20 g, 58 %) as a white solid. Mp = 155°-158 °C. 1H NMR (CDCl3, 300 
MHz) δ 7.52 (s, 1H), 7.13 (s, 1H), 7.01 (br t, 1H, exchangeable with D2O), 6.35-6.29 (dd, J = 
17.1, 1.5 Hz, 1H), 6.20-6.11 (dd, J = 17.1, 9.9 Hz, 1H), 5.86 (br t, 1H, exchangeable with D2O), 
5.71-5.67 (dd, J = 9.9, 1.2 Hz, 1H), 3.98 (s, 3H), 3.95 (s, 3H),  3.63 (q, J = 6.3 Hz, 2H), 3.44 (q, 
Chapter 6 
132 
J = 6.6 Hz, 2H), 1.80-1.25 (m, 8H). MS (ESI+) : m/z 393 [M+1]+. 
 
N
CO2Me
CO2Me
OH
Cl
54
 
Dimethyl 7-chloro-4-hydroxyquinoline-2,3-dicarboxylate (54).11 A stirred mixture of 
methyl 2-amino-4-chlorobenzoate (5.0 g, 27 mmol) and dimethyl acetylenedicarboxylate (5.1 g, 
35 mmol) in t-butanol (44 mL) was refluxed for 7 hr under a nitrogen atmosphere. After adding 
additional dimethyl acetylenedicarboxylate (2.32 g, 16 mmol) and refluxing another 9 hr the 
reaction mixture was allowed to cool to rt and potassium t-butoxide (3.0 g, 26.7 mmol) was 
added in one portion. A violet precipitate formed and the resulting mixture was refluxed for 1.5 
hr. The mixture was cooled to rt and filtered to separate the solids which are washed with t-
butanol and ether. The solids were dissolved in water and acidified with 1N sulfuric acid to form 
a green precipitate. The resulting mixture was extracted with CH2Cl2 and the combined extracts 
were washed with brine and water, dried over Na2SO4, filtered and concentrated to give a green 
solid. Recristallization of this material from MeOH provided  54 (2.00 g, 25%) as an off-white 
solid. Mp = 225-228 °C. 1H NMR (CDCl3, 200 MHz) δ 8.30 (d, J = 9.0 Hz, 1H), 8.06 (s, 1H), 
7.58 (d, J = 9.0, 1H), 4.03 (s, 6H). MS (ESI-) : m/z 294 [M-1]-. 
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Dimethyl 4,7-dichloroquinoline-2,3-dicarboxylate (55).11 A mixture of 54 (1.31 g, 4.43 
mmol), phosphorous oxychloride (5 mL, 53.64 mmol) and toluene (2 mL) was heated briefly at 
90 °C. After cooling at rt, the reaction mixture was quenched with ice-water and extracted with 
EtOAc. The combined extracts were dried over Na2SO4, filtered and concentrated to lead the title 
dichloroquinoline 55 (1.39 g, quantitative) as a crystalline yellow solid. Mp = 110-113 °C. 1H 
NMR (CDCl3, 200 MHz) δ 8.33 (dd, J = 4.0 , 1.4 Hz, 1H), 8.27 (s, 1H), 7.77 (dd, J = 8.8, 2.2 
Hz, 1H), 4.08 (s, 6H). MS (ESI+) : m/z 338 [M+23]+. 
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Dimethyl 7-chloro-4-(3-(6-chloro-1,2,3,4-tetrahydroacridin-9-
ylamino)propylamino)quinoline-2,3-dicarboxylate (18). A stirred solution of 55 (0.23 g, 0.73 
mmol) and N1-(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)propane-1,3-diamine 2312 (0.21 g, 0.73 
mmol) in EtOH (50 mL) and NEt3 (0.10 mL, 0.73 mmol) was refluxed for 24 hr. After the 
solvent removal under vacuum the crude was purified by flash chromatography (CH2Cl2/MeOH, 
9.5:0.5) to obtain 0.17 g of 18 (0.17 g, 40 %) as a white crystalline solid. Mp = 230-235 °C 
(dec.). 1H NMR (CDCl3, 200 MHz) δ 9.48 (br t, 1H, exchangeable with D2O) 8.20 (d, J = 9.2 
Hz, 1H), 8.15-8.00 (m, 2H), 7.83 (d, J = 2.2 Hz, 1H), 7.35 (d, J = 9.2 Hz, 1H), 7.20 (d, J = 9.2 
Hz, 1H), 6.30 (br t, 1H, exchangeable with D2O), 4.10-3.95 (m, 7H), 3.89 (s, 3H), 3.08 (t, 2H), 
2.65 (t, 2H) 2.34 (m, 2H), 1.81 (m, 4H).  MS (ESI+) : m/z 569 [M+1]+. 
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Dimethyl 4-(3-(tert-butoxycarbonylamino)propylamino)-7-chloroquinoline-2,3-
dicarboxylate (56). To a stirred solution of 55 (0.46 g, 1.46 mmol) in EtOH (100 mL) was added 
a solution of tert-butyl 3-aminopropylcarbamate (0.25 g, 1.46 mmol) in EtOH. The resulting 
mixture was refluxed for 5 hr. After adding an additional amine (0.10 g, 0.57 mmol) and 
refluxing another 8 hr the reaction mixture was allowed to cool to rt. The solvent was removed 
under pressure and the crude was purified by flash chromatography (petroleum ether/EtOAc 
88:12 to 100% EtOAc) to furnish title compound 56 (0.23 g, 40 %) as a yellow solid. Mp = 144-
146 °C. 1H NMR (CDCl3, 200 MHz) δ 9.48 (br s, 1H, exchangeable with D2O) 8.35 (d, J = 9.2 
Hz, 1H), 8.20 (s, 1H), 7.41 (d, J = 9.2 Hz, 1H), 5.25 (br s, 1H, exchangeable with D2O), 4.01 (s, 
3H), 3.90 (s, 3H), 3.82 (m, 2H), 3.30 (q, J = 5.4 Hz, 2H), 1.98 (m, 2H), 1.40 (m, 9H). MS (ESI+) 
: m/z 452 [M+1]+. 
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Dimethyl 4-(3-aminopropylamino)-7-chloroquinoline-2,3-dicarboxylate (57). To a stirred 
solution of 56 (0.23 g, 0.50 mmol) in CH2Cl2 (10 mL) at 0 °C was carefully added trifluoroacetic 
acid (2 mL) and was allowed to stir at rt in 2 hr. The solvent were evaporated under pressure, 
adding heptane for the azeotropic removal of trifluoroacetic acid to obtain 57 as trifluoroacetate 
salt. The product was dissolved in alkaline water (K2CO3) and extracted with  CH2Cl2. The 
solvent was removed under pressure to furnish the free amine 57 (0.17 g, quantitative) as a 
colourless oil. 1H NMR (CDCl3, 300 MHz) δ 9.13 (br s, 1H, exchangeable with D2O) 8.15 (d, J 
= 9.0 Hz, 1H), 8.00 (s, 1H), 7.41 (d, J = 9.0 Hz, 1H), 4.00 (s, 3H), 3.90 (s, 3H), 3.78 (q, J = 6.3 
Hz, 2H), 2.99 (t, J = 6.0 Hz, 2H), 1.89 (m, 2H), 1.48 (br s, 2H, exchangeable with D2O). MS 
(ESI+) : m/z 352 [M+1]+. 
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Dimethyl 4-(3-(5-(1,2-dithiolan-3-yl)pentanamido)propylamino)-7-chloroquinoline-2,3-
dicarboxylate (19). It was synthesised from 57 (0.20 g, 0.57 mmol), NEt3 (79 µL, 0.57 mmol), 
(±)-lipoic acid (0.117 g, 0.57 mmol) and EDCI·HCl (0.109 g, 0.57 mmol) following the 
procedure B. Purification by flash chromatography (CH2Cl2/MeOH 98:2) afforded 19 (0.21 g, 68 
%) as a yellowish oil. 1H NMR (CDCl3, 400 MHz) δ 8.67 (t, J = 4.4 Hz, 1H, exchangeable with 
D2O), 8.11 (d, J = 9.2 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 8.4, 1.6 Hz, 1H), 6.01 (t, J 
= 6.0 Hz, 1H, exchangeable with D2O), 3.94 (s, 3H), 3.86 (s, 3H), 3.70 (q, J = 5.6 Hz, 2H), 3.51 
(m, J = 8.0 Hz, 1H), 3.39 (q, J = 6.4 Hz, 2H), 3.15-3.05 (m, 2H), 2.41 (m, J = 6.0 Hz, 1H), 2.16 
(t, J = 7.6 Hz, 2H), 1.94-1.82 (m, 3H), 1.70-1.52 (m, 4H), 1.40 (q, J = 7.6 Hz, 2H). 13C-NMR 
(CDCl3, 100 MHz) δ 173.70, 168.38, 167.99, 155.40, 153.15, 149.66, 137.83, 129.14, 126.60, 
126.55, 118.02, 101.97, 56.63, 53.12, 52.69, 45.86, 40.46, 38.68, 36.76, 36.54, 34.77, 31.15, 
29.10, 25.59. MS (ESI+) : m/z 541 [M+1]+. 
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2-chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine (58). Following the procedure 
described in Kanuma et al.,13 to a stirred solution of 2,4-dichloro-6,7-dimethoxyquinazoline 45 
(0.50 g, 1.93 mmol) in THF (25 mL) was added 50 % aq. dimethylamine solution (0.49 mL, 3.86 
mmol). After stirring at rt for 2 hr, the solvent was removed under vacuum. The obtained residue 
was taken up in CHCl3 (100 mL) and washed with brine, the aqueous phase was re-extracted 
with CHCl3 (3 × 50 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated to obtain the title compound 58 (0.48 g, 93 %) as a yellow solid. Mp = 155°-160 
°C. 1H NMR (CDCl3, 300 MHz) δ 7.28 (s, 1H), 7.18 (s, 1H), 4.01 (s, 3H), 3.98 (s, 3H), 3.37 (s, 
6H). 
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tert-Butyl 3-(4-(dimethylamino)-6,7-dimethoxyquinazolin-2-ylamino)propylcarbamate 
(59). To a stirred solution of 58 (0.40 g, 1.49 mmol) in iso-amylalcohol (5 mL) was added a 
solution of tert-butyl 3-aminopropylcarbamate (0.49 g, 2.91 mmol) iso-amylalcohol and NEt3 
(0.21 mL, 1.49 mmol). The resulting mixture was stirred at 160 °C for 6 hr. After cooling at rt, 
the reaction mixture was concentrated and the obtained residue was taken up in CHCl3 (100 mL) 
and washed with brine. The organic phase was dried over Na2SO4 and concentrated to obtain a 
crude that was purified by flash chromatography (CH2Cl2/toluene/MeOH/aqueous 30% 
ammonia, 9:1:0.5:0.05) to obtain 59 (0.34 g, 56 %) as a white solid. 1H NMR (CDCl3, 200 MHz) 
δ 7.15 (s, 1H), 6.92 (s, 1H), 5.75 (br s, 1H, exchangeable with D2O),  5.05 (br s, 1H, 
exchangeable with D2O), 3.99 (s, 3H), 3.93 (s, 3H), 3.58 (q, J = 6.2 Hz, 2H), 3.25-3.16 (m, 8H), 
1.68-1.82 (m, 2H), 1.48 (m, 9H). 
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N2-(3-aminopropyl)-6,7-dimethoxy-N4,N4-dimethylquinazoline-2,4-diamine (60). To a 
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stirred solution of 59 (0.34 g, 0.806 mmol) in CH2Cl2 (5 mL) at 0 °C was carefully added 
trifluoroacetic acid (1 mL) and was allowed to stir at rt in 5 hr. The solvent was evaporated under 
pressure, adding heptane for the azeotropic removal of trifluoroacetic acid to obtain the 
trifluoroacetate salt. The product was dissolved in alkaline water (K2CO3) and extracted with  
CH2Cl2 (3 × 50 mL). The organic extract was dried over Na2SO4 and concentrated in vacuo to 
furnish the free amine 60 (0.26 g, quantitative) as a colourless oil. 1H NMR (CDCl3, 300 MHz) δ 
7.15 (s, 1H), 6.90 (s, 1H), 5.22 (br s, 1H, exchangeable with D2O), 3.99 (s, 3H), 3.93 (s, 3H), 
3.58 (q, J = 6.2 Hz, 2H), 3.17 (s, 6H), 2.82 (t, J = 5.4 Hz, 2H), 1.89 (s, 2H, exchangeable with 
D2O), 1.83-1.70 (m, 2H). 
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N-(3-(4-(dimethylamino)-6,7-dimethoxyquinazolin-2-ylamino)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide (20). It was synthesised from 60 (0.27 g, 0.882 mmol), NEt3 (123 µL, 0.882 
mmol), (±)-lipoic acid (0.182 g, 0.882 mmol) and EDCI·HCl (0.170 g, 0.882 mmol) following 
the procedure B. Purification by gravity chromatography (gradient elution from 
CH2Cl2/petroleum ether/MeOH 7.5:2:0.5 to 7.2: 2:0.8) to obtain 20 (0.200 g, 46 %) as a 
yellowish oil. 1H NMR (CDCl3, 300 MHz) δ 7.22 (s, 1H), 7.16 (s, 1H), 6.96 (br m, 1H, 
exchangeable with D2O), 6.72 (br m, 1H, exchangeable with D2O), 4.01 (s, 3H), 3.93 (s, 3H), 
3.60-3.45 (m, 2H), 3.45 (s, 6H), 3.45-3.35 (m, 2H), 3.09-3.18 (m, 2H), 2.50-2.40 (m, 1H), 2.24 
(t, J = 7.0 Hz, 2H), 2.00-1.20 (m, 10H). MS (ESI+) : m/z  494 [M+1]+. 
 
N
N
N
O
O N
H
21
N
H
O
OH
O
 
(E)-N-(3-(4-(dimethylamino)-6,7-dimethoxyquinazolin-2-ylamino)propyl)-3-(4-hydroxy-
3-methoxyphenyl)acrylamide (21). To a stirred solution of 60 (0.21 g, 0.69 mmol), trans-
ferulic acid (0.13 g, 0.69 mmol) and NEt3 (290 µL, 2.01 mmol) in CH2Cl2 (30 mL), a 50% 
solution of propylphosphonic anhydride10 in DMF (0.52 mL, 0.82 mmol) was added. The 
resulting mixture was allowed to stir at rt for 8 hr. After adding further amount of 
propylphosphonic anhydride in DMF (0.26 mL, 0.41 mmol) and stirring for 8 hr, the reaction 
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mixture was quenched with water, washed with water, diluted K2CO3, and 1N HCl. The organic 
phase was dried over Na2SO4 and concentrated to obtain a crude that was purified by flash 
column chromatography (CH2Cl2/MeOH 9:1 to CH2Cl2/MeOH/ aqueous 30% ammonia 9:1:0.1) 
to obtain 21 (0.175 g, 53 %) as a off-white solid. Mp = 140°-145 °C. 1H NMR (CDCl3, 400 
MHz) δ 8.05 (br s, 1H, exchangeable with D2O), 7.41 (d, J = 15.6 Hz, 1H), 7.25 (br s, 1H, 
exchangeable with D2O), 7.22 (s, 1H), 7.16 (s, 1H), 6.98 (s, 1H), 6.90 (d, J = 1.8 Hz, 1H), 6.89 
(br s, 1H, exchangeable with D2O), 6.80 (d, J = 1.8 Hz. 1H), 6.45 (d, J = 15.6 Hz, 1H), 3.89 (s, 
3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.70-3.55 (q, J = 5.4 Hz, 2H), 3.55-3.45 (q, J = 5.4 Hz, 2H), 3.40 
(s, 6H), 1.95 (t, J = 5.4 Hz, 2H). 13C-NMR (CDCl3, 100 MHz) δ 166.93, 147.53, 147.08, 145.58, 
140.10 (2C), 127.78 (2C), 122.29 (2C), 119.25 (2C), 114.91 (2C), 109.83 (2C), 107.34, 56.63, 
56.56, 56.18, 42.23 (2C), 39.54, 37.69, 29.90. MS (ESI+) : m/z  482 [M+1]+. 
O CO2Me
NO2
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Methyl 2-nitro-5-phenoxybenzoate (61). Following the procedure described in Dunn et al.,14 
to a stirred solution of phenol (4.18 g, 44.4 mmol) in N-methyl-2-pyrrolidone (40 mL) K2CO3 
powder (8.20 g, 59.4 mmol) was added in small portions. The obtained suspension was stirred at 
rt for 30 min, then methyl 5-chloro-2-nitrobenzoate (8.00 g, 59.4 mmol) was added in small 
portions to obtain a orange solution that was stirred at 160 °C for 3 hr. The reaction mixture was 
cooled to rt, poured in ice-water (150 mL) and extracted with EtOAc (2 × 70 mL). The organic 
layer was washed with water (2 × 50 mL), brine (2 × 50 mL), dried over Na2SO4, concentrated in 
vacuo, and the obtained residue was purified by flash chromatography (petroleum ether/EtOAc, 
95:5) to obtain 61 (5.46 g, 54%) as a yellow oil. 1H NMR (CDCl3, 300 MHz) δ 8.04 (d, J = 8.4 
Hz, 1H), 7.41 (m, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.13-7.06 (m, 4H), 3.93 (s, 3H). 13C NMR 
(CDCl3, 50 MHz) δ 166.17, 162.26, 154.41, 151.08, 131.23, 130.57 (2C), 126.79, 125.86, 120.65 
(2C), 118.71, 117.14, 53.46. 
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2-Nitro-5-phenoxybenzoic acid (62). Following the procedure described in Dunn et al.,14 to a 
solution of 61 (3.36 g, 13.2 mmol) in MeOH/water  (15/15 mL) was added NaOH pellets (1.58 g, 
39.56 mmol) at 0 °C. The reaction mixture was heated at 70 °C for 2 hr. After cooling to rt, the 
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reaction was acidified with 3 N HCl and extracted with EtOAc (3 × 100 mL). The organic layer 
was washed with brine, dried over Na2SO4, concentrated in vacuo. The obtained residue was 
purified by flash chromatography (petroleum ether/EtOAc/toluene/AcOH, 60:30:10:1.5) to 
obtain 62 (2.82 g, 83%) as a brown solid. Mp = 145°-147 °C. 1H NMR (CDCl3, 200 MHz) δ 9.41 
(br s, 1H), 8.00 (d, J = 8.8 Hz, 1H), 7.44-7.52 (m, 2H), 7.25-7.35 (m, 2H), 7.11-7.17 (m, 3H). 13C 
NMR (CDCl3, 75 MHz) δ 170.85, 162.28, 154.53, 141.95, 130.81 (2C), 129.81, 126.97, 126.16, 
120.83 (2C), 119.56, 117.72. 
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2-Amino-5-phenoxybenzoic acid (63). To a solution of 62 (2.82 g, 10.9 mmol) in EtOH (110 
mL) was added palladium on activated carbon, and the mixture was stirred under hydrogen for 6 
hr. The suspension was filtered through celite and the filtrate concentrated and dried in vacuo to 
yield 63 (2.39 g, 96 %) as a light brown solid. Mp = 140°-142 °C.  1H NMR (CDCl3, 200 MHz) 
δ 7.65 (d, J = 3.0 Hz, 1H), 7.34 (d, J = 8.2 Hz, 2H), 6.93-7.16 (m, 4H), 6.71 (d, J = 8.8 Hz, 1H). 
13C NMR (CDCl3, 75 MHz) δ 172.75, 158.76, 148.13, 146.51, 129.87 (2C), 128.77, 126.61 (2C), 
118.49, 117.42 (2C), 109.95. 
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6-Phenoxyquinazoline-2,4-diol (64). Following the procedure described in Wéber et al.,15 to 
a mechanically stirred suspension of 63 (1.73 g, 7.55 mmol) in water (30 mL) and acetic acid (1 
mL, 17.5 mmol) a solution of KOCN (1.35 g, 16.6 mmol) in water (10 mL) was added dropwise. 
After stirring at rt for 90 min, NaOH pellets (15.31 g, 383 mmol) were added in one portion and 
the solution was allowed to heat at 90-100 °C for 5 hr. After cooling to rt, the reaction was 
acidified with 6 N HCl until a brown precipitated was formed. The suspension was filtered under 
vacuum, the collected solid was washed repeatedly with water to obtain 64 (1.51 g, 61%) as a 
light brown solid. Mp = >260 °C.  1H NMR ((CD3)2SO, 200 MHz) δ 11.34 (s, 1H), 11.17 (s, 1H), 
7.32-7.45 (m, 5H), 7.23-7.13 (m, 2H), 7.05-7.01 (d, J = 7.6 Hz, 1H).  
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2,4-Dichloro-6-phenoxyquinazoline (65). Following the procedure described in Wéber et 
al.,15 to compound 64 (0.62 g, 2.43 mmol) was added POCl3 (3.34 mL, 36.0 mmol) dropwise and 
N,N-dimethylaniline (0.15 mL, 1.21 mmol) and toluene (2 mL). The reaction mixture was heated 
at 115 °C for 7 hr. After adding a further amount of POCl3 (3.00 mL, 32.3 mmol) and N,N-
dimethylaniline (0.15 mL, 1.21 mmol) and refluxing another 16 hr the reaction mixture was 
allowed to cool to rt, and POCl3 was distilled off, then the residue was poured into ice-water. The 
slurry was stirred, then the solid was filtered under vacuum, washed with water and dried to 
yield 65 (0.56 g, 80%) as a yellow solid. Mp = 98°-100 °C. 1H NMR (CDCl3, 200 MHz) δ 8.0 (d, 
J = 9.2 Hz, 1H), 7.81-7.70 (dd, J = 9.2, 2.4 Hz, 1H), 7.58-7.44 (m, 2H), 7.40-7.28 (m, 2H), 7.14 
(d, J = 8.0 Hz, 2H). 
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2-Chloro-N,N-dimethyl-6-phenoxyquinazolin-4-amine (66). Following the procedure 
described in Kanuma et al.,13 to a stirred solution of 65 (0.35 g, 1.20 mmol) in THF (15 mL) was 
added 50 % aq. dimethylamine solution (0.30 mL, 2.40 mmol). After stirring at rt for 2 hr, the 
solvent was removed under vacuum. The obtained residue was taken up in CHCl3 (70 mL) and 
washed with brine. The organic extracts were dried over Na2SO4 and concentrated to obtain the 
title 66 (0.34 g, 94 %) as a white solid. Mp = 106°-108 °C. 1H NMR (CDCl3, 200 MHz) δ 7.80 
(d, J = 9.2 Hz, 1H), 7.59-7.30 (m, 4H), 7.18 (t, J = 7.4 Hz, 1H), 7.05 (d, J = 8.2 Hz, 2H), 3.32 (s, 
6H). 
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tert-Butyl 3-(4-(dimethylamino)-6-phenoxyquinazolin-2-ylamino)propylcarbamate (67). 
To a stirred solution of 66 (0.34 g, 1.13 mmol) in iso-amylalcohol (3 mL) was added a solution 
of tert-butyl 3-aminopropylcarbamate (0.30 g, 1.70 mmol) iso-amylalcohol and NEt3 (0.1 mL, 
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0.70 mmol). The resulting mixture was stirred at 160 °C for 4 hr. After adding further amount of 
tert-butyl 3-aminopropylcarbamate (0.17 g, 0.97 mmol) and refluxing another hour, the reaction 
mixture was allowed to cool to rt and concentrated. The obtained residue was taken up in CHCl3 
(50 mL) and washed with brine. The organic phase was dried over Na2SO4 and concentrated to 
obtain a crude that was purified by flash chromatography (CH2Cl2/toluene/MeOH 9.7:1:0.3) to 
obtain 67 (0.36 g, 73 %) as a yellow oil. 1H NMR (CDCl3, 200 MHz) δ 7.58 (d, J = 9.2 Hz, 1H), 
7.45 (d, J = 2.2 Hz, 1H), 7.35-7.26 (m, 3H), 7.08 (t, J = 7.4 Hz, 1H), 6.98 (d, J = 7.8 Hz, 2H), 
6.25 (br s, 1H, exchangeable with D2O), 5.39 (br s, 1H, exchangeable with D2O), 3.60 (q, J = 6.2 
Hz, 2H), 3.25-3.15 (m, 8H), 1.69-1.81 (m, 2H), 1.47 (m, 9H). 
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N2-(3-Aminopropyl)-N4,N4-dimethyl-6-phenoxyquinazoline-2,4-diamine (68). To a stirred 
solution of 67 (0.36 g, 0.82 mmol) in CH2Cl2 (5 mL) at 0 °C was carefully added trifluoroacetic 
acid (0.64 mL, 8.32 mmol) and was allowed to stir at rt in 3 hr. The solvent were evaporated 
under pressure, adding heptane for the azeotropic removal of trifluoroacetic acid traces to obtain 
the trifluoroacetate salt. The product was dissolved in alkaline water (40 % NaOH) and extracted 
with  CH2Cl2 (5 × 20 mL). The organic extract was dried over Na2SO4 and concentrated to obtain 
a residue that was purified by flash chromatography (CH2Cl2/toluene/MeOH/30% aq. ammonia, 
9:1:1:0.1) to obtain 68 (0.23 g, 83 %) as a yellow oil. 1H NMR (CDCl3, 200 MHz) δ 7.47 (d, J = 
10.0 Hz, 2H), 7.31-7.27 (m, 3H), 7.10-6.93 (m, 3H), 5.22 (br s, 1H. exchangeable with D2O), 
3.58 (q, 2H, J = 6.2 Hz), 3.17 (s, 6H), 2.82 (t, 2H, J = 5.4 Hz), 1.88 (s, 2H, exchangeable with 
D2O), 1.83-1.70 (m, 2H). 
 
O
N
N
N
N
H
N
H
O
S S
22
 
N-(3-(4-(Dimethylamino)-6-phenoxyquinazolin-2-ylamino)propyl)-5-(1,2-dithiolan-3-
yl)pentanamide (22). It was synthesised from 68 (0.23 g, 0.68 mmol), NEt3 (95 µL, 0.68 mmol), 
(±)-lipoic acid (0.140 g, 0.068 mmol) and EDCI·HCl (0.130 g, 0.68 mmol) following the 
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procedure B. Purification by flash chromatography (CH2Cl2/petroleum ether/MeOH 8:1.5:0.5) 
gave 22 (0.200 g, 54 %) as a yellowish oil. 1H NMR (CDCl3, 200 MHz) δ 7.55-7.44 (m, 2H), 
7.40-7.04 (m, 4H), 6.97 (d, J = 8.2 Hz, 2H), 5.91 (br s, 2H, exchangeable with D2O), 3.56 (t, J = 
5.8 Hz, 2H), 3.45-3.20 (m+s, 8H), 3.10 (q, J = 6.2 Hz, 2H), 2.50-2.30 (m, J = 6.2 Hz, 1H), 2.24 
(t, J = 6.8 Hz, 2H), 2.00-1.20 (m, 10H). 13C-NMR (CDCl3, 50 MHz) δ 177.71, 175.61, 172.66, 
157.05, 150.12, 146.66, 128.57 (2C), 127.83, 125.33, 121.95, 117.55 (2C), 116.43, 104.07, 
56.35, 40.20, 42.12, 40.66 (2C), 37.74, 36.55, 35.23, 31.14, 28.84, 25.22, 24.61. MS (ESI+) : 
m/z 526 [M+1]+. 
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+
less polar
sy n-isomer
70
more polar
anti-isomer
71
dr
1 : 2.2
NO2
H O
NO2
H O
 
(S)-3-((S)-1-Nitropropyl)cyclohexanone (70) and (S)-3-((R)-1-nitropropyl)cyclohexanone 
(71). A mixture of 2-cyclohexene-1-one 69 (0.100 mL, 1.04 mmol), 1-nitropropane (0.195 mL, 
2.18 mmol), 2,5-dimethylpiperazine (0.120 g, 1.04 mmol) and a catalytic amount of D-proline 
(10 mol%) was stirred in reagent grade chloroform (8 mL) for 48 h at rt. The reaction mixture 
was diluted with CH2Cl2 and washed with aqueous HCl (3%). The organic phase was dried 
(MgSO4), filtered, evaporated and the residue was purified by chromatography (EtOAc:hexanes 
1:4) to obtain 1:2.2 diastereomeric mixture of 70 and 71 as a colourless oil (0.162 g, 84%). A 
portion of the crude product was separated by column chromatography for characterization.  
For less polar syn-isomer 70: [α]D20 –26 (c 0.1, CHCl3); IR (CHCl3) 1542, 1714, cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.31 (m, 1H), 2.54-2.40 (m, 2H), 2.37-2.24 (m, 2H) 2.16-2.08 (m, 
2H), 2.03-1.78 (m, 3H), 1.72-1.60 (m, 1H), 1.55-1.45 (m, 1H), 0.97 (t, J= 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 208.32, 93.86, 43.52, 41.16, 40.59, 27.13, 23.83, 23.74, 9.89. MS (FAB): 
m/z 186 [M+1]+, ee = 89%. The enantiomeric excess of the less polar syn-isomer was determined 
by RP-HPLC analysis with CHIRALPAK AD-RH column (∅ 0.46 cm × 15 cm) eluting in 
isocratic mode with 0.1 % Formic acid in CH3CN / 0.1 % Formic acid in H2O (30:70), flow = 0.5 
mL/min, retention times minor 34.90 min, major 39.02 min. 
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For more polar anti-isomer 71: [α]D20 +15 (c 0.1, CHCl3); IR (CHCl3) 1542, 1714, cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.36 (m, 1H), 2.45-2.34 (m, 2H), 2.32-2.20 (m, 3H), 2.17-2.08 (m, 
1H), 2.05-1.95 (m, 2H), 1.86-1.78 (m, 1H),1.73-1.61 (m, 1H), 1.50-1.36 (m, 1H), 0.97 (t, J= 7.2 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 208.33, 93.87, 43.02, 40.98, 40.53, 27.33, 24.09, 
23.73,10.01; MS (FAB): m/z 186 [M+1]+, ee = 74%. The enantiomeric excess of the more polar 
anti-isomer was determined by RP-HPLC analysis with CHIRALPAK AD-RH column (∅ 0.46 
cm × 15 cm) eluting in isocratic mode with 0.1 % Formic acid in CH3CN / 0.1 % Formic acid in 
H2O (28:72), flow = 0.5 mL/min, retention times minor 44.33 min, major 47.25 min. 
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Peak 
Name 
R. 
Time 
Area Area 
% 
1 34.90 2500539.25 5.39 
2 39.02 43910696.00 94.61 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 34.76 25787958.00 53.57 
2 39.86 22348432.00 46.43 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 44.33 2203832.50 12.95 
2 47.26 14813406.00 87.05 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 43.92 24985658.00 48.27 
2 47.66 26776176.00 51.73 
Chapter 6 
144 
 
74
NO2
H
S
S
 
2-((S)-3-((S)-1-Nitropropyl)cyclohexylidene)-1,3-dithiane (74). In a stirring solution of 
[1,3]dithian-2-yl-phosphonic acid diethyl ester (0.097 g, 0.378 mmol) in THF (2 mL) at -78 °C 
was added n-BuLi (0.258 mL, 0.412 mmol, 1.6 M in hexane) dropwise during 15 min. After 1 h 
70 (0.07 g, 0.378 mmol) in THF (1 mL) was added, stirred for 15 min at -78 ºC and was allowed 
to warm to rt. The reaction mixture was quenched after 1 h by adding saturated solution of 
NH4Cl (2 mL) and extracted with EtOAc (3×10 mL). The organic phase was washed with brine, 
dried, concentrated and the residue was purified by chromatography (5% EtOAc in hexanes) to 
give 74 as colourless oil (0.092 g, 85%) [α]D20 –0.91 (c 1, CHCl3); IR (CHCl3) 1547 cm-1; 1H 
NMR (CDCl3) δ 4.33-4.25 (m, 1H), 3.09-2.88 (m, 5H), 2.16-1.66 (m, 9H), 1.40-1.26 (m, 2H), 
0.98 (t, J=7.0 Hz, 3H); 13C NMR (CDCl3) δ 140.04, 122.90, 94.19, 40.96, 33.57, 31.12, 29.93, 
29.85, 28.57, 24.78, 24.61, 24.29, 10.00. MS (FAB): m/z 288 [M+1]+, HRMS (FAB) Calc. for 
C13H22NO2S2 [M+1]+ 288.1086, found 288.1101. 
 
+
76 77
dr
1 : 1.0
NO2
H CO2Me
NO2
H CO2Me
H H
 
(1R,3S)-Methyl 3-((S)-1-nitropropyl)cyclohexanecarboxylate (76) and (1S,3S)-methyl 3-
((S)-1-nitropropyl)cyclohexanecarboxylate (77) A solution of 74 (0.09 g, 0.313 mmol), 
mercuric chloride (0.591 g, 1.25 mmol), MeOH (6 mL), and perchloric acid (0.132 mL of a 70% 
aqueous solution, 0.939 mmol) was heated at reflux for 2 hr. After cooling and filtration, the 
reaction mixture was neutralized with saturated solution of NaHCO3 and extracted with CH2Cl2. 
The combined organic extracts were washed with brine, dried, concentrated and the residue was 
purified by chromatography (EtOAc:hexanes 1:4) to give 1:1 mixture of ester 76 and 77 as 
colourless oils (0.057g, 80%). A portion of the crude product was separated by column 
chromatography for characterization. For 76 (0.027 g): [α]D20 -9.0 (c 1, CHCl3); IR (CHCl3) 
1549, 1735 cm-1; 1H NMR (CDCl3) δ 4.21 (m, 1H), 3.68 (s, 3H), 2.34 (m, 1H), 2.18-1.84 (m, 
6H), 1.65-1.58 (m, 1H), 1.33-1.04 (m, 4H), 0.94 (t, J=7.2 Hz, 3H); 13C NMR (CDCl3) δ 175.91, 
96.03, 52.17, 43.07, 31.36, 29.06, 28.93, 25.05, 24.39, 10.79; MS (FAB): m/z 288 [M+1]+. 
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HRMS (FAB) Calc. for C11H19NO4 [M+1]+ 229.1314 found 229.1309. 
 
80
NHAc
H CO2Me
H
 
(1R,3S)-Methyl 3-((S)-1-acetamidopropyl)cyclohexanecarboxylate (80). To a solution of 
nitro compound 76 (14.8 mg, 0.065 mmol) in dry MeOH (0.3 mL) was added successively under 
Argon atmosphere, ammonium formate (28 mg, 0.45 mmol), and 10% palladium-on-carbon (10 
mg). The suspension was stirred for 4h at rt then filtered through a short pad of Celite, then 
washed with MeOH (10 mL). Concentration of the solvent afforded the corresponding amine (13 
mg, quantitative) which was dissolved in CH2Cl2, then Ac2O (18.4 µL, 0.105 mmol) Et3N (27 
µL, 0.195 mmol) and DMAP (catalytic amount). The solution was stirred at rt for 3 h then 
quenched with NH4Cl. The organic phase was diluted with EtOAc (10 mL), washed with HCl 
(1N) and NaHCO3, dried, concentrated, and residue was purified by chromatography 
(EtOAc/hexanes, 1/1) to give 80 as a colourless solid (12 mg, 76%); [α]D20 –36.1 (c 1, CHCl3); 
IR (neat) 3285, 1739, 1648 cm-1; 1H NMR (CDCl3) δ 5.20-5.18 (d, J = 8.5 Hz, 1H), 3.79-3.73 
(m, 1H), 3.66 (s, 3H), 2.30 (m, 1H), 2.00 (s, 3H), 1.92-1.87 (m, 2H), 1.71-1.55 (m, 2H), 1.47-
1.36 (m, 1H), 1.33-1.13 (m, 4H), 1.00-0.94 (m, 1H), 0.89 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3) 
δ 176.6, 170.2, 55.2, 51.9, 43.6, 41.3, 32.1, 29.2, 27.9, 25.6, 24.9, 23.9, 11.0; MS (FAB): m/z 
242 [M+1]+; HRMS (FAB) Cald. for C13H23NO3 241.1677, found 241.1672.  
 
Et
NHAc
H H
O
N
H
NHBu
OH
O
Ph
28
 
(1R,3S)-3-((S)-1-Acetamidopropyl)-N-((2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-
oxo-1-phenylhexan-2-yl)cyclohexanecarboxamide (28). In a solution of ester 80 (8 mg, 0.0332 
mmol) in MeOH (1 mL) was added LiOH solution (100 µL, 1N solution in water) and stirred for 
12 h at rt. The reaction mixture was diluted with EtOAc (10 mL) and neutralized with diluted 
HCl, washed with brine, dried (Na2SO4) and concentrated. The crude product was used directly 
for coupling without purification. In a solution of Boc protected amine (26 mg, 0.0664 mmol) in 
CH2Cl2 (1 mL) was added TMSI (38 µL, 0.26 mmol) at rt for 30 min. The reaction mixture was 
quenched with Na2S2O3 solution and extracted with EtOAc. The organic layer was washed with 
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NHCO3 solution, brine, dried (Na2SO4) and concentrated. It was used immediately without 
purification. The acid and amine were taken in a solution of co-solvent (CH2Cl2:H2O, 1:1, 1 mL). 
HOBt (9 mg, 0.065 mmol) and EDC (13 mg, 0.066 mmol) were added and stirred at 4 °C for 24 
h. The reaction mixture was diluted with EtOAc (10 mL) and washed with diluted HCl, 
NaHCO3, brine and dried (Na2SO4). After concentration, the crude product was purified by 
careful column chromatography (5% MeOH in CH2Cl2) to give amide 28 (8 mg, 50%) as white 
solid. [α]D20 –24 (c 0.22, MeOH); 1H NMR (CD3OD) δ 7.26-7.16 (m, 5H), 4.04-4.03 (m, 1H), 
3.54 (t, J = 4.0 Hz, 2H), 3.12 (t, J = 7.1 Hz, 2H), 2.73 (dd, J = 5.8, 5.7 Hz, 1H), 2.73 (dd, J = 9.4, 
9.3 Hz, 1H), 2.57-2.52 (m, 1H), 2.15-2.10 (m, 1H), 1.95 (s, 3H), 1.85-1.75 (m, 1H), 1.75-1.60 
(m, 3H), 1.60-1.50 (m, 2H), 1.50-1.40 (m, 4H), 1.40-1.20 (m, 7H), 1.08 (d, J = 6.9 Hz, 2H), 
1.05-0.99 (m, 1H), 0.93 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H); 13C NMR (MeOD) δ 177.9, 
177.7, 172.1, 139.2, 129.3 (2C), 128.3 (2C), 126.2, 69.9, 55.6, 54.9, 45.4, 41.3, 39.0, 38.1, 37.7, 
37.0, 32.6, 31.6, 29.6, 27.8, 25.4, 24.4, 21.5, 20.0, 17.5, 13.0, 9.8; MS (ESI) m/z 502.2 [M+1]+; 
HRMS (FAB) Cald. for C29H48N3O4 [M+1]+ 502.3567, found 502.3599. 
 
+
less polar
syn-isomer
72
more polar
ant i-isomer
73
dr
1 : 2.0
NO2
H O
NO2
H O
 
(S)-3-((S)-1-Nitrobutyl)cyclohexanone (72) and (S)-3-((R)-1-nitrobutyl)cyclohexanone 
(73). A mixture of 2-cyclohexene-1-one 69 (0.100 mL, 1.04 mmol), 1-nitrobutane (0.220 mL, 
2.08 mmol), 2,5-dimethylpiperazine (0.120 g, 1.04 mmol) and a catalytic amount of D-proline 
(10 mol%) were stirred in reagent grade chloroform (8 mL) for 48 h at rt. The reaction mixture 
was diluted with CH2Cl2 and washed with aqueous HCl (3%). The organic phase was dried 
(MgSO4), filtered, evaporated and purified by chromatography (hexanes:EtOAc, 4:1) to obtain a 
1:2 diastereomeric mixture of 72 and 73 as colourless oil (0.200 g, 97%). A portion of the crude 
product was separated by column chromatography for characterization. For the less polar syn-
isomer 72: [α]D20 –18 (c 0.1, CHCl3); IR (CHCl3) 1548, 1717, cm-1; 1H NMR (400 MHz, CDCl3) 
δ 4.42-4.36 (m, 1H), 2.54-2.40 (m, 2H), 2.35-2.24 (m, 2H), 2.16-2.06 (m, 2H) 2.05-1.84 (m, 2H), 
1.73-1.44 (m, 3H), 1.40-1.24 (m, 2H), 0.96 (t, J= 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
208.26, 92.11, 44.56, 41.36, 40.57, 32.32, 27.07, 23.83, 18.72, 13.01; MS (FAB): m/z 200 
[M+1]+, ee = 89 %. The enantiomeric excess of the less polar syn-isomer was determined by RP-
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HPLC analysis with CHIRALPAK AD-RH column (∅ 0.46 cm × 15 cm) eluting in isocratic 
mode with 0.1 % Formic acid in CH3CN / 0.1 % Formic acid in H2O (35:65), flow = 0.5 
mL/min, retention times minor 48.32 min, major 44.50 min. 
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For the more polar anti-isomer 73: [α]D20 + 20 (c 0.1, CHCl3); IR (CHCl3) 1548, 1717, cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.48-4.43 (m, 1H), 2.48-2.37 (m, 2H), 2.33-2.20 (m, 3H), 2.19-
2.11 (m, 1 H), 2.10-1.98 (m, 2H), 1.76-1.62 (m, 2H), 1.52-1.20 (m, 3H), 0.98 (t, J= 7.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 209.52, 93.25, 44.17, 42.37, 41.75, 33.50, 28.58, 25.29, 20.05, 
14.25; MS (FAB): m/z 200 [M+1]+, ee = 71 %. The enantiomeric excess of the more polar anti-
isomer was determined by RP-HPLC analysis with CHIRALPAK AD-RH column (∅ 0.46 cm × 
15 cm) eluting in isocratic mode with 0.1 % Formic acid in CH3CN / 0.1 % Formic acid in H2O 
(35:65), flow = 0.5 mL/min, retention times minor 39.65 min, major 50.59 min. 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 44.50 43450976.00 94.66 
2 48.32 2452799.75 5.34 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 42.80 10646814.00 53.29 
2 45.72 9333523.00 46.71 
Chapter 6 
148 
0
5 0
1 0 0
%
 
M
o
b
il
e
 
P
h
a
s
e
- 5 0
0
5 0
1 0 0
m
V
o
lt
s
4 0 5 0
M i n u t e s
1
2 3
4
   
0
5 0
1 0 0
%
 
M
o
b
il
e
 
P
h
a
s
e
0
1 0 0
m
V
o
lt
s
4 0 5 0
M i n u t e s
1
2 3
4
 
 
 
 
 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 39.65 4311732.50 14.36 
2 44.86 550930.88 1.83 
3 47.10 126960.65 0.42 
4 50.59 25034252.00 83.38 
Peak 
Name 
R. 
Time 
Area Area 
% 
1 37.55 17431646.00 41.24 
2 42.85 1262070.88 2.99 
3 45.51 1007719.69 2.38 
4 49.57 22563528.00 53.39 
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32
NO2H
S
S
 
2-((S)-3-((S)-1-Nitrobutyl)cyclohexylidene)-1,3-dithiane (75). In a stirring solution of 
[1,3]dithian-2-yl-phosphonic acid diethyl ester (0.129 g, 0.502 mmol) in THF (2 mL) at -78 °C 
was added n-BuLi (0.48 mL, 0.552 mmol, 1.6 M in hexane) dropwise during 15 min.  After 1 h, 
ketone 72 (0.100 g, 0.502 mmol) in THF (1 mL) was added and stirred for 15 min at -78 ºC and 
then cooling bath was removed. The reaction mixture was quenched after 1 h by adding saturated 
solution of NH4Cl (2 mL) and extracted with EtOAc (3×10 mL). The organic phase was washed 
with brine, dried over Na2SO4 and concentrated. The purification of crude product by column 
chromatography (5% EtOAc in hexanes) furnished a ketene dithioacetal 75 as colourless oil 
(0.124 g, 82%). [α]D20 –1.3 (c 1, CHCl3); IR (CHCl3) 1547 cm-1; 1H NMR (CDCl3) δ 4.30 (m, 
1H), 3.0 (m, 1H), 2.67-2.56 (m, 3H), 1.99-1.73 (m, 9H), 1.41-1.28 (m, 6H), 0.95 (t, J=7.2 Hz, 
3H); 13C NMR δ 140.66, 119.54, 93.20, 41.92, 34.36, 33.61, 31.88, 30.60, 29.28, 28.30, 25.52, 
25.37, 19.66, 13.91; MS (FAB): m/z 302 [M+1]+, HRMS (FAB) Calc. for C14H24NO2S2 [M+1]+ 
302.1243, found 302.1351. 
 
+
78 79
dr
1 : 1.2
NO2
H CO2Me
NO2
H CO2Me
H H
 
(1R,3S)-Methyl 3-((S)-1-nitrobutyl)cyclohexanecarboxylate (78) and (1S,3S)-methyl 3-
((S)-1-nitrobutyl)cyclohexanecarboxylate (79). A solution of 75 (0.120 g, 0.398 mmol), 
mercuric chloride (0.752 g, 1.59 mmol), MeOH (7 mL), and perchloric acid (0.17 mL of a 70% 
aqueous solution, 1.19 mmol) was heated at reflux for 2 h. After cooling and filtration, the 
reaction mixture was neutralized with saturated solution of NaHCO3 and extracted with CH2Cl2. 
The combined organic extract were washed with brine, dried (Na2SO4) and concentrated to give 
a 1:1 diastereomeric mixture of the ester 78 and 79 as colourless oils (0.069 g, 72%). A portion 
of the crude product was separated by column chromatography for characterization. For 75 (0.32 
g): [α]D20 -13.7 (c 1, CHCl3); IR (CHCl3) 1548, 1733 cm-1; 1H NMR (CDCl3) δ 4.27 (m, 1H), 
3.68 (s, 3H), 2.34 (m, 1H), 2.03-1.56 (m, 7H), 1.33-1.15 (m, 1H), 0.94 (t, J=7.3 Hz, 3H); 13C 
NMR (CDCl3) δ 175.76, 94.16, 52.02, 43.04, 40.90, 32.95, 31.38, 28.96, 28.91, 25.03, 19.57, 
Chapter 6 
150 
13.76; MS (FAB): m/z 244 [M+1]+, HRMS (FAB) Calc. for C12H22NO4 [M+1]+ 244.1543, found 
244.1601. 
 
81 (X-Ray)
NHAc
H CO2Me
H
 
(1R,3S)-Methyl 3-((S)-1-acetamidobutyl)cyclohexanecarboxylate (81). To a solution of 
nitro compound 78 (14.8 mg, 0.061 mmol) in MeOH (0.3 mL) was added successively under Ar 
atmosphere, ammonium formate (28 mg, 0.45 mmol), and 10% palladium on carbon (10 mg). 
The suspension was stirred for 4h at rt then filtered through a short pad of Celite, then washed 
with MeOH (10 mL). Concentration of the combined organic phase afforded an amine (13 mg, 
quantitative) which was dissolved in CH2Cl2, and Ac2O (18.4 µL, 0.105 mmol) was added 
followed by Et3N (27 µL, 0.195 mmol) and DMAP (catalytic amount). The reaction mixture was 
stirred at rt for 3 h then quenched by adding NH4Cl. The organic phase was diluted with EtOAc 
(10 mL) and was washed with HCl (1N) and NaHCO3, dried, concentrated and the residue was 
purified by chromatography (EtOAc/hexanes, 1/1) to give 81 as colourless solid (12 mg, 76%); 
[α]D20 -34.5 (c 1, CHCl3); IR (neat) 3282, 1734, 1641 cm-1; 1H NMR (CDCl3) δ 5.22 (d, J = 8.6 
Hz, 1H), 3.83 (m, 1H), 3.65 (s, 3H), 2.28 (m, 1H), 1.98-1.70 (m, 6H), 1.49-1.15 (m, 9H), 0.97-
0.87 (m, 4H); 13C NMR (CDCl3) δ 176.62, 170.08, 53.47, 51.98, 43.62, 41.68, 34.29, 32.01, 
29.23, 27.99, 25.59, 23.93, 19.83, 14.39; MS (FAB): m/z 256 [M+1]+ (X-ray provided).  
 
Pr
NHAc
H H
O
N
H
NHBu
OH
O
Ph
29
 
(1R,3S)-3-((S)-1-Acetamidobutyl)-N-((2S,3S,5R)-6-(butylamino)-3-hydroxy-5-methyl-6-
oxo-1-phenylhexan-2-yl)cyclohexanecarboxamide (29). In a solution of ester 81 (10 mg, 0.039 
mmol) in MeOH (1 mL) was added LiOH solution (150 µL, 1N solution in water) and stirred for 
12 h at rt. The reaction mixture was diluted with EtOAc (10 mL) and neutralized with diluted 
HCl, washed with brine, dried (Na2SO4) and concentrated. The crude product was used directly 
for coupling without purification. In a solution of Boc protected amine (16 mg, 0.039 mmol) in 
CH2Cl2 (1 mL) was added TMSI (22 µL) at rt for 30 min. The reaction mixture was quenched 
with Na2S2O3 solution and extracted with EtOAc. The organic layer was washed with NaHCO3 
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solution, brine, dried (Na2SO4) and concentrated. It was used immediately without purification. 
The acid and amine were taken in a solution of co-solvent (CH2Cl2:H2O, 1:1, 1 mL). HOBt (5.3 
mg, 0.039 mmol) and EDC (7.5 mg, 0.039 mmol) were added and stirred at 4 °C for 24 h. The 
reaction mixture was diluted with EtOAc (10 mL) and washed with diluted HCl, NaHCO3, brine 
and dried (Na2SO4). After concentration, the crude product was purified by careful column 
chromatography (5% MeOH in CH2Cl2) to give amide 29 (8 mg, 40%) as white solid. [α]D20 –50 
(c 0.25, MeOH:CHCl3[1:1]); IR (neat) 3315, 1648, 1630 cm-1; 1H NMR (MeOD:CDCl3 [5:1]) δ 
8.11 (s, 1H), 7.59-7.48 (m,4H), 4.38 (t, J = 6.7 Hz, 1H), 3.97 (bs,1H), 3.86 (m, 1H), 3.44 (t, J = 
7.1 Hz, 2H), 3.22 (dd, J = 5.7, 6.0 Hz, 1H), 3.00 ( dd, J = 9.3, 9.2 Hz, 1H), 2.85-2.80 (m, 1H), 
2.55 (s, 1H), 2.50-2.40 (m, 1H), 2.28 (s, 3H), 2.20-2.10 (m, 1H), 2.05-1.95 (m, 3H), 1.90 (d, J = 
12.5 Hz, 1H), 1.80-1.50 (m, 12H), 1.40 (d, J = 6.8 Hz, 4H), 1.25 (t, J = 7.0 Hz, 6H); 13C NMR 
(CD3OD:CDCl3 [5:1]) δ 177.2, 177.0, 171.2, 138.2, 128.6 (2C), 127.6 (2C), 125.6, 68.9, 53.9, 
52.9, 44.6, 40.8, 38.3, 37.5, 36.8, 36.5, 32.9, 31.7, 30.8, 29.3, 28.8, 27.1, 24.7, 21.1, 19.4, 18.7, 
16.8, 12.8, 12.6; MS (ESI) m/z 516 [M+1]+; HRMS (FAB) Calc. for C30H50N3O4 [M+1]+ 
516.3723, found 516.3720. 
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Crystal structure determination and refinement of compound 81 and 
ORTEP representation 
 
Identification code   han408 (81)  
Empirical formula   C14H25NO3    
Formula weight   255.35  
Temperature    293(2)K    
Wavelength    1.54178 Å  
Crystal system   Orthorhombic 
Space group   P212121 
Unit cell dimensions  a =  5.0354(14) Å α = 90° 
     b = 16.767(4) Å β = 90° 
     c = 17.907(5) Å γ = 90° 
Volume    511.9(7)Å3 
Z     4 
Density (calculated)  1.122 Mg/m3 
Absorption coefficient  0.624 mm-1 
F(000)    560 
Crystal size    0.62 × 0.11 × 0.09 mm  
Theta range for data collection 3.61 to 69.94° 
Index ranges   -6<h<6, -20<k<20, -21<λ<21 
Reflections collected  21134 
Independent reflections  2865 [Rint = 0.039] 
Absorption correction  None 
Max. and min. transmission 0.9500 and 0.7000 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters 2865 / 0 / 167  
Goodness-of-fit on F2  0.717  
Final R indices [I>2sigma(I)] R1 = 0.0387, wR2 = 0.0769 
R indices (all data)   R1 = 0.0723, wR2 = 0.0853   
Absolute structure parameter  0.1(4) 
Extinction coefficient  0.0043(3)  
Largest diff. peak and hole  0.165 and -0.107 e/Å3 
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6.2 Biology 
6.2.1. BACE1 inhibition   
Method A: Panvera peptide and Invitrogen Enzyme 
Purified Baculovirus-expressed BACE1 (β-secretase) and rhodamine derivative substrate were 
purchased from Panvera (Madison, WI, U.S). Sodium acetate and DMSO were from Sigma 
Aldrich (Milan, Italy). Purified water from Milli-RX system (Millipore, Milford, MA, USA) was 
used to prepare buffers and standard solutions. Spectrofluorometric analyses were carried out on 
a Fluoroskan Ascent multiwell spectrofluorimeter (excitation: 544 nm; emission: 590 nm) by 
using black microwell (96 wells) Corning plates (Sigma, Italy). Stock solutions of the tested 
compounds were prepared in DMSO and diluted with 50 mM sodium acetate buffer pH = 4.5.  
Specifically, 20 µL of BACE1 enzyme (25 nM) were incubated with 20 µL of test compound 
for 60 minutes. To start the reaction, 20 µL of substrate (0.25 µM) were added to the well. The 
mixture was incubated at 37 °C for 60 minutes. To stop the reaction, 20 µL of BACE1 stop 
solution (sodium acetate 2.5 M) were added to each well. Then the spectrofluorometric assay 
was performed by reading the fluorescence signal at 590 nm.  
Assays were done with a blank containing all components except BACE1 in order to account 
for non enzymatic reaction. The reaction rates were compared and the percent inhibition due to 
the presence of test compounds was calculated. Each concentration was analyzed in triplicate. 
The percent inhibition of the enzyme activity due to the presence of increasing test compound 
concentration was calculated by the following expression: 100-(vi/vo × 100), where vi is the 
initial rate calculated in the presence of inhibitor and vo is the enzyme activity. To demonstrate 
inhibition of BACE1 activity, inhibitor IV (Calbiochem, Darmstadt, Germany) was used as 
reference inhibitor (IC50=12.89 nM). 
Method B: Casein-FITC and Invitrogen Enzyme 
Purified Baculovirus-expressed BACE1 (β-secretase) in 50 mM Tris (pH = 7.5), 10% glycerol 
(5 Units) was purchased from Panvera (Madison, WI, U.S). Casein from bovine milk, labelled 
with Fluorescein isothiocyanate (Casein-FITC) type III (61 µg FITC per mg solid) and sodium 
acetate were from Sigma Aldrich (Milan, Italy). Methanol was grade pure from Carlo Erba 
(Milan, Italy). Purified water from Milli-RX system (Millipore, Milford, MA, USA) was used to 
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prepare buffers and standard solutions. Spectrofluorometric analyses were carried out on a 
Fluoroskan Ascent multiwell spectrofluorimeter (excitation: 485 nm; emission: 538 nm) by using 
black microwell (96 wells) Cliniplate plates (Thermo LabSystems, Helsinki, Finland). 
Stock solutions of the tested compounds were prepared in methanol and diluted with 50 mM 
sodium acetate buffer pH = 4.5.  
Specifically, 20 µL of BACE1 enzyme (1 U/mL) were incubated with 20 µL of test compound 
for 60 minutes. To start the reaction, 20 µL of Casein-FITC (400 nM) were added to the well. 
The mixture was incubated at 37 °C for 60 minutes. To stop the reaction, 20 µL of BACE1 stop 
solution (sodium acetate 2.5 M) were added to each well. Then the spectrofluorometric assay 
was performed by reading the fluorescence signal at 538 nm.  
Assays were done with a blank containing all components except BACE1 in order to account 
for non enzymatic reaction. BACE1 maximum activity was expressed as ∆F/h at 538 nm. The 
reaction rates were compared and the percent inhibition due to the presence of test compounds 
was calculated. Each concentration was analyzed in triplicate. The percent inhibition of the 
enzyme activity due to the presence of increasing test compound concentration was calculated by 
the following expression: 100-(vi/vo × 100), where vi is the initial rate calculated in the presence 
of inhibitor and vo is the enzyme activity. To demonstrate inhibition of BACE1 activity 
Donepezil was used as reference inhibitor (IC50=586 nM) or a statine-derived inhibitor (IC50 = 61  
± 2.0 nM). 
 
Method C: M-2420 substrate and Sigma enzyme 
Human recombinant BACE1 (β-secretase), sodium acetate, CHAPS and DMSO were 
purchased from Sigma Aldrich (Milan, Italy). The substrate, M-2420, was from Bachem, 
(Torrance, CA, USA). Purified water from Milli-RX system (Millipore, Milford, MA, USA) was 
used to prepare buffers and standard solutions. Spectrofluorometric analyses were carried out on 
a Fluoroskan Ascent multiwell spectrofluorimeter (excitation: 320 nm; emission: 405 nm) by 
using black microwell (96 wells) Corning plates (Sigma, Italy). 
Stock solutions of the tested compounds were prepared in DMSO and diluted with DMSO.  
Specifically, 175 µL of BACE1 enzyme (25 nM in NaOAc 20 mM pH 4.5, containing 0.1% 
w/v CHAPS) were incubated with 5 µL of test compound for 60 minutes. To start the reaction, 
20 µL of M-2420 (3 µM in Hepes 10 mM pH 7.5) were added to the well. The mixture was 
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incubated at room temperature for 15 minutes and the fluorescence signal was read at 405 nm.  
Assays were done with a blank containing all components except BACE1 in order to account 
for non enzymatic reaction. The reaction rates were compared and the percent inhibition due to 
the presence of test compounds was calculated. Each concentration was analyzed in duplicate. 
The percent inhibition of the enzyme activity due to the presence of increasing test compound 
concentration was calculated by the following expression: 100-(vi/vo × 100), where vi is the 
initial rate calculated in the presence of inhibitor and vo is the enzyme activity. To demonstrate 
inhibition of BACE1 activity, inhibitor IV (Calbiochem, Darmstadt, Germany) was used as 
reference inhibitor (IC50=13.61 nM). 
BACE1 fluorogenic substrate evaluation 
The kinetic parameters for the three enzymatic assays (A, B and C) were evaluated in order to 
optimize the test conditions. Hydrolysis of the fluorogenic substrates was monitored in a 200 µL 
reaction volume by measuring the fluorescence increase in a Fluoroskan Ascent 
spectrofluorimeter (beam diameter: 3 mm) by using black microwells (96 wells) Corning plates. 
λex/λem pairs were set at 544/590, 485/538 and 320/405 nm when substrates A (Invitrogen 
peptide, Panvera), B (Casein-FITC, Sigma) or C (M-2420, Bachem) were employed. 
Specificity constants (kcat/KM) were determined under pseudo-first-order conditions, via the 
“progress curve method”16 using a substrate concentration (0.04 or 0.05 µM) far below KM, and a 
final enzyme concentration of 10 or 34 nM (E0). The {time; fluorescence} data pairs were fitted 
to equation (F(t) = ΛF [1-exp(-kobs ·  t)] + Finit), and the apparent first-order rate constant (kobs) 
was calculated. The second-order rate constant, kcat/KM values were calculated according to the 
following equation: kcat/KM = kobs/[E0]. Quenching efficiency was determined according to the 
equation: q.e.(%) = (1-F0/F1) × 100, were F0 = Finit-Fbuffer and F1=Fmax- Fbuffer. 
6.2.2. Cathepsin D inhibition  
20 µL of CatD (0.05 µM) were incubated with 20 µL of test compound for 30 minutes. To start 
the reaction, 20 µL of Casein-FITC (1.44 µM) were added to the well. The mixture was 
incubated at 37 °C for 90 min. To stop the reaction, 20 µL of BACE1 stop solution (sodium 
acetate 2.5 M) were added to each well. Pepstatin A was used as a reference inhibitor 
(IC50=0.011 ± 0.002 µM) . 
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6.2.3. AChE and BChE inhibition  
The method of Ellman et al. was followed.17 Five different concentrations of each compound 
were used in order to obtain inhibition of AChE or BChE activity comprised between 20-80%. 
The assay solution consisted of a 0.1 M phosphate buffer pH 8.0, with the addition of 340 µM 
5,5'-dithio-bis(2-nitrobenzoic acid), 0.02 unit/mL of human recombinant AChE or human serum 
BChE (Sigma Chemical), and 550 µM of substrate (acetylthiocholine iodide or 
butyrylthiocholine iodide). Test compounds were added to the assay solution and pre-incubated 
at 37 °C with the enzyme for 20 min followed by the addition of substrate. Assays were done 
with a blank containing all components except AChE or BChE in order to account for non-
enzymatic reaction. The reaction rates were compared and the percent inhibition due to the 
presence of test compounds was calculated. Each concentration was analyzed in triplicate, and 
IC50 values were determined graphically from log concentration–inhibition curves. 
Determination of Steady State Inhibition Constant. To obtain estimates of the competitive 
inhibition constant Ki, reciprocal plots of 1/V versus 1/[S] were constructed at relatively low 
concentration of substrate (below 0.5 mM). The plots were assessed by a weighted least square 
analysis that assumed the variance of V to be a constant percentage of V for the entire data set. 
Slopes of these reciprocal plots were then plotted against the concentration of 6 (range 0 – 0.344 
nM) in a weighted analysis and Ki was determined as the ratio of the replot intercept to the replot 
slope. Reciprocal plots involving tacrine (not shown) or 6 inhibition show both increasing slopes 
(decreased Vmax at increasing inhibitor’s concentrations) and increasing intercepts (higher Km) 
with higher inhibitor concentration. This pattern indicates mixed inhibition, arising from 
significant inhibitor interaction with both the free enzyme and the acetylated enzyme. Replots of 
the slope versus the concentration of 6 or tacrine gives estimate of competitive inhibition 
constant, Ki = 0.155 ± 0.046 nM or Ki = 0.151 ± 0.016 µM, respectively. So the pattern in the 
graphical representation shows 6 able to bind to the peripheral anionic site as well as the active 
site of AChE. 
 
6.2.4. Inhibition of AChE-induced Aβ aggregation 
Aliquots of 2 µL Aβ peptide, lyophilized from 2 mg mL-1 1,1,1,3,3,3-hexafluoro-2-propanol 
solution and dissolved in DMSO, were incubated for 24 h at room temperature in 0.215 M 
sodium phosphate buffer (pH 8.0) at a final concentration of 230 µM. For co-incubation 
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experiments aliquots (16 µL) of AChE (final concentration 2.30 µM, Aβ/AChE molar ratio 
100:1) and AChE in the presence of 2 µL of the tested inhibitor in 0.215 M sodium phosphate 
buffer pH 8.0 solution (final inhibitor concentration 100 µM) were added. Blanks containing Aβ, 
AChE, and Aβ plus inhibitors at various concentrations, in 0.215 M sodium phosphate buffer 
(pH 8.0) were prepared. The final volume of each vial was 20 µL. Each assay was run in 
duplicate. To quantify amyloid fibril formation, the thioflavin T (ThT) fluorescence method was 
then applied.18 After dilution with glycine-NaOH buffer (pH 8.5), containing 1.5 mM ThT, the 
fluorescence intensities due to β-sheet conformation was monitored for 300 s at λem = 490 nm 
(λex = 446 nm). The percent inhibition of the AChE induced aggregation due to the presence of 
the test compound was calculated by the following expression: 100-(IFi/IFo × 100) where IFi and 
IFo are the fluorescence intensities obtained for Aβ plus AChE in the presence and in the absence 
of inhibitor, respectively, minus the fluorescent intensities due to the respective blanks.  
 
6.2.5. Animal studies 
All the mice used in these experiments were housed at constant temperature (22 ± 1 °C) and 
relative humidity (60 ± 1%) under a 12 hours light/dark cycle. Food and water were provided ad 
libitum. Effects of treatment on body weight and mortality were recorded. All the experiments 
were conducted according to the guidelines of the European Animal Health and Welfare Act.  
AD11 anti-NGF mice were produced as described in Section 4.3.19 The treatment pattern 
shown below was therefore followed. 
 
Table 4. Treatment pattern of selected compound in anti-NGF mice. 
Compound Numbers 
of mice 
Administration 
routea 
Dosageb Duration 
6 (lipocrine) 4 i.p. 0.165 mg/kg/day (0.104 mM) 15 
8 5 i.p. 0.52 mg/kg/day (0.37 mM) 15 
9 4 i.p. 0.52 mg/kg/day) (0.37 mM) 15 
10 4 i.p. 2.5 mg/kg/day (1.658 mM) 15 
23 3 i.p. 0.1 mg/kg/day (0.104 mM) 15 
Rivastigmine 4 i.p. 0.5 mg/kg/day (0.37 mM) 15 
Memoquin 3 i.p. 3.5 mg/kg/day (1.658 mM) 15 
LA 4 i.p. 0.254 mg/kg/day (0.37 mM) 15 
LA 4 i.p. 1.14 mg/kg/day (1.658 mM) 15 
a
 i.p. = indicates intraperitoneal injection 
b duration of treatment expressed in days, and molarity refers to solution administered to the anti-NGF mice. 
 
After the treatment, the mice were anaesthetised with 2,2,2-tribromoethanol (8 µL/g of body 
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weight) and the encephala were removed from the cranial box. The front part of the brain, 
containing the basal forebrain and one of the two occipital poled was fixed in 4% 
paraformaldehyde, cryoprotected in 30% in saccarose and treated for immunoistochemistry. The 
second occipital pole was frozen on dry ice and treated so as to be subjected to Western Blot to 
assess the presence of phosphorylated tau. 
Immunoistochemistry was carried out to show the number of cholinergic neurones in the basal 
forebrain. For this purpose, sections were incubated with the monoclonal antibody anticholine 
acetyltransferase (1 : 500, Chemicon International Inc., Temecula, CA). The reaction was 
developed using the avidin-biotin alkaline phosphatase Elite standard lit (Vector laboratories, 
Burligame, CA), followed by a development with 3, 3’ diaminobenzidine HCl (Sigma, Saint 
Louis, MO) and 5-bromo-4-chloro-3-indolyl phosphate toluidine salt (Sigma). 
To carry out a Western blot analysis an iced solution was prepared (50 mM Tris-HCl, pH 7.5, 
50 mM EDTA, 250 mM Spermidine, 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mM 
iodoacetamide, 10 µM/mL turkey egg white inhibitor, 0.1 % Triton X-100). 
The homogenates were centrifuged at 13,400 rpm for 30 minutes at 4 °C, collecting the 
surnatant, re-centrifuged and kept at -80 °C until use. The proteic content was determined by 
diluting the samples ten times and using the BIO-RAD “DC protein assay kit” (Hercules, CA, 
USA). The samples (20 µg protein) were loaded on polyacrylamide gel NuPAGE 10% 
(Invitrogen, Carlsbad, CA) and SDS-PAGE and a Western blot were carried out in order to detect 
phosphorylated tau. In particular, phosphorylated tau was found using monoclonal antibodies 
AT270 (1:1000, Innogenetics, Gand, Belgium) which detect the phosphorylated tau in the 
Thr181 residue. A pre-stained proteic marker (New England Biolabs, Ipswich, MA) was loaded 
to find the dimension of the bands. The reaction was developed using an anti-mouse HRP 
(1:5000, GE Healthcare, Little Chalfont, England) and a developing solution ECL (GE, 
Healthcare). 
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